



Kenneth Mahaffey

Professor of Medicine (Cardiovascular Medicine)

Medicine - Cardiovascular Medicine

CLINICAL OFFICE (PRIMARY)

- **Portola Valley Cardiology Clinic**

3260 Alpine Rd

Portola Valley, CA 94028

Tel (650) 498-7555 **Fax** (650) 724-1444

ACADEMIC CONTACT INFORMATION

- **Administrative Contact**

Christina Milcarek - Administrative Associate

Email christina.milcarek@stanford.edu

Tel 650-723-3096

Bio

BIO

Clinical Focus: Cardiovascular Medicine: Atrial Fibrillation; Chronic CAD; ACS;

Research Focus:

My primary research interest is the design and conduct of multicenter clinical trials and analyses of important clinical cardiac issues using large patient databases. My research focuses on novel anticoagulation agents for the treatment of acute coronary syndromes and atrial fibrillation, the study of agents targeted to protect the myocardium during reperfusion therapy for acute myocardial infarction, and the evaluation of cardiovascular safety of diabetic therapies. I am also interested in the methodology of clinical trials. Current research activities include standardization of the definition of myocardial infarction used in clinical trials, the adjudication of suspected clinical endpoint events by Clinical Event Committees (CEC), and the efficient operational conduct of large multinational clinical trials.

Administrative Focus: Associate Dean, Clinical Research School of Medicine; Vice Chair of Clinical Research Department of Medicine; Director Stanford Center for Clinical Research; Member of the Stanford IRB

Professional Training:

1985 Stanford University, BS Chemistry

1989 University of Washington, MD

1993 University of Arizona, Internship/Residency/Chief Residency

1996 Duke University, Fellowship in Cardiology

1996 Duke University, Faculty in Cardiology

2013 Stanford University, Faculty Cardiovascular Medicine

CLINICAL FOCUS

- Cardiovascular Disease

ACADEMIC APPOINTMENTS

- Professor - University Medical Line, Medicine - Cardiovascular Medicine
- Member, Cardiovascular Institute
- Member, SPARK at Stanford

ADMINISTRATIVE APPOINTMENTS

- Vice Chair of Clinical Research, Department of Medicine, (2013- present)
- Member, Stanford Diabetes Research Center, (2017- present)
- Steering Committee Member, Department of Medicine Team Science Initiative, Department of Medicine, (2022- present)

BOARDS, ADVISORY COMMITTEES, PROFESSIONAL ORGANIZATIONS

- Editorial Board Member, Current Cardiology Reviews (2004 - present)
- Associate Editor, American Heart Journal (2005 - present)
- Editorial Board Member, Current Cardiology Reports (2012 - present)
- Editorial Board Member, Cardiology & Therapy Journal (2012 - present)

PROFESSIONAL EDUCATION

- Fellowship: Duke University Hospital (1996) NC
- Board Certification: Cardiovascular Disease, American Board of Internal Medicine (2006)
- Residency: University of Arizona Internal Medicine Residency (1993) AZ
- Medical Education: University of Washington Medical Center (1989) WA

Research & Scholarship

CLINICAL TRIALS

- Engaging Self-regulation Targets to Improve Mood and Weight and Understand Mechanism in Depressed and Obese Adults, Not Recruiting
- Project Baseline, Not Recruiting

PROJECTS

- Dr. Mahaffey's Disclosures

Publications

PUBLICATIONS

- **Adaptive AI for Cardiovascular Event Adjudication: Cardiovascular Event Adjudication Across Different Definitions in the ODYSSEY OUTCOMES and EUCLID Trials.** *Circulation*
Vemulapalli, S., Pena Guerra, K., Wojdyla, D., Jones, W. S., Mahaffey, K. W., Harrington, R. A., Steg, P. G., Schwartz, G. G., Patel, M. R., Lopes, R. D., Henao, R.
2026
- **Effect of semaglutide on COVID-19 and other infections: an analysis from the FLOW randomized clinical trial.** *Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association*
Rayner, B., Mahaffey, K. W., Mann, J. F., Pratley, R. E., Rossing, P., Belmar, N., Bosch-Traberg, H., Jeppesen, O. K., Tran, M. C., Chernin, G., Tuttle, K. R.
2026

- **Major adverse cardiovascular and bleeding outcomes in paroxysmal vs. non-paroxysmal atrial fibrillation: an individual patient-level data analysis of a large cohort of patients from the COMBINE-AF.** *European journal of internal medicine*
Ntaios, G., Goette, A., Palazzolo, M. G., Ruff, C., Link, M. S., Mahaffey, K. W., Carnicelli, A. P., Eikelboom, J., Granger, C. B., Patel, M., Wallentin, L., Giugliano, R. P.
2026: 106774
- **Kidney and Survival Outcomes with Semaglutide by Chronic Kidney Disease Severity in the FLOW Trial.** *Clinical journal of the American Society of Nephrology : CJASN*
Tuttle, K. R., Mann, J. F., Mayrdorfer, M. M., Rayner, B., Pugliese, G., Pratley, R. E., Perkovic, V., Mahaffey, K. W., Kashihara, N., Jeppesen, O. K., Gumprecht, J., Correa-Rotter, R., Cherney, et al
2026
- **Effects of Sodium Glucose Cotransporter 2 Inhibitors by Diabetes Status and Level of Albuminuria: A Meta-Analysis.** *JAMA*
Staplin, N., Roddick, A. J., Neuen, B. L., Anker, S. D., Bhatt, D. L., Butler, J., Cherney, D. Z., Docherty, K. F., Fletcher, R. A., Inzucchi, S. E., Jardine, M., Mahaffey, K. W., McGuire, et al
2025
- **SGLT2 Inhibitors and Kidney Outcomes by Glomerular Filtration Rate and Albuminuria: A Meta-Analysis.** *JAMA*
Neuen, B. L., Fletcher, R. A., Anker, S. D., Bhatt, D. L., Butler, J., Cherney, D. Z., Docherty, K. F., Inzucchi, S. E., Jardine, M. J., Mahaffey, K. W., McCausland, F. R., McGuire, D. K., McMurray, et al
2025
- **Target Product Profile to Evaluate the Clinical Utility, Financial Impact, and Ethical Implications of an AI-Based HCM Detection Model**
Parsa, S., Keyes, T., Dash, D., Mello, M., Salisbury, H., Callahan, A., Goto, S., Salerno, M., Parikh, V., Mahaffey, K., Ashley, E., Shah, N., Jain, et al
LIPPINCOTT WILLIAMS & WILKINS.2025
- **Cardiovascular Diagnoses Following Smartwatch Irregular Pulse Notifications: Insights from the Apple Heart Study**
Perez Guerrero, E., Parsa, S., Gjermeni, D., Sakalaki, M., Alipour, P., Yu, K., Hedlin, H., Desai, M., Phillips, A., Russo, A., Granger, C., Kowey, P., Hills, et al
LIPPINCOTT WILLIAMS & WILKINS.2025
- **Leveraging deep learning applied to chest radiograph images to identify individuals at high risk of chronic obstructive pulmonary disease: a retrospective model validation study** *LANCET DIGITAL HEALTH*
Jorshery, S., Chandra, J., Walia, A. S., Stumilo, A., Corey, K., Zekavat, S., Zinzuwadia, A. N., Patel, K., Short, S., Mega, J. L., Plowman, R., Pagidipati, N., Sullivan, et al
2025; 7 (9)
- **Digital Strategies for Recruitment to Improve Diversity and Inclusion in Prospective Cardiovascular Clinical Research.** *Cardiology and therapy*
Jain, S. S., Rodriguez, F., Perez, M. V., Yu, J., Shashidhar, S., Swope, S., Nguyen, K., Desai, M., Hedlin, H., Shah, S. H., Hernandez, A. F., Turakhia, M. P., Mahaffey, et al
2025
- **CARS2Hypermethylation Is a Risk Factor for Heart Failure: A Project Baseline Health Substudy.** *Circulation. Genomic and precision medicine*
Regan, J. A., Franklin, J., Kottlilil, K., Cauwenberghs, N., Mahaffey, K. W., Douglas, P. S., Rodriguez, F., Haddad, F., Hernandez, A. F., Shah, S. H., Kwee, L. C., Project Baseline Health Study Group
2025: e005073
- **Approach to the Postmarket Evaluation of Consumer Wearable Technologies.** *JAMA cardiology*
Pundi, K., Bhavnani, S., Seninger, C., Zuckerman, B., Paulsen, J., Aguel, F., Din, N., Viggiano, B., Yoo, R. M., Dalal, N., Go, A. S., Granger, C., Krumholz, et al
2025
- **Racial and Ethnic Representation and Study Engagement in a Siteless Digital Clinical Trial Using a Smartwatch: Findings From the Apple Heart Study.** *Mayo Clinic proceedings. Digital health*
Nguyen, K. T., Yu, J., Hedlin, H., Phillips, A. T., Desai, S., Cheung, L., Kowey, P. R., Jain, S. S., Rumsfeld, J. S., Russo, A. M., Granger, C. B., Hills, M. T., Desai, et al
2025; 3 (3): 100232
- **Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy.** *The New England journal of medicine*
Desai, M. Y., Owens, A. T., Abraham, T., Olivotto, I., Garcia-Pavia, P., Lopes, R. D., Elliott, P., Fernandes, F., Verheyen, N., Maier, L., Meder, B., Azevedo, O., Kitaoka, et al

2025

- **Deep Learning Chest X-Ray Age, Epigenetic Aging Clocks and Associations with Age-Related Subclinical Disease in the Project Baseline Health Study.** *The journals of gerontology. Series A, Biological sciences and medical sciences*
Chandra, J., Short, S., Rodriguez, F., Maron, D. J., Pagidipati, N., Hernandez, A. F., Mahaffey, K. W., Shah, S. H., Kiel, D. P., Lu, M. T., Raghu, V. K.
2025
- **Effects of Semaglutide With or Without Concomitant Mineralocorticoid Receptor Antagonist Use in Participants With Type 2 Diabetes and Chronic Kidney Disease: A FLOW Trial Prespecified Secondary Analysis.** *Diabetes care*
Rossing, P., Bakris, G., Perkovic, V., Pratley, R., Tuttle, K. R., Mahaffey, K. W., Idorn, T., Belmar, N., Bosch-Traberg, H., Rasmussen, S., Busch, R. S., Schmieder, R. E., Gillard, et al
2025
- **SGLT2 Inhibition and Hospitalizations in Patients with CKD: A Meta-Analysis of Kidney Outcome Trials.** *Clinical journal of the American Society of Nephrology : CJASN*
Oshima, M., Buizen, L., Jongs, N., Levin, A., Chertow, G. M., Wheeler, D. C., Heerspink, H. J., Arnott, C., Jardine, M. J., Mahaffey, K. W., Pollock, C., Herrington, W. G., Perkovic, et al
2025
- **Retention and characteristics associated with remote questionnaire completion in a general population cohort study: the project baseline health study.** *Frontiers in digital health*
Carroll, M. K., Faheem, S., Bouteiller, J., Hernandez, A., Mahaffey, K. W., Mega, J. L., Pagidipati, N., Schaack, T., Shah, S. H., Shashidhar, S., Swope, S., Williams, D., Plowman, et al
2025; 7: 1520132
- **Returning Individual-Level Urgent or Emergent Research Results to Participants: The Project Baseline Health Study Experience.** *American journal of medicine open*
Pagidipati, N., Heidenfelder, B., Kwee, L. C., Rodriguez, F., Chatterjee, R., Parikh, K. S., Khouri, M. G., Stiller, J., Eckstrand, J., Marcom, P. K., Mettu, P. S., Jaffe, G. J., Shashidhar, et al
2025; 13: 100092
- **CARS2 Hypermethylation Is a Risk Factor for Stage B Heart Failure and Hospitalizations in the Project Baseline Health Study.** *medRxiv : the preprint server for health sciences*
Regan, J. A., Franklin, J., Kottillil, K., Cauwenberghs, N., Mahaffey, K. W., Douglas, P. S., Rodriguez, F., Haddad, F., Hernandez, A. F., Shah, S. H., Kwee, L. C.
2025
- **AGE AND COMORBIDITIES ASSOCIATED WITH HEALTHCARE UTILIZATION AFTER RECEIVING A SMARTWATCH IRREGULAR PULSE NOTIFICATION SUGGESTIVE OF ATRIAL FIBRILLATION: FINDINGS FROM THE APPLE HEART STUDY**
Guerrero, E., Sakalaki, M., Yu, K., Hedlin, H., Mahaffey, K. W., Russo, A. M., Granger, C. B., Kowey, P. R., Desai, M., Hils, M., Phillips, A., Rumsfeld, J. S., Turakhia, et al
ELSEVIER SCIENCE INC.2025: 2534
- **Impact of Apolipoprotein A-I Infusions on Cardiovascular Events Post-MI by Neutrophil-Lymphocyte Ratio and LDL-Cholesterol Levels.** *JACC. Advances*
Rikken, S. A., Gibson, C. M., Bahit, M. C., Duffy, D., Chi, G., Korjian, S., Mohammadnia, N., White, H., Anschuetz, G., Kingwell, B. A., Ophuis, T. O., Nicolau, J. C., Lopes, et al
2025; 4 (5): 101727
- **Outcomes after fractional flow reserve-guided percutaneous coronary intervention versus coronary artery bypass grafting (FAME 3): 5-year follow-up of a multicentre, open-label, randomised trial.** *Lancet (London, England)*
Fearon, W. F., Zimmermann, F. M., Ding, V. Y., Takahashi, K., Piroth, Z., van Straten, A. H., Szekely, L., Davidavičius, G., Kalinauskas, G., Mansour, S., Kharbanda, R., Östlund-Papadogeorgos, N., Aminian, et al
2025
- **The Efficacy and Safety of Canagliflozin by Frailty Status in Participants of the CANVAS and CREDENCE Trials.** *Journal of the American Geriatrics Society*
Nguyen, T. N., Yu, J., Perkovic, V., Jardine, M., Mahaffey, K. W., Chow, C. K., Arnott, C., Lindley, R. I.
2025
- **Efficacy of Acoramidis on All-Cause Mortality and Cardiovascular Hospitalization in Transthyretin Amyloid Cardiomyopathy.** *Journal of the American College of Cardiology*

- Judge, D. P., Alexander, K. M., Cappelli, F., Fontana, M., Garcia-Pavia, P., Gibbs, S. D., Grogan, M., Hanna, M., Masri, A., Maurer, M. S., Obici, L., Soman, P., Cao, et al
2025; 85 (10): 1003-1014
- **Oral Factor Xla Inhibitor Milvexian After a Recent Acute Coronary Syndrome: Rationale and Design of the Phase 3 (Librexia ACS).** *American heart journal*
Gibson, C. M., Bahit, M. C., Mehran, R., Mehta, S. R., Lamee, R. A., Goto, S., Weitz, J. I., Horrow, J., Barnathan, E. S., Harrington, R. A., Mahaffey, K. W., Lam, C. S., Pieper, et al
2025
 - **Effects of Clazakizumab on Anemia and Iron Metabolism in Patients with Kidney Failure.** *Journal of the American Society of Nephrology : JASN*
Neuen, B. L., Catanese, B., Chang, A., Heise, M., Tricoli, P., Felker, G. M., Mahaffey, K. W., Wolf, M., Chertow, G. M.
2025
 - **Canagliflozin reduces oral loop diuretic intensification in patients with type 2 diabetes: A participant-level pooled analysis of the CANVAS and CREDENCE trials.** *European journal of heart failure*
Chatur, S., Vaduganathan, M., Fletcher, R. A., Perkovic, V., Heerspink, H., Arnett, C., Pollock, C., Mahaffey, K. W., Neal, B., Jardine, M., Solomon, S. D., Neuen, B. L.
2025
 - **Abnormal Exercise Electrocardiography With Normal Stress Echocardiography Is Associated With Subclinical Coronary Atherosclerosis.** *Circulation. Cardiovascular imaging*
Duran, J. M., Shrader, P., Hong, C., Haddad, F., Santana, E. J., Cauwenberghs, N., Kouznetsova, T., Salerno, M., Bloomfield, G., Koweek, L., Hernandez, A., Mahaffey, K. W., Shah, et al
2025: e017380
 - **Resting Heart Rate and Associations With Clinical Measures From the Project Baseline Health Study: Observational Study.** *Journal of medical Internet research*
Feng, K. Y., Short, S. A., Saeb, S., Carroll, M. K., Olivier, C. B., Simard, E. P., Swope, S., Williams, D., Eckstrand, J., Pagidipati, N., Shah, S. H., Hernandez, A. F., Mahaffey, et al
2024; 26: e60493
 - **Stroke-bleeding risk score pairings within individuals in the outcomes registry for better informed treatment of atrial fibrillation (ORBIT-AF) registry.** *International journal of cardiology*
Jason, M. J., Marzec, L. N., Piccini, J. P., Shrader, P., Pieper, K. S., Blanco, R. G., Fonarow, G. C., Gersh, B. J., Ho, P. M., Hylek, E., Kowey, P. R., Mahaffey, K. W., Steinberg, et al
2024: 132912
 - **Benefits of Semaglutide on Chronic Kidney Disease Outcomes by Cardiovascular Status or Risk in the FLOW trial**
Tuttle, K., Bakris, G., Bang, C., Bax, W., Belmar, N., Brown, P., Cherney, D., Chernin, G., Lim, S., Mann, J., Perkovic, V., Pratley, R., Ridker, et al
LIPPINCOTT WILLIAMS & WILKINS.2024: E746
 - **Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials.** *The lancet. Diabetes & endocrinology*
Badve, S. V., Bilal, A., Lee, M. M., Sattar, N., Gerstein, H. C., Ruff, C. T., McMurray, J. J., Rossing, P., Bakris, G., Mahaffey, K. W., Mann, J. F., Colhoun, H. M., Tuttle, et al
2024
 - **The Coming AI Revolution in ClinicalTrials.** *Journal of the American College of Cardiology*
Jain, S. S., Sarraju, A., Shah, N. H., Schulman, K. A., Ashley, E. A., Harrington, R. A., Mahaffey, K. W.
2024
 - **Impact of Semaglutide on Infections and COVID-19: Data from the FLOW Trial**
Rayner, B., Mahaffey, K. W., Mann, J. F., Pratley, R. E., Tuttle, K. R., Belmar, N., Bosch-Traberg, H., Jeppesen, O. K., Tran, M., Chernin, G., Rossing, P.
AMER SOC NEPHROLOGY.2024
 - **Effect of Semaglutide on Mortality Outcomes in the FLOW Trial**
Pratley, R. E., Mahaffey, K. W., Mann, J. F., Tuttle, K. R., Rossing, P., Idorn, T., David, J., Bosch-Traberg, H., Jeppesen, O. K., Bax, W. A., Gillard, P., Arici, M., Shamkhalova, et al
AMER SOC NEPHROLOGY.2024

- **Semaglutide Reduced Risks of Major Kidney Outcomes Irrespective of CKD Severity in the FLOW Trial**
Tuttle, K. R., Mann, J. F., Sokareva, E., Rayner, B., Pugliese, G., Pratley, R. E., Perkovic, V., Mahaffey, K. W., Kashihara, N., Jeppesen, O. K., Gumprecht, J., Correa-Rotter, R., Cherney, et al
AMER SOC NEPHROLOGY.2024
- **Canagliflozin and iron metabolism in the CREDENCE trial.** *Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association*
Koshino, A., Heerspink, H. J., Jongs, N., Badve, S. V., Arnott, C., Neal, B., Jardine, M., Mahaffey, K. W., Pollock, C., Perkovic, V., Hansen, M. K., Bakker, S. J., Wada, et al
2024
- **Apolipoprotein A-I Infusions and Cardiovascular Outcomes in Acute Myocardial Infarction According to Baseline LDL-Cholesterol Levels: The AEGIS-II Trial.** *European heart journal*
Gibson, C. M., Duffy, D., Bahit, M. C., Chi, G., White, H., Korjian, S., Alexander, J. H., Lincoff, A. M., Heise, M., Kingwell, B. A., Nicolau, J. C., Lopes, R. D., Cornel, et al
2024
- **Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial.** *European heart journal*
Mahaffey, K. W., Tuttle, K. R., Arici, M., Baeres, F. M., Bakris, G., Charytan, D. M., Cherney, D. Z., Chernin, G., Correa-Rotter, R., Gumprecht, J., Idorn, T., Pugliese, G., Rasmussen, et al
2024
- **Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials.** *Lancet (London, England)*
Kosiborod, M. N., Deanfield, J., Pratley, R., Borlaug, B. A., Butler, J., Davies, M. J., Emerson, S. S., Kahn, S. E., Kitzman, D. W., Lingvay, I., Mahaffey, K. W., Petrie, M. C., Plutzky, et al
2024
- **Milvexian vs apixaban for stroke prevention in atrial fibrillation: The LIBREXIA atrial fibrillation trial rationale and design.** *American heart journal*
Jain, S. S., Mahaffey, K. W., Pieper, K. S., Shimizu, W., Potpara, T., Ruff, C. T., Kamel, H., Lewis, B. S., Cornel, J. H., Kowey, P. R., Horrow, J., Strony, J., Plotnikov, et al
2024
- **Bidirectional Relationship Between Kidney Disease Progression and Cardiovascular Events in Type 2 Diabetes.** *Journal of the American College of Cardiology*
Neuen, B. L., Ostrominski, J. W., Claggett, B., Beldhuis, I. E., Chatur, S., McCausland, F. R., Badve, S. V., Arnott, C., Heerspink, H. J., Jun, M., Falster, M., de Oliveira Costa, J., Pollock, et al
2024
- **Effects of Semaglutide on HeartFailure Outcomes in Diabetes and Chronic Kidney Disease in the FLOW Trial.** *Journal of the American College of Cardiology*
Pratley, R. E., Tuttle, K. R., Rossing, P., Rasmussen, S., Perkovic, V., Nielsen, O. W., Mann, J. F., MacIsaac, R. J., Kosiborod, M. N., Kamenov, Z., Idorn, T., Hansen, M. B., Hadjadj, et al
2024
- **ApoA-I Infusions and Burden of Ischemic Events After Acute Myocardial Infarction: Insights From the AEGIS-II Trial.** *Journal of the American College of Cardiology*
Gibson, C. M., Chi, G., Duffy, D., Bahit, M. C., White, H., Korjian, S., Alexander, J. H., Lincoff, A. M., Anschuetz, G., Girgis, I. G., Nicolau, J. C., Lopes, R. D., Cornel, et al
2024
- **Milvexian: An Oral, Bioavailable Factor XIa Inhibitor.** *Cardiology and therapy*
Parsa, S., Jain, S. S., Akinrimisi, O., Lam, C. S., Mahaffey, K. W.
2024
- **Selonsertib in Patients with Diabetic Kidney Disease: A Phase 2b Randomized Active Run-In Clinical Trial.** *Journal of the American Society of Nephrology : JASN*
Heerspink, H. J., Perkovic, V., Tuttle, K. R., Pergola, P. E., Mahaffey, K. W., Patel, U. D., Ishida, J. H., Kuo, A., Chen, F., Kustra, R., Petrovic, V., Rossing, P., Kashihara, et al
2024

- **Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials.** *The lancet. Diabetes & endocrinology*
Apperloo, E. M., Neuen, B. L., Fletcher, R. A., Jongs, N., Anker, S. D., Bhatt, D. L., Butler, J., Cherney, D. Z., Herrington, W. G., Inzucchi, S. E., Jardine, M. J., Liu, C. C., Mahaffey, et al
2024
- **Author Correction: IL-6 inhibition with clazakizumab in patients receiving maintenance dialysis: a randomized phase 2b trial.** *Nature medicine*
Chertow, G. M., Chang, A. M., Felker, G. M., Heise, M., Velkoska, E., Fellström, B., Charytan, D. M., Clementi, R., Gibson, C. M., Goodman, S. G., Jardine, M., Levin, A., Lokhnygina, et al
2024
- **Characterization of Peripheral Artery Disease and Associations with Traditional Risk Factors, Mobility, and Biomarkers in the Project Baseline Health Study.** *American heart journal*
Kercheval, J. B., Narcisse, D. I., Nguyen, M., Rao, S. V., Gutierrez, J. A., Leeper, N. J., Maron, D. J., Rodriguez, F., Hernandez, A. F., Mahaffey, K. W., Shah, S. H., Swaminathan, R. V.
2024
- **Effects of canagliflozin on total heart failure events across the kidney function spectrum: Participant-level pooled analysis from the CANVAS Program and CREDENCE trial.** *European journal of heart failure*
Vaduganathan, M., Cannon, C. P., Jardine, M. J., Heerspink, H. J., Arnott, C., Neuen, B. L., Sarraju, A., Gogate, J., Seufert, J., Neal, B., Perkovic, V., Mahaffey, K. W., Kosiborod, et al
2024
- **Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial.** *Nature medicine*
Mann, J. F., Rossing, P., Bakris, G., Belmar, N., Bosch-Traberg, H., Busch, R., Charytan, D. M., Hadjadj, S., Gillard, P., Gorriz, J. L., Idorn, T., Ji, L., Mahaffey, et al
2024
- **Geographic and racial variability in kidney, cardiovascular and safety outcomes with canagliflozin: A secondary analysis of the CREDENCE randomized trial.** *Diabetes, obesity & metabolism*
Cardoza, K., Kang, A., Smyth, B., Yi, T. W., Pollock, C., Agarwal, R., Bakris, G., Charytan, D. M., de Zeeuw, D., Wheeler, D. C., Zhang, H., Cannon, C. P., Perkovic, et al
2024
- **Relationship between body mass index and cardiometabolic health in a multi-ethnic population: A project baseline health study.** *American journal of preventive cardiology*
Shah, N. P., Lu, R., Haddad, F., Shore, S., Schaack, T., Mega, J., Pagidipati, N. J., Palaniappan, L., Mahaffey, K., Shah, S. H., Rodriguez, F.
2024; 18: 100646
- **Machine learning for prediction of chronic kidney disease progression: Validation of the Klinrisk model in the CANVAS Program and CREDENCE trial.** *Diabetes, obesity & metabolism*
Tangri, N., Ferguson, T. W., Bamforth, R. J., Leon, S. J., Arnott, C., Mahaffey, K. W., Kotwal, S., Heerspink, H. J., Perkovic, V., Fletcher, R. A., Neuen, B. L.
2024
- **IL-6 inhibition with clazakizumab in patients receiving maintenance dialysis: a randomized phase 2b trial.** *Nature medicine*
Chertow, G. M., Chang, A. M., Felker, G. M., Heise, M., Velkoska, E., Fellström, B., Charytan, D. M., Clementi, R., Gibson, C. M., Goodman, S. G., Jardine, M., Levin, A., Lokhnygina, et al
2024
- **Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.** *The New England journal of medicine*
Perkovic, V., Tuttle, K. R., Rossing, P., Mahaffey, K. W., Mann, J. F., Bakris, G., Baeres, F. M., Idorn, T., Bosch-Traberg, H., Lausvig, N. L., Pratley, R., FLOW Trial Committees and Investigators
2024
- **Assessment of Days Alive Out of Hospital as a Possible End Point in Trials of Stroke Prevention for Atrial Fibrillation: A ROCKET AF Analysis.** *Journal of the American Heart Association*
Harrington, J., Hellkamp, A. S., Mahaffey, K. W., Breithardt, G., Halperin, J. L., Hankey, G. J., Becker, R. C., Nessel, C. C., Berkowitz, S. D., Fox, K. A., Singer, D. E., Goodman, S. G., Patel, et al
2024: e028951

- **Acoramidis achieves early reduction in cardiovascular death or hospitalization in transthyretin amyloid cardiomyopathy (ATTR-CM): results from the ATTRIBUTE-CM clinical trial**
Alexander, K., Judge, D., Cappelli, F., Fontana, M., Garcia-Pavia, P., Grogan, M., Hanna, M., Masri, A., Maurer, M., Obici, L., Soman, P., Cao, X., Tamby, et al
TAYLOR & FRANCIS LTD.2024: S116-S117
- **Timing of Cardio-Kidney Protection With SGLT2 Inhibitors: Insights From Four Large-Scale Placebo-Controlled Outcome Trials.** *Circulation*
Neuen, B. L., Claggett, B. L., Perkovic, V., Jardine, M., Heerspink, H. J., Mahaffey, K. W., McMurray, J. J., Solomon, S. D., Vaduganathan, M.
2024
- **Effects of SGLT2 inhibitors on cause-specific cardiovascular death in patients with chronic kidney disease: a meta-analysis of CKD progression trials.** *Clinical journal of the American Society of Nephrology : CJASN*
Fletcher, R. A., Herrington, W. G., Agarwal, R., Mayne, K. J., Arnott, C., Jardine, M. J., Mahaffey, K. W., Perkovic, V., Staplin, N., Wheeler, D. C., Chertow, G. M., Heerspink, H. J., Neuen, et al
2024
- **Natriuretic Peptides and Prognosis in Patients with Type 2 Diabetes Mellitus and High Risk for Cardiovascular Events.** *Journal of cardiac failure*
Khan, M. S., Januzzi, J. L., Liu, Y., Xu, J., Shaw, W., Sattar, N., Mahaffey, K. W., Neal, B., Hansen, M. K., Butler, J.
2024
- **Sodium Glucose Co-transporter 2 Inhibitors and Major Adverse Cardiovascular Outcomes: A SMART-C Collaborative Meta-Analysis.** *Circulation*
Patel, S. M., Kang, Y. M., Im, K., Neuen, B. L., Anker, S. D., Bhatt, D. L., Butler, J., Cherney, D. Z., Claggett, B. L., Fletcher, R. A., Herrington, W. G., Inzucchi, S. E., Jardine, et al
2024
- **Apolipoprotein A1 Infusions and Cardiovascular Outcomes after Acute Myocardial Infarction.** *The New England journal of medicine*
Gibson, C. M., Duffy, D., Korjian, S., Bahit, M. C., Chi, G., Alexander, J. H., Lincoff, A. M., Heise, M., Tricoci, P., Deckelbaum, L. I., Mears, S. J., Nicolau, J. C., Lopes, et al
2024
- **Real-world walking behaviors are associated with early-stage heart failure: a Project Baseline Health Study.** *Journal of cardiac failure*
Shin, S., Kowahl, N., Hansen, T., Ling, A. Y., Barman, P., Cauwenberghs, N., Rainaldi, E., Short, S., Dunn, J., Shandhi, M. M., Shah, S. H., Mahaffey, K. W., Kuznetsova, et al
2024
- **Accuracy of Event Rate and Effect Size Estimation in Major Cardiovascular Trials: A Systematic Review.** *JAMA network open*
Olivier, C. B., Struß, L., Sünnen, N., Kaier, K., Heger, L. A., Westermann, D., Meerpohl, J. J., Mahaffey, K. W.
2024; 7 (4): e248818
- **A Phase II randomized controlled trial evaluated antithrombotic treatment with fesomersen in patients with kidney failure on hemodialysis.** *Kidney international*
Winkelmayer, W. C., Lensing, A. W., Thadhani, R. I., Mahaffey, K. W., Walsh, M., Pap, Á. F., Willmann, S., Thelen, K., Hodge, S., Solms, A., Ingham, S. J., Eikelboom, J.
2024
- **Effect of CSL112 on Recurrent Myocardial Infarction and Cardiovascular Death: Insights from the AEGIS-II Trial.** *Journal of the American College of Cardiology*
Povsic, T. J., Korjian, S., Bahit, M. C., Chi, G., Duffy, D., Alexander, J. H., Vinereanu, D., Tricoci, P., Mears, S. J., Deckelbaum, L. I., Bonaca, M., Ridker, P. M., Goodman, et al
2024
- **Smartphone-Based Recognition of Heart Failure by Means of Microelectromechanical Sensors.** *JACC. Heart failure*
Haddad, F., Saraste, A., Santalahti, K. M., Pänkäälä, M., Kaisti, M., Kandolin, R., Simonen, P., Nammas, W., Jafarian Dehkordi, K., Koivisto, T., Knuuti, J., Mahaffey, K. W., Blomster, et al
2024
- **Autoantibodies to Erythropoietin Receptor and Clinical Outcomes in Patients With Type 2 Diabetes and CKD: A Post Hoc Analysis of CREDESCENCE Trial.** *Kidney international reports*
Koshino, A., Neuen, B. L., Oshima, M., Toyama, T., Hara, A., Arnott, C., Neal, B., Jardine, M., Badve, S. V., Mahaffey, K. W., Pollock, C., Hansen, M. K., Wada, et al

2024; 9 (2): 347-355

- **Impact of Canagliflozin on Kidney and Cardiovascular Outcomes by Type 2 Diabetes Duration: A Pooled Analysis of the CANVAS Program and CREDENCE trials.** *Diabetes care*
Tobe, S. W., Mavranakas, T. A., Bajaj, H. S., Levin, A., Tangri, N., Slee, A., Neuen, B. L., Perkovic, V., Mahaffey, K. W., Rapattoni, W., Ang, F. G.
2024
- **Primary and Secondary Cardiovascular and Kidney Prevention With Canagliflozin: Insights From the CANVAS Program and CREDENCE Trial.** *Journal of the American Heart Association*
Sharma, A., Razaghizad, A., Joury, A., Levin, A., Bajaj, H. S., Mancini, G. B., Wong, N. C., Slee, A., Ang, F. G., Rapattoni, W., Neuen, B. L., Arnott, C., Perkovic, et al
2024: e031586
- **Identifying a stable and generalizable factor structure of major depressive disorder across three large longitudinal cohorts.** *Psychiatry research*
Tseng, V. W., Tharp, J. A., Reiter, J. E., Ferrer, W., Hong, D. S., Doraiswamy, P. M., Nickels, S.
2023; 333: 115702
- **Estimated Lifetime Cardiovascular, Kidney and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Non-steroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria.** *Circulation*
Neuen, B. L., Heerspink, H. J., Vart, P., Claggett, B. L., Fletcher, R. A., Arnott, C., de Oliveira Costa, J., Falster, M. O., Pearson, S. A., Mahaffey, K. W., Neal, B., Agarwal, R., Bakris, et al
2023
- **Innovation in Event Adjudication-Human vs Machine.** *JAMA cardiology*
Mahaffey, K. W., Gibson, C. M., Lopes, R. D.
2023
- **Timing of statistical benefit of canagliflozin in patients with type 2 diabetes for cardiovascular and heart failure outcomes: Insights from the CANVAS Program and CREDENCE trial.** *Diabetes, obesity & metabolism*
Sharma, A., Marques, P., Neuen, B. L., Fletcher, R. A., Slee, A., Rapattoni, W., Ang, F. G., Arnott, C., Levin, A., Verma, S., Perkovic, V., Mahaffey, K. W.
2023
- **Effect of SGLT2 Inhibitors on Discontinuation of Renin-angiotensin System Blockade: A Joint Analysis of the CREDENCE and DAPA-CKD Trials.** *Journal of the American Society of Nephrology : JASN*
Fletcher, R. A., Jongs, N., Chertow, G. M., McMurray, J. J., Arnott, C., Jardine, M. J., Mahaffey, K. W., Perkovic, V., Rockenschaub, P., Rossing, P., Correa-Rotter, R., Toto, R. D., Vaduganathan, et al
2023
- **Treatment effect of canagliflozin for patients on therapy for heart failure: Pooled analysis of the CANVAS program and CREDENCE trial.** *International journal of cardiology*
Jain, S. S., Yu, J., Arnott, C., Neal, B., Perkovic, V., Neuen, B. L., Jardine, M., Mahaffey, K. W.
2023: 131444
- **Training New DMC Members: A Call to Action.** *Therapeutic innovation & regulatory science*
Rockhold, F., Mahaffey, K., DeMets, D.
2023
- **Fractional Flow Reserve-Guided PCI or Coronary Bypass Surgery for 3-Vessel Coronary Artery Disease: 3-Year Follow-Up of the FAME 3 Trial.** *Circulation*
Zimmermann, F. M., Ding, V. Y., Pijls, N. H., Piroth, Z., van Straten, A. H., Szekely, L., Davidavicius, G., Kalinauskas, G., Mansour, S., Kharbada, R., Östlund-Papadogeorgos, N., Aminian, A., Oldroyd, et al
2023
- **Predictors of intracranial hemorrhage in patients with atrial fibrillation treated with oral anticoagulants: Insights from the GARFIELD-AF and ORBIT-AF registries.** *Clinical cardiology*
Lim, T. W., Camm, A. J., Virdone, S., Singer, D. E., Bassand, J. P., Fonarow, G. C., Fox, K. A., Ezekowitz, M., Gersh, B. J., Kayani, G., Hylek, E. M., Kakkur, A. K., Mahaffey, et al
2023

- **The evolving role of data & safety monitoring boards for real-world clinical trials** *JOURNAL OF CLINICAL AND TRANSLATIONAL SCIENCE*
Bunning, B. J., Hedlin, H., Chen, J. H., Ciolino, J. D., Ferstad, J., Fox, E., Garcia, A., Go, A., Johari, R., Lee, J., Maahs, D. M., Mahaffey, K. W., Opsahl-Ong, et al
2023; 7 (1)
- **The evolving role of data & safety monitoring boards for real-world clinical trials.** *Journal of clinical and translational science*
Bunning, B. J., Hedlin, H., Chen, J. H., Ciolino, J. D., Ferstad, J. O., Fox, E., Garcia, A., Go, A., Johari, R., Lee, J., Maahs, D. M., Mahaffey, K. W., Opsahl-Ong, et al
2023; 7 (1): e179
- **Canagliflozin, Blood Pressure Variability, and Risk of Cardiovascular, Kidney, and Mortality Outcomes: Pooled Individual Participant Data From the CANVAS and CREDENCE Trials.** *Journal of the American Heart Association*
Fletcher, R. A., Arnott, C., Rockenschaub, P., Schutte, A. E., Carpenter, L., Vaduganathan, M., Agarwal, R., Bakris, G., Chang, T. I., Heerspink, H. J., Jardine, M. J., Mahaffey, K. W., Neal, et al
2023: e028516
- **Cardiorenal protective effects of canagliflozin in CREDENCE according to glucose lowering.** *BMJ open diabetes research & care*
Charytan, D. M., Mahaffey, K. W., Jardine, M. J., Cannon, C. P., Neal, B., Lambers Heerspink, H. J., Agarwal, R., Bakris, G. L., de Zeeuw, D., Levin, A., Pollock, C., Zhang, H., Zinman, et al
2023; 11 (3)
- **The sodium-glucose cotransporter-2 inhibitor canagliflozin does not increase risk of non-genital skin and soft tissue infections in people with type 2 diabetes mellitus: A pooled post hoc analysis from the CANVAS Program and CREDENCE randomized double-blind trials.** *Diabetes, obesity & metabolism*
Kang, A., Smyth, B., Neuen, B. L., Heerspink, H. J., Di Tanna, G. L., Zhang, H., Arnott, C., Hockham, C., Agarwal, R., Bakris, G., Charytan, D. M., de Zeeuw, D., Greene, et al
2023
- **Extremes of both weight gain and weight loss are associated with increased incidence of heart failure and cardiovascular death: evidence from the CANVAS Program and CREDENCE.** *Cardiovascular diabetology*
Ferrannini, G., Pollock, C., Natali, A., Yavin, Y., Mahaffey, K. W., Ferrannini, E.
2023; 22 (1): 100
- **Clinical and echocardiographic diversity associated with physical fitness in the Project Baseline Health Study: implications for heart failure staging.** *Journal of cardiac failure*
Cauwenberghs, N., Haddad, F., Daubert, M. A., Chatterjee, R., Salerno, M., Mega, J. L., Heidenreich, P., Hernandez, A., Amsallem, M., Kobayashi, Y., Mahaffey, K. W., Shah, S. H., Bloomfield, et al
2023
- **Accelerated Epigenetic Aging Is Associated With Multiple Cardiometabolic, Hematologic, and Renal Abnormalities: A Project Baseline Health Substudy.** *Circulation. Genomic and precision medicine*
Uchegara, B., Coulter Kwee, L., Regan, J., Chatterjee, R., Eckstrand, J., Swope, S., Gold, G., Schaack, T., Douglas, P., Mettu, P., Haddad, F., Shore, S., Hernandez, et al
2023: e003772
- **Defining Myocardial Infarction in trials of people receiving hemodialysis: consensus report from the SONG-HD MI Expert Working group.** *Kidney international*
O'Lone, E., Apple, F. S., Burton, J. O., Caskey, F. J., Craig, J. C., de Filippi, C. R., Forfang, D., Hicks, K. A., Jha, V., Mahaffey, K. W., Mark, P. B., Rossignol, P., Scholes-Robertson, et al
2023
- **Design and development of a digital shared decision-making tool for stroke prevention in atrial fibrillation.** *JAMIA open*
Nunes, J. C., Baykaner, T., Pundi, K., DeSutter, K., True Hills, M., Mahaffey, K. W., Sears, S. F., Morin, D. P., Lin, B., Wang, P. J., Stafford, R. S.
2023; 6 (1): ooad003
- **Glycemic Control and Effects of Canagliflozin in Reducing Albuminuria and eGFR: A Post Hoc Analysis of the CREDENCE Trial.** *Clinical journal of the American Society of Nephrology : CJASN*
van der Hoek, S., Jongs, N., Oshima, M., Neuen, B. L., Stevens, J., Perkovic, V., Levin, A., Mahaffey, K. W., Pollock, C., Greene, T., Wheeler, D. C., Jardine, M. J., Heerspink, et al
2023

- **Effects of canagliflozin on cardiovascular and kidney events in patients with chronic kidney disease with and without peripheral arterial disease: integrated analysis from the CANVAS Program and CREDESCENCE trial.** *Diabetes, obesity & metabolism*
Yi, T. W., Wong, M. M., Neuen, B. L., Arnott, C., Poirier, P., Seufert, J., Slee, A., Rapattoni, W., Ang, F. G., Wheeler, D. C., Mahaffey, K. W., Perkovic, V., Levin, et al
2023
- **Cardiovascular and kidney outcomes with canagliflozin according to type 2 diabetes treatment targets at baseline: Data from the CANVAS Program and CREDESCENCE.** *Diabetes, obesity & metabolism*
Tsoukas, M. A., Woo, V., Tobe, S. W., Slee, A., Rapattoni, W., Ang, F. G., Seufert, J., Neuen, B. L., Arnott, C., Mahaffey, K. W., Wheeler, D. C.
2023
- **TREATMENT EFFECT OF CANAGLIFLOZIN FOR PATIENTS ON THERAPY FOR HEART FAILURE: POOLED ANALYSIS OF THE CANVAS PROGRAM AND CREDESCENCE TRIAL**
Jain, S. S., Yu, J., Arnott, C., Neal, B., Perkovic, V., Neuen, B., Jardine, M., Mahaffey, K. W.
ELSEVIER SCIENCE INC.2023: 283
- **SOCIAL DETERMINANTS OF HEALTH AND CORONARY ARTERY CALCIUM: RESULTS FROM THE PROJECT BASELINE HEALTH STUDY**
Dudum, R., Ling, A., Short, S., Koweek, L. H., Carroll, M., Daubert, M. A., Haddad, F., Hernandez, A. F., Shah, S., Mahaffey, K. W., Douglas, P. S., Mega, J., Maron, et al
ELSEVIER SCIENCE INC.2023: 1843
- **Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex: A Post Hoc Analysis of the CREDESCENCE Randomized Clinical Trial.** *American journal of kidney diseases : the official journal of the National Kidney Foundation*
Yi, T. W., Smyth, B., Di Tanna, G. L., Arnott, C., Cardoza, K., Kang, A., Pollock, C., Agarwal, R., Bakris, G., Charytan, D. M., de Zeeuw, D., Heerspink, H. J., Neal, et al
2023
- **Effects of canagliflozin on liver steatosis and fibrosis markers in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis of the CREDESCENCE trial.** *Diabetes, obesity & metabolism*
Koshino, A., Oshima, M., Arnott, C., Fletcher, R. A., Bakris, G. L., Jardine, M., Mahaffey, K. W., Perkovic, V., Pollock, C., Heerspink, H. J., Neuen, B. L.
2023
- **The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease.** *Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association*
Rossing, P., Baeres, F. M., Bakris, G., Bosch-Traberger, H., Gislum, M., Gough, S. C., Idorn, T., Lawson, J., Mahaffey, K. W., Mann, J. F., Mersebach, H., Perkovic, V., Tuttle, et al
2023
- **Clinical Trial to Evaluate an Atrial Fibrillation Stroke Prevention Shared DecisionMaking Pathway**
Wang, P. J., Lu, Y., Mahaffey, K. W., Lin, A., Morin, D. P., Sears, S. F., Chung, M. K., Russo, A. M., Lin, B., Piccini, J. P., Hills, M. T., Berube, C., Pundi, et al
LIPPINCOTT WILLIAMS & WILKINS.2022: E582-E583
- **The development of a mobile app-focused deduplication strategy for the Apple Heart Study that informs recommendations for future digital trials.** *Stat (International Statistical Institute)*
Garcia, A., Lee, J., Balasubramanian, V., Gardner, R., Gummidiipundi, S. E., Hung, G., Ferris, T., Cheung, L., Desai, S., Granger, C. B., Hills, M. T., Kowey, P., Nag, et al
2022; 11 (1): e470
- **A Randomized Clinical Trial to Evaluate an Atrial Fibrillation Stroke Prevention Shared Decision-Making Pathway.** *Journal of the American Heart Association*
Wang, P. J., Lu, Y., Mahaffey, K. W., Lin, A., Morin, D. P., Sears, S. F., Chung, M. K., Russo, A. M., Lin, B., Piccini, J., Hills, M. T., Berube, C., Pundi, et al
2022: e8009
- **Apixaban for Patients with Atrial Fibrillation on Hemodialysis: A Multicenter Randomized Controlled Trial.** *Circulation*
Pokorney, S. D., Chertow, G. M., Al-Khalidi, H. R., Gallup, D., Dignaco, P., Mussina, K., Bansal, N., Gadegbeku, C. A., Garcia, D. A., Garonzik, S., Lopes, R. D., Mahaffey, K. W., Matsuda, et al
2022

- **Biomarker-Based Prediction of Recurrent Ischemic Events in Patients With Acute Coronary Syndromes.** *Journal of the American College of Cardiology*
Batra, G., Lindback, J., Becker, R. C., Harrington, R. A., Held, C., James, S. K., Kempf, T., Lopes, R. D., Mahaffey, K. W., Steg, P. G., Storey, R. F., Swahn, E., Wollert, et al
2022; 80 (18): 1735-1747
- **A Phase 2b Randomized Controlled Trial of Selonsertib in Moderate to Severe Diabetic Kidney Disease (MOSAIC)**
Perkovic, V., Tuttle, K. R., Pergola, P. E., Mahaffey, K. W., Patel, U. D., Ishida, J. H., Chen, F., Crans, G., Kustra, R., Trivedi, M., Heerspink, H. J. L., Rossing, P., Kashihara, et al
AMER SOC NEPHROLOGY.2022: 28
- **Cardiovascular Effects of Canagliflozin in Relation to Renal Function and Albuminuria.** *Journal of the American College of Cardiology*
Sarraj, A., Bakris, G., Cannon, C. P., Cherney, D., Damaraju, C. V., Figtree, G. A., Gogate, J., Greene, T., Heerspink, H. J., Januzzi, J. L., Neal, B., Jardine, M. J., Blais, et al
2022; 80 (18): 1721-1731
- **CANAGLIFLOZIN AND DIURETIC USE IN TYPE 2 DIABETES AND CHRONIC KIDNEY DISEASE: INSIGHTS FROM THE CREDENCE TRIAL**
Neuen, B., Fletcher, R., Arnott, C., Vadaganathan, M., Perkovic, V., Jardine, M., Neal, B., Mahaffey, K., Heerspink, H., Pollock, C.
WILEY.2022: 15
- **A Post Hoc Analysis of KidneyIntelX and Cardiorenal Outcomes in Diabetic Kidney Disease.** *Kidney360*
Nadkarni, G. N., Takale, D., Neal, B., Mahaffey, K. W., Yavin, Y., Hansen, M. K., Fleming, F., Heerspink, H. J., Coca, S. G.
2022; 3 (9): 1599-1602
- **Initiation of the SGLT2 inhibitor canagliflozin to prevent kidney and heart failure outcomes guided by HbA1c, albuminuria, and predicted risk of kidney failure.** *Cardiovascular diabetology*
Tye, S. C., Jongs, N., Coca, S. G., Sundstrom, J., Arnott, C., Neal, B., Perkovic, V., Mahaffey, K. W., Vart, P., Heerspink, H. J.
2022; 21 (1): 194
- **General Anxiety Disorder-7 Questionnaire as a marker of low socioeconomic status and inequity.** *Journal of affective disorders*
Nunes, J. C., Carroll, M. K., Mahaffey, K. W., Califf, R. M., Doraiswamy, P. M., Short, S., Shah, S. H., Swope, S., Williams, D., Hernandez, A. F., Hong, D. S.
2022
- **CANAGLIFLOZIN, MENTAL HEALTH ADVERSE EVENTS, AND DIABETES: EXPLORATORY ANALYSIS OF THE CREDENCE TRIAL AND CANVAS PROGRAM.** *Diabetes, obesity & metabolism*
Nunes, J. C., Yu, J., Arnott, C., Jardine, M. J., Perkovic, V., Mahaffey, K. W.
2022
- **Effect of Canagliflozin on Total Cardiovascular Burden in Patients With Diabetes and Chronic Kidney Disease: A Post Hoc Analysis From the CREDENCE Trial.** *Journal of the American Heart Association*
Li, J., Arnott, C., Heerspink, H. J., MBIostat, Q. L., Cannon, C. P., Wheeler, D. C., Charytan, D. M., Barraclough, J., Figtree, G. A., Agarwal, R., Bakris, G., de Zeeuw, D., Greene, et al
2022: e025045
- **Multi-dimensional characterization of prediabetes in the Project Baseline Health Study.** *Cardiovascular diabetology*
Chatterjee, R., Kwee, L. C., Pagidipati, N., Koweek, L. H., Mettu, P. S., Haddad, F., Maron, D. J., Rodriguez, F., Mega, J. L., Hernandez, A., Mahaffey, K., Palaniappan, L., Shah, et al
2022; 21 (1): 134
- **Understanding Study Drug Discontinuation Through EUCLID** *FRONTIERS IN CARDIOVASCULAR MEDICINE*
Weissler, E., Mulder, H., Rockhold, F. W., Baumgartner, I., Norgren, L., Blomster, J., Katona, B. G., Fowkes, F. R., Mahaffey, K., Bonaca, M., Patel, M. R., Jones, W.
2022; 9: 947645
- **Outcomes After Acute Coronary Syndrome in Patients With Diabetes Mellitus and Peripheral Artery Disease (from the TRACER, TRILOGY-ACS, APPRAISE-2, and PLATO Clinical Trials).** *The American journal of cardiology*
Attar, R., Wu, A., Wojdyla, D., Jensen, S. E., Andell, P., Mahaffey, K. W., Roe, M. T., James, S. K., Wallentin, L., Vemulapalli, S., Alexander, J. H., Lopes, R. D., Ohman, et al
2022

- **Association of left ventricular diastolic function with coronary artery calcium score: A Project Baseline Health Study.** *Journal of cardiovascular computed tomography*
Haddad, F., Cauwenberghs, N., Daubert, M. A., Kobayashi, Y., Bloomfield, G. S., Fleischman, D., Koweek, L., Maron, D. J., Rodriguez, F., Liao, Y. J., Moneghetti, K., Amsallem, M., Mega, et al
2022
- **Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab.** *Circulation*
Hagström, E., Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Danchin, N., Diaz, R., Goodman, S. G., Harrington, R. A., Jukema, J. W., Liberopoulos, E., Marx, N., McGinniss, et al
2022: 101161CIRCULATIONAHA121057807
- **Pandemic-proof recruitment and engagement in a fully decentralized trial in atrial fibrillation patients (DeTAP).** *NPJ digital medicine*
Sarraj, A., Seninger, C., Parameswaran, V., Petlura, C., Bazouzi, T., Josan, K., Grewal, U., Viethen, T., Mundl, H., Luithle, J., Basobas, L., Touros, A., Senior, et al
2022; 5 (1): 80
- **Cardiovascular and Renal Outcomes with Finerenone, a Selective Mineralocorticoid Receptor Antagonist.** *Cardiology and therapy*
Palanisamy, S., Funes Hernandez, M., Chang, T. I., Mahaffey, K. W.
2022
- **Fasting Substrate Concentrations Predict Cardiovascular Outcomes in the CANagliflozin cardioVascular Assessment Study (CANVAS).** *Diabetes care*
Ferrannini, E., Baldi, S., Scozzaro, T., Tsimihodimos, V., Tesfaye, F., Shaw, W., Rosenthal, N., Figtree, G. A., Neal, B., Mahaffey, K. W., Perkovic, V., Hansen, M. K.
2022
- **Lessons learned in the Apple Heart Study and implications for the data management of future digital clinical trials.** *Journal of biopharmaceutical statistics*
Garcia, A., Balasubramanian, V., Lee, J., Gardner, R., Gummidipundi, S., Hung, G., Ferris, T., Cheung, L., Granger, C., Kowey, P., Rumsfeld, J., Russo, A., Hills, et al
2022: 1-15
- **Total Cardiovascular and Limb Events and the Impact of Polyvascular Disease in Chronic Symptomatic Peripheral Artery Disease.** *Journal of the American Heart Association*
Szarek, M., Hess, C., Patel, M. R., Jones, W. S., Berger, J. S., Baumgartner, I., Katona, B., Mahaffey, K. W., Norgren, L., Blomster, J., Rockhold, F. W., Hsia, J., Fowkes, et al
2022: e025504
- **Canagliflozin and Atrial Fibrillation in Type 2 Diabetes Mellitus: A secondary analysis from the CANVAS Program and CREDENCE trials and meta-analysis.** *Diabetes, obesity & metabolism*
Li, C., Yu, J., Hockham, C., Perkovic, V., Neuen, B. L., Badve, S. V., Houston, L., Lee, V. Y., Barraclough, J. Y., Fletcher, R. A., Mahaffey, K. W., Heerspink, H. J., Cannon, et al
2022
- **BASELINE CHARACTERISTICS OF THE FLOW TRIAL POPULATION: KIDNEY OUTCOMES TRIAL WITH ONCE-WEEKLY SEMAGLUTIDE IN PEOPLE WITH TYPE 2 DIABETES AND CHRONIC KIDNEY DISEASE**
Perkovic, V., Baeres, F., Bakris, G., Bosch-Traberg, H., Idorn, T., Mahaffey, K., Mann, J., Mersebach, H., Rossing, P., Tuttle, K., Pratley, R.
OXFORD UNIV PRESS.2022: 1893-1894
- **Sodium-glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People with Type 2 diabetes: A Meta-analysis of Individual Participant Data from Randomized Controlled Trials.** *Circulation*
Neuen, B. L., Oshima, M., Agarwal, R., Arnott, C., Cherney, D. Z., Edwards, R., Langkilde, A. M., Mahaffey, K. W., McGuire, D. K., Neal, B., Perkovic, V., Pong, A., Sabatine, et al
2022
- **Independence of Clinical Events Committees: A Consensus Statement from Clinical Research Organizations.** *American heart journal*
Spitzer, E., Fanaroff, A. C., Gibson, C. M., Seltzer, J., McFadden, E., Ali, M., Wilson, M., Menon, V., Mehran, R., Held, C., Mahaffey, K. W., Lopes, R. D.
2022
- **Effect of Platelet Inhibition by Cangrelor Among Obese Patients Undergoing Coronary Stenting: Insights From CHAMPION.** *Circulation. Cardiovascular interventions*

Peterson, B. E., Harrington, R. A., Stone, G. W., Steg, P. G., Gibson, C. M., Hamm, C. W., Price, M. J., Lopes, R. D., Leonardi, S., Prats, J., Deliargyris, E. N., Mahaffey, K. W., White, et al
2022: CIRCINTERVENTIONS121011069

- **Stress Cardiac Biomarkers, Cardiovascular and Renal Outcomes, and Response to Canagliflozin.** *Journal of the American College of Cardiology*
Vaduganathan, M., Sattar, N., Xu, J., Butler, J., Mahaffey, K. W., Neal, B., Shaw, W., Rosenthal, N., Pfeifer, M., Hansen, M. K., Januzzi, J. L.
1800; 79 (5): 432-444
- **Potential Effects of Elimination of the Black Race Coefficient in eGFR Calculations in the CREDENCE Trial.** *Clinical journal of the American Society of Nephrology : CJASN*
Charytan, D., Yu, J., Jardine, M., Cannon, C., Agarwal, R., Bakris, G., Greene, T., Levin, A., Pollock, C., Powe, N., Arnott, C., Mahaffey, K.
1800
- **Direct Oral Anticoagulants versus Warfarin in Patients with Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials with Interaction Testing by Age and Sex.** *Circulation*
Carnicelli, A. P., Hong, H., Connolly, S. J., Eikelboom, J., Giugliano, R. P., Morrow, D. A., Patel, M. R., Wallentin, L., Alexander, J. H., Bahit, M. C., Benz, A. P., Bohula, E. A., Chao, et al
1800
- **Biological and clinical correlates of the patient health questionnaire-9: exploratory cross-sectional analyses of the baseline health study.** *BMJ open*
Califf, R. M., Wong, C., Doraiswamy, P. M., Hong, D. S., Miller, D. P., Mega, J. L.
2022; 12 (1): e054741
- **The ENHANCE-AF Clinical Trial to Evaluate an Atrial Fibrillation Shared Decision-Making Pathway: Rationale and Study Design.** *American heart journal*
Baykaner, T., Pundi, K., Lin, B., Lu, Y., DeSutter, K., Lhamo, K., Garay, G., Nunes, J. C., Morin, D. P., Sears, S. F., Chung, M. K., Paasche-Orlow, M. K., Sanders, et al
2022
- **Risk Factors for Fracture in Patients with Coexisting Chronic Kidney Disease and Type 2 Diabetes: An Observational Analysis from the CREDENCE Trial.** *Journal of diabetes research*
Young, T. K., Toussaint, N. D., Di Tanna, G. L., Arnott, C., Hockham, C., Kang, A., Schutte, A. E., Perkovic, V., Mahaffey, K. W., Agarwal, R., Bakris, G. L., Charytan, D. M., Heerspink, et al
2022; 2022: 9998891
- **The impact of canagliflozin on the risk of neuropathy events: a post-hoc exploratory analysis of the CREDENCE trial.** *Diabetes & metabolism*
Liao, J., Kang, A., Xia, C., Young, T., Tanna, G. L., Arnott, C., Pollock, C., Krishnan, A. V., Agarwal, R., Bakris, G., Charytan, D. M., de Zeeuw, D., Heerspink, et al
2022: 101331
- **Cardiovascular and Renal Outcomes with Canagliflozin in Patients with Peripheral Artery Disease: Data from the CANVAS program and CREDENCE trials.** *Diabetes, obesity & metabolism*
Barracough, J. Y., Yu, J., Figtree, G. A., Perkovic, V., Heerspink, H. J., Neuen, B. L., Cannon, C. P., Mahaffey, K. W., Schutte, A. E., Neal, B., Arnott, C.
2022
- **Clinical Utility of KidneyIntelX in Early Stages of Diabetic Kidney Disease in the CANVAS Trial.** *American journal of nephrology*
Lam, D., Nadkarni, G. N., Mosoyan, G., Neal, B., Mahaffey, K. W., Rosenthal, N., Hansen, M. K., Heerspink, H. J., Fleming, F., Coca, S. G.
2022: 1-11
- **Clinical Events Classification (CEC) in Clinical Trials: Report on the Current Landscape and Future Directions - Proceedings from the CEC Summit 2018.** *American heart journal*
Sharma, A., Mahaffey, K. W., Gibson, C. M., Hicks, K. A., Alexander, K. P., Ali, M., Chaitman, B. R., Held, C., Hlatky, M., Jones, W. S., Mehran, R., Menon, V., Rockhold, et al
1800
- **Milvexian For Prevention of Venous Thromboembolism After Elective Knee Arthroplasty: The AXIOMATIC-TKR Study**
Weitz, J. I., Strony, J., Ageno, W., Gailani, D., Hylek, E., Lassen, M., Lee, E., Lu, W., Mahaffey, K. W., Notani, R., Roberts, R., Segers, A., Raskob, et al

LIPPINCOTT WILLIAMS & WILKINS.2021: E574

- **Milvexian For Prevention of Venous Thromboembolism After Elective Knee Arthroplasty: The AXIOMATIC-TKR Study**
Weitz, J. I., Strony, J., Ageno, W., Gailani, D., Hylek, E., Lassen, M., Lee, E., Lu, W., Mahaffey, K. W., Notani, R., Roberts, R., Segers, A., Raskob, et al
LIPPINCOTT WILLIAMS & WILKINS.2021: E574
- **Ischemic Events Occur Early in Patients Undergoing Percutaneous Coronary Intervention and Are Reduced With Cangrelor: Findings From CHAMPION PHOENIX.** *Circulation. Cardiovascular interventions*
Cavender, M. A., Harrington, R. A., Stone, G. W., Steg, P. G., Gibson, C. M., Hamm, C. W., Price, M. J., Lopes, R. D., Leonardi, S., Deliangryis, E. N., Prats, J., Mahaffey, K. W., White, et al
1800: CIRCINTERVENTIONS120010390
- **Effect of the Glucagon-like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: a Pooled Analysis of SUSTAIN 6 and LEADER Trials.** *Circulation*
Shaman, A. M., Bain, S. C., Bakris, G. L., Buse, J. B., Idorn, T., Mahaffey, K. W., Mann, J. F., Nauck, M. A., Rasmussen, S., Rossing, P., Wolthers, B., Zinman, B., Perkovic, et al
1800
- **Association between TNF Receptors and KIM-1 with Kidney Outcomes in Early-Stage Diabetic Kidney Disease.** *Clinical journal of the American Society of Nephrology : CJASN*
Waijjer, S., Sen, T., Arnott, C., Neal, B., Kosterink, J., Mahaffey, K., Parikh, C., de Zeeuw, D., Perkovic, V., Neuen, B., Coca, S., Hansen, M., Gansevoort, et al
2021
- **Association Between Circulating GDF-15 and Cardio-Renal Outcomes and Effect of Canagliflozin: Results From the CANVAS Trial.** *Journal of the American Heart Association*
Sen, T., Li, J., Neuen, B. L., Arnott, C., Neal, B., Perkovic, V., Mahaffey, K. W., Shaw, W., Canovatchel, W., Hansen, M. K., Heerspink, H. J.
2021: e021661
- **Fractional Flow Reserve-Guided PCI as Compared with Coronary Bypass Surgery.** *The New England journal of medicine*
Fearon, W. F., Zimmermann, F. M., De Bruyne, B., Piroth, Z., van Straten, A. H., Szekely, L., Davidavicius, G., Kalinauskas, G., Mansour, S., Kharbanda, R., Ostlund-Papadogeorgos, N., Aminian, A., Oldroyd, et al
2021
- **Circulating Metabolites to Predict Renal Outcomes in CANVAS Type 2 Diabetes Mellitus Population**
Darshi, M., Tefera, E., Gao, B., Weidner-Wells, M., Reilly, D. F., Coorey, C., Tang, O., Yang, J., Neal, B., Arnott, C. G., Mahaffey, K. W., Perkovic, V., Hansen, et al
AMER SOC NEPHROLOGY.2021: 47
- **Maintaining Operational Excellence During the COVID-19 Pandemic in the FLOW Trial**
Pratley, R. E., Bakris, G. L., Bax, W. A., Bosch-Traberg, H., Mahaffey, K. W., Rossing, P., Tuttle, K. R., Lawson, J., Montegaard, C., Wassermann, A., Mann, J. F.
AMER SOC NEPHROLOGY.2021: B6
- **KidneyIntelX as an Enrichment Tool for Clinical Trials in Early Diabetic Kidney Disease**
Vasquez-Rios, G., Nadkarni, G. N., Neal, B., Mahaffey, K. W., Hansen, M. K., Fleming, F., Heerspink, H. J. L., Coca, S. G.
AMER SOC NEPHROLOGY.2021: 263
- **Etiology and Outcomes of Amputation in Patients with Peripheral Artery Disease: Insights from the EUCLID Trial.** *Journal of vascular surgery*
Govsveyev, N., Nehler, M. R., Low Wang, C. C., Kavanagh, S., Hiatt, W. R., Long, C., Jones, W. S., Fowkes, F. G., Berger, J. S., Baumgartner, I., Patel, M. R., Goodney, P. P., Beckman, et al
2021
- **Termination Based on Event Accrual in Per Protocol Versus Intention to Treat in the ROCKET AF Trial.** *Journal of the American Heart Association*
Carnicelli, A. P., Hellkamp, A. S., Mahaffey, K. W., Singer, D. E., Breithardt, G., Halperin, J. L., Hankey, G. J., Piccini, J. P., Becker, R. C., Nessel, C. C., Berkowitz, S. D., Fox, K. A., Califf, et al
2021: e022485

- **World regional differences in outcomes for patients with peripheral artery disease: Insights from the EUCLID trial.** *Vascular medicine (London, England)*
Norgren, L., North, R., Baumgartner, I., Berger, J. S., Blomster, J. I., Hiatt, W. R., Jones, W. S., Katona, B. G., Mahaffey, K. W., Mulder, H., Patel, M. R., Rockhold, F. W., Fowkes, et al
2021: 1358863X211038620
- **Efficacy and safety of cangrelor in patients with peripheral artery disease undergoing percutaneous coronary intervention - Insights from the CHAMPION program.** *American heart journal plus : cardiology research and practice*
Gutierrez, J. A., Harrington, R. A., Stone, G. W., Steg, P. G., Gibson, C. M., Hamm, C. W., Price, M. J., Lopes, R. D., Leonardi, S., Prats, J., Deliargyris, E. N., Mahaffey, K. W., White, et al
2021; 9: 100043
- **Effects of canagliflozin on major adverse cardiovascular events (MACE) by baseline estimated glomerular filtration rate: pooled Hispanic subgroup analyses from the CANVAS Program and CREDENCE trial.** *Diabetes, obesity & metabolism*
Weir, M. R., Gogate, J., Damaraju, C. V., Correa-Rotter, R., Mahaffey, K. W.
2021
- **Effects of canagliflozin compared with placebo on major adverse cardiovascular and kidney events in patient groups with different baseline levels of HbA1c, disease duration and treatment intensity: results from the CANVAS Program.** *Diabetologia*
Young, T. K., Li, J., Kang, A., Heerspink, H. J., Hockham, C., Arnott, C., Neuen, B. L., Zoungas, S., Mahaffey, K. W., Perkovic, V., de Zeeuw, D., Fulcher, G., Neal, et al
2021
- **Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial.** *European heart journal*
Neuen, B. L., Oshima, M., Perkovic, V., Agarwal, R., Arnott, C., Bakris, G., Cannon, C. P., Charytan, D. M., Edwards, R., Gorriz, J. L., Jardine, M. J., Levin, A., Neal, et al
2021
- **Effects of the SGLT2 inhibitor canagliflozin on plasma biomarkers TNFR-1, TNFR-2 and KIM-1 in the CANVAS trial.** *Diabetologia*
Sen, T., Li, J., Neuen, B. L., Neal, B., Arnott, C., Parikh, C. R., Coca, S. G., Perkovic, V., Mahaffey, K. W., Yavin, Y., Rosenthal, N., Hansen, M. K., Heerspink, et al
2021
- **Reasons for hospitalizations in patients with type 2 diabetes mellitus in the CANVAS Program: a secondary analysis.** *Diabetes, obesity & metabolism*
Feng, K. Y., Li, J., Ianus, J., de Zeeuw, D., Fulcher, G. R., Pfeifer, M., Matthews, D. R., Jardine, M. J., Perkovic, V., Neal, B., Mahaffey, K. W.
2021
- **Cost-Consequence Analysis of Using Cangrelor in High Angiographic Risk Percutaneous Coronary Intervention Patients: A US Hospital Perspective.** *American journal of cardiovascular drugs : drugs, devices, and other interventions*
Jensen, I. S., Wu, E., Cyr, P. L., Claussen, M., Winkler, T., Salahuddin, K., Prats, J., Mahaffey, K. W., Gibson, C. M., Steg, P. G., Stone, G. W., Bhatt, D. L.
2021
- **Ankle-Brachial Index for Risk Stratification in Patients With Symptomatic Peripheral Artery Disease With and Without Prior Lower Extremity Revascularization: Observations From the EUCLID Trial.** *Circulation. Cardiovascular interventions*
Hiatt, W. R., Hess, C. N., Bonaca, M. P., Kavanagh, S., Patel, M. R., Baumgartner, I., Berger, J. S., Blomster, J. I., Jones, W. S., Katona, B. G., Mahaffey, K. W., Norgren, L., Rockhold, et al
2021: CIRCINTERVENTIONS120009871
- **Assessment of North American Clinical Research Site Performance During the Start-up of Large Cardiovascular Clinical Trials.** *JAMA network open*
Goyal, A., Schibler, T., Alhanti, B., Hannan, K. L., Granger, C. B., Blazing, M. A., Lopes, R. D., Alexander, J. H., Peterson, E. D., Rao, S. V., Green, J. B., Roe, M. T., Rorick, et al
2021; 4 (7): e2117963
- **Canagliflozin, serum magnesium and cardiovascular outcomes-Analysis from the CANVAS Program.** *Endocrinology, diabetes & metabolism*
Wang, K. M., Li, J., Bhalla, V., Jardine, M. J., Neal, B., de Zeeuw, D., Fulcher, G., Perkovic, V., Mahaffey, K. W., Chang, T. I.
2021; 4 (3): e00247

- **Impact of chronic kidney disease on hemoglobin among patients with peripheral artery disease treated with P2Y12 inhibitors: Insights from the EUCLID trial.** *Vascular medicine (London, England)*
Hsia, J., Kavanagh, S. T., Hopley, C. W., Baumgartner, I., Berger, J. S., Fowkes, G. R., Jones, W. S., Mahaffey, K. W., Norgren, L., Patel, M. R., Rockhold, F., Blomster, J., Katona, et al
2021: 1358863X211017641
- **Pharmacotherapy for diabetes and stroke risk: Results from ROCKET AF.** *Heart rhythm O2*
Ugowe, F. E., Hellkamp, A. S., Wang, A., Becker, R. C., Berkowitz, S. D., Breithardt, G., Fox, K. A., Halperin, J. L., Hankey, G. J., Mahaffey, K. W., Nessel, C. C., Singer, D. E., Patel, et al
2021; 2 (3): 215-222
- **Association of Heart Failure With Outcomes Among Patients With Peripheral Artery Disease: Insights From EUCLID.** *Journal of the American Heart Association*
Samsky, M. D., Hellkamp, A., Hiatt, W. R., Fowkes, F. G., Baumgartner, I., Berger, J. S., Katona, B. G., Mahaffey, K. W., Norgren, L., Blomster, J. I., Rockhold, F. W., DeVore, A. D., Patel, et al
2021: e018684
- **EFFECTS OF CANAGLIFLOZIN ON MAJOR ADVERSE CARDIOVASCULAR EVENTS BY BASELINE ALBUMINURIA: INTEGRATED ANALYSIS FROM THE CANVAS PROGRAM AND CREDENCE TRIAL**
Wheeler, D. C., Weir, M., Gogate, J., Perkovic, V., Mahaffey, K. W.
OXFORD UNIV PRESS.2021
- **Effect of SGLT2 Inhibitors on Stroke and Atrial Fibrillation in Diabetic Kidney Disease: Results From the CREDENCE Trial and Meta-Analysis.** *Stroke*
Zhou, Z., Jardine, M. J., Li, Q., Neuen, B. L., Cannon, C. P., de Zeeuw, D., Edwards, R., Levin, A., Mahaffey, K. W., Perkovic, V., Neal, B., Lindley, R. I., CREDENCE Trial Investigators, et al
2021: STROKEAHA120031623
- **Effects of canagliflozin on myocardial infarction: a post hoc analysis of the CANVAS Program and CREDENCE trial.** *Cardiovascular research*
Yu, J., Li, J., Leaver, P. J., Arnott, C., Huffman, M. D., Udell, J. A., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Matthews, D. R., Shaw, W., Rosenthal, et al
2021
- **Dosing of Direct Oral Anticoagulants in Patients with Moderate Chronic Kidney Disease in US Clinical Practice: Results from the Outcomes Registry for Better Informed Treatment of AF (ORBIT-AF II).** *American journal of cardiovascular drugs : drugs, devices, and other interventions*
Jackson, L. R., Schrader, P., Thomas, L., Steinberg, B. A., Blanco, R., Allen, L. A., Fonarow, G. C., Freeman, J. V., Gersh, B. J., Kowey, P. R., Mahaffey, K. W., Naccarelli, G., Reiffel, et al
2021
- **The Effects of Canagliflozin on Heart Failure and Cardiovascular Death by Baseline Participant Characteristics: Analysis of the CREDENCE Trial.** *Diabetes, obesity & metabolism*
Arnott, C., Li, J., Cannon, C. P., de Zeeuw, D., Neuen, B. L., Heerspink, H. J., Charytan, D. M., Agarwal, A., Huffman, M. D., Figtree, G. A., Bakris, G., Chang, T. I., Feng, et al
2021
- **Canagliflozin Reduces All-cause Hospitalization in Patients with Type 2 Diabetes Mellitus**
Feng, K. Y., Gogate, J., Damaraju, C. V., Li, J., Jardine, M. J., Perkovic, V., Blais, J. D., Pfeifer, M., Neal, B., Mahaffey, K. W.
W B SAUNDERS CO-ELSEVIER INC.2021: 17-18
- **Kidney, Cardiovascular, and Safety Outcomes of Canagliflozin according to Baseline Albuminuria: A CREDENCE Secondary Analysis.** *Clinical journal of the American Society of Nephrology : CJASN*
Jardine, M., Zhou, Z., Lambers Heerspink, H. J., Hockham, C., Li, Q., Agarwal, R., Bakris, G. L., Cannon, C. P., Charytan, D. M., Greene, T., Levin, A., Li, J., Neuen, et al
2021
- **Cardiovascular and renal outcomes with canagliflozin according to baseline diuretic use: a post hoc analysis from the CANVAS Program.** *ESC heart failure*
Yu, J., Arnott, C., Neuen, B. L., Heerspink, H. L., Mahaffey, K. W., Cannon, C. P., Khan, S. S., Baldridge, A. S., Shah, S. J., Huang, Y., Li, C., Figtree, G. A., Perkovic, et al
2021

- **The ARREST Pneumonia (Arrest Respiratory Failure due to Pneumonia) Trial: Rationale and Design.** *Annals of the American Thoracic Society*
Levitt, J. E., Festic, E., Desai, M., Hedlin, H., Mahaffey, K. W., Rogers, A. J., Gajic, O., Matthay, M. A., ARREST Pneumonia Clinical Trial Investigators
2021
- **Efficacy of a Centralized, Blended Electronic and Human Intervention to Improve Direct Oral Anticoagulant Adherence: Smartphones to improve rivaroxaban ADHEREncE in Atrial Fibrillation (SmartADHERE) A Randomized Clinical Trial: SmartADHERE rivaroxaban adherence trial.** *American heart journal*
Turakhia, M. n., Sundaram, V. n., Smith, S. N., Ding, V. n., Michael Ho, P. n., Kowey, P. R., Piccini, J. P., Foody, J. n., Birmingham, M. n., Ianus, J. n., Rajmane, A. n., Mahaffey, K. W.
2021
- **Milvexian for the Prevention of Venous Thromboembolism.** *The New England journal of medicine*
Weitz, J. I., Strony, J., Ageno, W., Gailani, D., Hylek, E. M., Lassen, M. R., Mahaffey, K. W., Notani, R. S., Roberts, R., Segers, A., Raskob, G. E.
2021
- **Return of individual research results: What do participants prefer and expect?** *PloS one*
Sayeed, S., Califf, R., Green, R., Wong, C., Mahaffey, K., Gambhir, S. S., Mega, J., Patrick-Lake, B., Frazier, K., Pignone, M., Hernandez, A., Shah, S. H., Fan, et al
2021; 16 (7): e0254153
- **Arrhythmias Other Than Atrial Fibrillation in Those With an Irregular Pulse Detected With a Smartwatch: Findings From the Apple Heart Study.** *Circulation. Arrhythmia and electrophysiology*
Perino, A. C., Gummidipundi, S. E., Lee, J., Hedlin, H., Garcia, A., Ferris, T., Balasubramanian, V., Gardner, R. M., Cheung, L., Hung, G., Granger, C. B., Kowey, P., Rumsfeld, et al
2021: CIRCEP121010063
- **Why digital health trials can fail: Lessons learned from a randomized trial of health coaching and virtual cardiac rehabilitation.** *Cardiovascular digital health journal*
Olivier, C. B., Middleton, S. K., Purington, N., Shashidhar, S., Hereford, J., Mahaffey, K. W., Turakhia, M. P.
2021; 2 (2): 101-108
- **Association of Chronic Obstructive Pulmonary Disease with Morbidity and Mortality in Patients with Peripheral Artery Disease: Insights from the EUCLID Trial.** *International journal of chronic obstructive pulmonary disease*
Galani, J., Mulder, H., Rockhold, F. W., Weissler, E. H., Baumgartner, I., Berger, J. S., Blomster, J. I., Fowkes, F. G., Hiatt, W. R., Katona, B. G., Norgren, L., Mahaffey, K. W., Quint, et al
2021; 16: 841–51
- **Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease: Insights from the CREDENCE Trial.** *Circulation*
Ye, N. n., Jardine, M. J., Oshima, M. n., Hockham, C. n., Heerspink, H. J., Agarwal, R. n., Bakris, G. n., Schutte, A. E., Arnott, C. n., Chang, T. I., Górriz, J. L., Cannon, C. P., Charytan, et al
2021
- **Rivaroxaban versus Warfarin in Patients with Atrial Fibrillation Enrolled in Latin America: Insights from ROCKET AF.** *American heart journal*
Blumer, V. n., Rivera, M. n., Corbalán, R. n., Becker, R. C., Berkowitz, S. D., Breithardt, G. n., Hacke, W. n., Halperin, J. L., Hankey, G. J., Mahaffey, K. W., Nessel, C. C., Piccini, J. P., Hellkamp, et al
2021
- **Effects of Canagliflozin on Cardiovascular, Renal, and Safety Outcomes in Participants With Type 2 Diabetes and Chronic Kidney Disease According to History of Heart Failure: Results From the CREDENCE Trial.** *American heart journal*
Sarraj, A., Li, J., Cannon, C. P., Chang, T. I., Agarwal, R., Bakris, G., Charytan, D. M., de Zeeuw, D., Greene, T., Heerspink, H. J., Levin, A., Neal, B., Pollock, et al
2020
- **Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice.** *Kidney international*
Oshima, M., Jardine, M. J., Agarwal, R., Bakris, G., Cannon, C. P., Charytan, D. M., de Zeeuw, D., Edwards, R., Greene, T., Levin, A., Lim, S. K., Mahaffey, K. W., Neal, et al
2020

- **Cause of Death Among Patients With Peripheral Artery Disease: Insights From the EUCLID Trial.** *Circulation. Cardiovascular quality and outcomes*
Kochar, A., Mulder, H., Rockhold, F. W., Baumgartner, I., Berger, J. S., Blomster, J. I., Fowkes, F. G., Katona, B. G., Lopes, R. D., Al-Khalidi, H. R., Mahaffey, K. W., Norgren, L., Hiatt, et al
2020: CIRCOUTCOMES120006550
- **Insulin-Like Growth Factor Binding Protein 7 Predicts Renal and Cardiovascular Outcomes in the Canagliflozin Cardiovascular Assessment Study.** *Diabetes care*
Januzzi, J. L., Butler, J., Sattar, N., Xu, J., Shaw, W., Rosenthal, N., Pfeifer, M., Mahaffey, K. W., Neal, B., Hansen, M. K.
2020
- **Effects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis from the CREDESCENCE trial.** *The lancet. Diabetes & endocrinology*
Oshima, M., Neuen, B. L., Jardine, M. J., Bakris, G., Edwards, R., Levin, A., Mahaffey, K. W., Neal, B., Pollock, C., Rosenthal, N., Wada, T., Wheeler, D. C., Perkovic, et al
2020; 8 (11): 903–14
- **Effects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis from the CREDESCENCE trial** *LANCET DIABETES & ENDOCRINOLOGY*
Oshima, M., Neuen, B. L., Jardine, M. J., Bakris, G., Edwards, R., Levin, A., Mahaffey, K. W., Neal, B., Pollock, C., Rosenthal, N., Wada, T., Wheeler, D. C., Perkovic, et al
2020; 8 (11): 903–14
- **International consensus definitions of clinical trial outcomes for kidney failure: 2020.** *Kidney international*
Levin, A., Agarwal, R., Herrington, W. G., Heerspink, H. L., Mann, J. F., Shahinfar, S., Tuttle, K. R., Donner, J., Jha, V., Nangaku, M., de Zeeuw, D., Jardine, M. J., Mahaffey, et al
2020; 98 (4): 849–59
- **Appropriateness of Direct Oral Anticoagulant Dosing in Patients With Atrial Fibrillation: Insights From the Veterans Health Administration** *JOURNAL OF PHARMACY PRACTICE*
Leef, G. C., Perino, A. C., Askari, M., Fan, J., Ho, P., Olivier, C. B., Longo, L., Mahaffey, K. W., Turakhia, M. P.
2020; 33 (5): 647–53
- **Early Change in Albuminuria with Canagliflozin Predicts Kidney and Cardiovascular Outcomes: A PostHoc Analysis from the CREDESCENCE Trial.** *Journal of the American Society of Nephrology : JASN*
Oshima, M., Neuen, B. L., Li, J., Perkovic, V., Charytan, D. M., de Zeeuw, D., Edwards, R., Greene, T., Levin, A., Mahaffey, K. W., De Nicola, L., Pollock, C., Rosenthal, et al
2020
- **An exploration of the heterogeneity in effects of SGLT2 inhibition on cardiovascular and all-cause mortality in the EMPA-REG OUTCOME, CANVAS Program, DECLARE-TIMI 58, and CREDESCENCE trials.** *International journal of cardiology*
Yu, J., Zhou, Z., Mahaffey, K. W., Matthews, D. R., Neuen, B. L., Heerspink, H. J., Jardine, M., Li, J., Perkovic, V., Neal, B., Arnott, C.
2020
- **Association of Health Status Scores With Cardiovascular and Limb Outcomes in Patients With Symptomatic Peripheral Artery Disease: Insights From the EUCLID (Examining Use of Ticagrelor in Symptomatic Peripheral Artery Disease) Trial.** *Journal of the American Heart Association*
Rymer, J. A., Mulder, H., Smolderen, K. G., Hiatt, W. R., Conte, M. S., Berger, J. S., Norgren, L., Mahaffey, K. W., Baumgartner, I., Fowkes, F. G., Katona, B. G., Rockhold, F., Jones, et al
2020: e016573
- **2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants A Report of the American College of Cardiology Solution Set Oversight Committee** *JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY*
Tomaselli, G. F., Mahaffey, K. W., Cuker, A., Dobesh, P. P., Doherty, J. U., Eikelboom, J. W., Florido, R., Gluckman, T. J., Hucker, W. J., Mehran, R., Messe, S. R., Perino, A. C., Rodriguez, et al
2020; 76 (5): 594–622
- **Different eGFR Decline Thresholds and Renal Effects of Canagliflozin: Data from the CANVAS Program.** *Journal of the American Society of Nephrology : JASN*
Oshima, M., Neal, B., Toyama, T., Ohkuma, T., Li, Q., de Zeeuw, D., Heerspink, H. J., Mahaffey, K. W., Fulcher, G., Canovatchel, W., Matthews, D. R., Perkovic, V.
2020

- **Effects of canagliflozin on initiation of insulin and other antihyperglycaemic agents in the CANVAS Program.** *Diabetes, obesity & metabolism*
Matthews, D. R., Wysham, C., Davies, M., Slee, A., Alba, M., Lee, M., Perkovic, V., Mahaffey, K. W., Neal, B.
2020
- **A Call for a New Paradigm for Diabetes Care in the Era of Sodium-Glucose Cotransporter2 Inhibitors (SGLT2i).** *Cardiology and therapy*
Kim, S. H., Chang, T. I., Mahaffey, K. W.
2020
- **Effect of Temporary Interruption of Warfarin Due to an Intervention on Downstream Time in Therapeutic Range in Patients With Atrial Fibrillation (from ORBIT AF).** *The American journal of cardiology*
Madhavan, M., Holmes, D. N., Piccini, J. P., Freeman, J. V., Fonarow, G. C., Hylek, E. M., Kowey, P. R., Mahaffey, K. W., Pieper, K., Peterson, E. D., Chan, P. S., Allen, L. A., Singer, et al
2020
- **Patterns of oral anticoagulation use with cardioversion in clinical practice.** *Heart (British Cardiac Society)*
Geurink, K., Holmes, D., Ezekowitz, M. D., Pieper, K., Fonarow, G., Kowey, P. R., Reiffel, J. A., Singer, D. E., Freeman, J., Gersh, B. J., Mahaffey, K. W., Hylek, E. M., Naccarelli, et al
2020
- **The effects of combination canagliflozin and glucagon-like peptide-1 receptor agonist therapy on intermediate markers of cardiovascular risk in the CANVAS program.** *International journal of cardiology*
Arnott, C., Neuen, B. L., Heerspink, H. J., Figtree, G. A., Kosiborod, M., Lam, C. S., Cannon, C. P., Rosenthal, N., Shaw, W., Mahaffey, K. W., Jardine, M. J., Perkovic, V., Neal, et al
2020
- **The Project Baseline Health Study: a step towards a broader mission to map human health** *NPJ DIGITAL MEDICINE*
Arges, K., Assimes, T., Bajaj, V., Balu, S., Bashir, M. R., Beskow, L., Blanco, R., Califf, R., Campbell, P., Carin, L., Christian, V., Cousins, S., Das, et al
2020; 3 (1): 84
- **The Project Baseline Health Study: a step towards a broader mission to map human health.** *NPJ digital medicine*
Arges, K., Assimes, T., Bajaj, V., Balu, S., Bashir, M. R., Beskow, L., Blanco, R., Califf, R., Campbell, P., Carin, L., Christian, V., Cousins, S., Das, et al
2020; 3 (1): 84
- **CANAGLIFLOZIN AND RISK OF GENITAL INFECTIONS AND URINARY TRACT INFECTIONS IN PEOPLE WITH DIABETES MELLITUS AND KIDNEY DISEASE- A POST-HOC ANALYSIS OF THE CREDENCE TRIAL**
Kang, A., Neuen, B., Heerspink, H., Di Tanna, G., Neal, B., Zhang, H., Hockham, C., Agarwal, R., Bakris, G., Charytan, D. M., De Zeeuw, D., Greene, T., Levin, et al
OXFORD UNIV PRESS.2020: 1336
- **EFFECTS OF CANAGLIFLOZIN ON MAJOR ADVERSE CARDIOVASCULAR OUTCOMES IN PATIENTS WITH DIFFERENT BASELINE LEVELS OF TYPE 2 DIABETES MELLITUS DISEASE SEVERITY: RESULTS FROM THE CANVAS PROGRAM**
Young, T., Li, J., Kang, A., Heerspink, H., Hockham, C., Arnott, C., Neuen, B., Zoungas, S., Mahaffey, K. W., Perkovic, V., De Zeeuw, D., Fulcher, G., Neal, et al
OXFORD UNIV PRESS.2020: 1351
- **CANAGLIFLOZIN AND RISK OF SKIN AND SOFT TISSUE INFECTIONS IN PEOPLE WITH DIABETES MELLITUS AND KIDNEY DISEASE - A POST-HOC ANALYSIS OF THE CREDENCE TRIAL**
Kang, A., Smyth, B., Neuen, B., Heerspink, H., Di Tanna, G., Neal, B., Zhang, H., Hockham, C., Agarwal, R., Bakris, G., Charytan, D. M., De Zeeuw, D., Greene, et al
OXFORD UNIV PRESS.2020: 1342
- **The effect of canagliflozin on amputation risk in the CANVAS Program and the CREDENCE trial.** *Diabetes, obesity & metabolism*
Arnott, C., Huang, Y., Neuen, B., Di Tanna, G. L., Cannon, C. P., Oh, R., Edwards, R., Kavalam, M., Rosenthal, N., Perkovic, V., Jardine, M., Mahaffey, K., Neal, et al
2020
- **Shared Decision Making in Atrial Fibrillation: Patient-Reported Involvement in Treatment Decisions.** *European heart journal. Quality of care & clinical outcomes*
Ali-Ahmed, F., Pieper, K., North, R., Allen, L. A., Chan, P. S., Ezekowitz, M. D., Fonarow, G. C., Freeman, J. V., Go, A. S., Gersh, B. J., Kowey, P. R., Mahaffey, K. W., Naccarelli, et al

2020

- **Outpatient Inhaled Nitric Oxide in a Patient with Vasoreactive IPAH and COVID-19 Infection.** *American journal of respiratory and critical care medicine*
Zamanian, R. T., Pollack, C. V., Gentile, M. A., Rashid, M., Fox, J. C., Mahaffey, K. W., de Jesus Perez, V.
2020
- **Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDESCENCE Randomized Trial.** *Journal of the American Society of Nephrology : JASN*
Jardine, M. J., Zhou, Z., Mahaffey, K. W., Oshima, M., Agarwal, R., Bakris, G., Bajaj, H. S., Bull, S., Cannon, C. P., Charytan, D. M., de Zeeuw, D., Di Tanna, G. L., Greene, et al
2020; 31 (5): 1128–39
- **Outcomes of Cardiac Catheterization in Patients With Atrial Fibrillation on Anticoagulation in Contemporary in Practice: An Analysis of the ORBIT II Registry.** *Circulation. Cardiovascular interventions*
Sherwood, M. W., Piccini, J. P., Holmes, D. N., Pieper, K. S., Steinberg, B. A., Fonarow, G. C., Allen, L. A., Naccarelli, G. V., Kowey, P. R., Gersh, B. J., Mahaffey, K. W., Singer, D. E., Ansell, et al
2020; 13 (5): e008274
- **Preventing Atrial Fibrillation With Treatments for Diabetes Mellitus.** *Circulation*
Granger, C. B., Mahaffey, K. W.
2020; 141 (15): 1235–37
- **Methods for safety and endpoint ascertainment: identification of adverse events through scrutiny of negatively adjudicated events.** *Trials*
Fanaroff, A. C., Haque, G., Thomas, B., Stone, A. E., Perkins, L. M., Wilson, M., Jones, W. S., Melloni, C., Mahaffey, K. W., Alexander, K. P., Lopes, R. D.
2020; 21 (1): 323
- **CANAGLIFLOZIN (CANA) REDUCES CARDIOVASCULAR (CV) AND RENAL EVENTS INDEPENDENT OF BASELINE HEART FAILURE (HF): A CREDESCENCE SECONDARY ANALYSIS**
Sarraj, A., Li, J., Cannon, C. P., Chang, T. I., Agarwal, R., Bakris, G. L., Charytan, D. M., de Zeeuw, D., Greene, T., Heerspink, H. J. L., Levin, A., Neal, B., Pollock, et al
ELSEVIER SCIENCE INC.2020: 1018
- **Cangrelor in clinical use.** *Future cardiology*
Feng, K. Y., Mahaffey, K. W.
2020
- **Risk of major cardiovascular and neurologic events with obstructive sleep apnea among patients with atrial fibrillation.** *American heart journal*
Dalgaard, F., North, R., Pieper, K., Fonarow, G. C., Kowey, P. R., Gersh, B. J., Mahaffey, K. W., Pokorney, S., Steinberg, B. A., Naccarelli, G., Allen, L. A., Reiffel, J. A., Ezekowitz, et al
2020; 223: 65–71
- **Decline in renal function and oral anticoagulation dose reduction among patients with atrial fibrillation.** *Heart (British Cardiac Society)*
Inohara, T., Holmes, D. N., Pieper, K., Blanco, R. G., Allen, L. A., Fonarow, G. C., Gersh, B. J., Hylek, E. M., Ezekowitz, M. D., Kowey, P. R., Reiffel, J. A., Naccarelli, G. V., Chan, et al
2020
- **Mediators of the effects of canagliflozin on kidney protection in patients with type 2 diabetes.** *Kidney international*
Li, J. n., Neal, B. n., Perkovic, V. n., de Zeeuw, D. n., Neuen, B. L., Arnott, C. n., Simpson, R. n., Oh, R. n., Mahaffey, K. W., Heerspink, H. J.
2020
- **Dedicated kidney disease-focused outcome trials with sodium-glucose cotransporter-2 inhibitors: Lessons from CREDESCENCE and expectations from DAPA-HF, DAPA-CKD, and EMPA-KIDNEY.** *Diabetes, obesity & metabolism*
Rhee, J. J., Jardine, M. J., Chertow, G. M., Mahaffey, K. W.
2020; 22 Suppl 1: 46–54
- **Incremental value of diastolic stress test in identifying subclinical heart failure in patients with diabetes mellitus.** *European heart journal cardiovascular imaging*
Nishi, T. n., Kobayashi, Y. n., Christle, J. W., Cauwenberghs, N. n., Boralkar, K. n., Moneghetti, K. n., Amsallem, M. n., Hedman, K. n., Contrepolis, K. n., Myers, J. n., Mahaffey, K. W., Schnittger, I. n., Kuznetsova, et al

2020

- **Canagliflozin and cardiovascular outcomes in Type 2 diabetes.** *Future cardiology*
Sarraju, A. n., Spencer-Bonilla, G. n., Rodriguez, F. n., Mahaffey, K. W.
2020
- **Association of Hypertension and Arterial Blood Pressure on Limb and Cardiovascular Outcomes in Symptomatic Peripheral Artery Disease: The EUCLID Trial.** *Circulation. Cardiovascular quality and outcomes*
Fudim, M. n., Hopley, C. W., Huang, Z. n., Kavanagh, S. n., Rockhold, F. W., Baumgartner, I. n., Berger, J. S., Blomster, J. I., Fowkes, F. G., Katona, B. G., Mahaffey, K. W., Norgren, L. n., Ostrom, et al
2020: CIRCOUTCOMES120006512
- **CYP2C19 status and risk of major adverse cardiovascular events in peripheral artery disease: Insights from the EUCLID Trial.** *American heart journal*
Gutierrez, J. A., Heizer, G. M., Jones, W. S., Rockhold, F. W., Mahaffey, K. W., Fowkes, F. G., Berger, J. S., Baumgartner, I. n., Held, P. n., Katona, B. G., Norgren, L. n., Blomster, J. I., Hiatt, et al
2020; 229: 118–20
- **Association of Disease Progression With Cardiovascular and Limb Outcomes in Patients With Peripheral Artery Disease: Insights From the EUCLID Trial.** *Circulation. Cardiovascular interventions*
Rymer, J. A., Mulder, H. n., Narcisse, D. I., Rockhold, F. n., Hiatt, W. R., Fowkes, F. G., Baumgartner, I. n., Berger, J. S., Katona, B. G., Mahaffey, K. n., Norgren, L. n., Blomster, J. I., Jones, et al
2020: CIRCINTERVENTIONS120009326
- **SGLT2 inhibitors with and without metformin: a meta-analysis of cardiovascular, kidney and mortality outcomes.** *Diabetes, obesity & metabolism*
Neuen, B. L., Arnott, C. n., Perkovic, V. n., Figtree, G. n., de Zeeuw, D. n., Fulcher, G. n., Jun, M. n., Jardine, M. J., Zoungas, S. n., Pollock, C. n., Mahaffey, K. W., Neal, B. n., Heerspink, et al
2020
- **Factors Associated with Large Improvements in Health-Related Quality of Life in Patients with Atrial Fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF).** *Circulation. Arrhythmia and electrophysiology*
Steinberg, B. A., Holmes, D. N., Pieper, K. n., Allen, L. A., Chan, P. S., Ezekowitz, M. D., Freeman, J. V., Fonarow, G. C., Gersh, B. J., Hylek, E. M., Kowey, P. R., Mahaffey, K. W., Naccarelli, et al
2020
- **Cost-Effectiveness of Alirocumab in Patients With Acute Coronary Syndromes: The ODYSSEY OUTCOMES Trial.** *Journal of the American College of Cardiology*
Bhatt, D. L., Briggs, A. H., Reed, S. D., Annemans, L. n., Szarek, M. n., Bittner, V. A., Diaz, R. n., Goodman, S. G., Harrington, R. A., Higuchi, K. n., Joulain, F. n., Jukema, J. W., Li, et al
2020; 75 (18): 2297–2308
- **Discontinuation rates of warfarin versus direct acting oral anticoagulants in US clinical practice: Results from Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II).** *American heart journal*
Jackson, L. R., Kim, S. n., Blanco, R. n., Thomas, L. n., Ansell, J. n., Fonarow, G. C., Gersh, B. J., Go, A. S., Kowey, P. R., Mahaffey, K. W., Hylek, E. M., Peterson, E. D., Piccini, et al
2020; 226: 85–93
- **Sex-Specific Risks of Major Cardiovascular and Limb Events in Patients With Symptomatic Peripheral Artery Disease.** *Journal of the American College of Cardiology*
Haine, A. n., Kavanagh, S. n., Berger, J. S., Hess, C. N., Norgren, L. n., Fowkes, F. G., Katona, B. G., Mahaffey, K. W., Blomster, J. I., Patel, M. R., Jones, W. S., Rockhold, F. W., Hiatt, et al
2020; 75 (6): 608–17
- **Effects of Canagliflozin on Amino-Terminal Pro-B-Type Natriuretic Peptide: Implications for Cardiovascular Risk Reduction.** *Journal of the American College of Cardiology*
Januzzi, J. L., Xu, J. n., Li, J. n., Shaw, W. n., Oh, R. n., Pfeifer, M. n., Butler, J. n., Sattar, N. n., Mahaffey, K. W., Neal, B. n., Hansen, M. K.
2020; 76 (18): 2076–85
- **Incidence and Factors Associated With Major Amputation in Patients With Peripheral Artery Disease: Insights From the EUCLID Trial.** *Circulation. Cardiovascular quality and outcomes*
Long, C. A., Mulder, H. n., Fowkes, F. G., Baumgartner, I. n., Berger, J. S., Katona, B. G., Mahaffey, K. W., Norgren, L. n., Blomster, J. I., Rockhold, F. W., Hiatt, W. R., Patel, M. R., Jones, et al

2020: CIRCOUTCOMES119006399

- **Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m²: Subgroup Analysis of the Randomized CREDENCE Trial.** *Clinical journal of the American Society of Nephrology : CJASN*
Bakris, G. n., Oshima, M. n., Mahaffey, K. W., Agarwal, R. n., Cannon, C. P., Capuano, G. n., Charytan, D. M., de Zeeuw, D. n., Edwards, R. n., Greene, T. n., Heerspink, H. J., Levin, A. n., Neal, et al
2020
- **Relative and Absolute Risk Reductions in Cardiovascular and Kidney Outcomes With Canagliflozin Across KDIGO Risk Categories: Findings From the CANVAS Program.** *American journal of kidney diseases : the official journal of the National Kidney Foundation*
Neuen, B. L., Ohkuma, T. n., Neal, B. n., Matthews, D. R., de Zeeuw, D. n., Mahaffey, K. W., Fulcher, G. n., Blais, J. n., Li MBiostat, Q. n., Jardine, M. J., Perkovic, V. n., Wheeler, D. C.
2020
- **Diabetes and heart failure post-acute myocardial infarction: Important associations and need for evidence-based interventions.** *European journal of preventive cardiology*
Parizo, J. n., Mahaffey, K. W.
2020: 2047487320904232
- **Post-Discharge Bleeding and Mortality Following Acute Coronary Syndromes With or Without PCI.** *Journal of the American College of Cardiology*
Marquis-Gravel, G. n., Dalgaard, F. n., Jones, A. D., Lokhnygina, Y. n., James, S. K., Harrington, R. A., Wallentin, L. n., Steg, P. G., Lopes, R. D., Storey, R. F., Goodman, S. G., Mahaffey, K. W., Tricoci, et al
2020; 76 (2): 162–71
- **Sodium-Glucose Cotransporter 2 Inhibition for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis.** *Journal of the American Heart Association*
Arnott, C. n., Li, Q. n., Kang, A. n., Neuen, B. L., Bompont, S. n., Lam, C. S., Rodgers, A. n., Mahaffey, K. W., Cannon, C. P., Perkovic, V. n., Jardine, M. J., Neal, B. n.
2020; 9 (3): e014908
- **Apixaban versus Warfarin for Stroke Prevention in Patients With End Stage Renal Disease on Hemodialysis and Atrial Fibrillation: Results of a Randomized Clinical Trial Assessing Safety**
Pokorney, S. D., Chertow, G. M., Al-Khalidi, H., Gallup, D., Dignacco, P., Mussina, K., Bansal, N., Gadegbeku, C. A., Garcia, D., Jones-Burton, C., Lopes, R. D., Mahaffey, K. W., Middleton, et al
LIPPINCOTT WILLIAMS & WILKINS.2019: E988–E989
- **Amino-Terminal Pro-B Type Natriuretic Peptide in the Canagliflozin Cardiovascular Assessment Study (CANVAS) Program**
Januzzi, J. L., Xu, J., Shaw, W., Oh, R., Ranadive, G., Butler, J., Sattar, N., Mahaffey, K., Neal, B., Hansen, M. K.
LIPPINCOTT WILLIAMS & WILKINS.2019: E996
- **Apple Watch App Identifies Clinically Important Arrhythmias Other Than Atrial Fibrillation: Results From the Apple Heart Study**
Perez, M. V., Mahaffey, K., Hedlin, H., Rumsfeld, J. S., Garcia, A., Ferris, T., Balasubramanian, V., Russo, A. M., Rajmane, A., Cheung, L., Hung, G., Lee, J., Kowey, et al
LIPPINCOTT WILLIAMS & WILKINS.2019: E988
- **The effects of canagliflozin on gout in type 2 diabetes: a post-hoc analysis of the CANVAS Program** *LANCET RHEUMATOLOGY*
Li, J., Badve, S., Zhou, Z., Rodgers, A., Day, R., Oh, R., Lee, M., Perkovic, V., de Zeeuw, D., Mahaffey, K. W., Futcher, G., Matthews, D. R., Neal, et al
2019; 1 (4): E220–E228
- **The effects of canagliflozin on gout in type 2 diabetes: a post-hoc analysis of the CANVAS Program.** *The Lancet. Rheumatology*
Li, J., Badve, S. V., Zhou, Z., Rodgers, A., Day, R., Oh, R., Lee, M., Perkovic, V., de Zeeuw, D., Mahaffey, K. W., Fulcher, G., Matthews, D. R., Neal, et al
2019; 1 (4): e220-e228
- **Outcomes and Anticoagulation Use After Catheter Ablation for Atrial Fibrillation.** *Circulation. Arrhythmia and electrophysiology*
Freeman, J. V., Shrader, P., Pieper, K. S., Allen, L. A., Chan, P. S., Fonarow, G. C., Gersh, B. J., Kowey, P. R., Mahaffey, K. W., Naccarelli, G., Reiffel, J. A., Singer, D. E., Go, et al
2019; 12 (12): e007612

- **A double-blind, randomized, placebo-controlled pilot trial to evaluate safety and efficacy of vorapaxar on arteriovenous fistula maturation.** *The journal of vascular access*
Olivier, C. B., Sundaram, V., Chertow, G. M., Shashidhar, S., McDonnell, L. K., Ding, V. Y., Desai, M., Mahaffey, K. W., Mell, M.
2019: 1129729819887269
- **Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients with Type 2 Diabetes and Chronic Kidney Disease According to Baseline HbA1c, Including Those with HbA1c <7%: Results From the CREDENCE Trial.** *Circulation*
Cannon, C. P., Perkovic, V., Agarwal, R., Baldassarre, J., Bakris, G., Charytan, D. M., de Zeeuw, D., Edwards, R., Greene, T., Heerspink, H. J., Jardine, M. J., Levin, A., Li, et al
2019
- **Guideline-directed therapies for comorbidities and clinical outcomes among individuals with atrial fibrillation.** *American heart journal*
Loring, Z., Shrader, P., Allen, L. A., Blanco, R., Chan, P. S., Ezekowitz, M. D., Fonarow, G. C., Freeman, J. V., Gersh, B. J., Mahaffey, K. W., Naccarelli, G. V., Pieper, K., Reiffel, et al
2019; 219: 21–30
- **Mediators of the Effects of Canagliflozin on Heart Failure in Patients With Type 2 Diabetes.** *JACC. Heart failure*
Li, J., Woodward, M., Perkovic, V., Figtree, G. A., Heerspink, H. J., Mahaffey, K. W., de Zeeuw, D., Vercruyse, F., Shaw, W., Matthews, D. R., Neal, B.
2019
- **Patterns of amiodarone use and outcomes in clinical practice for atrial fibrillation.** *American heart journal*
Pokorney, S. D., Holmes, D. N., Shrader, P., Thomas, L., Fonarow, G. C., Mahaffey, K. W., Gersh, B. J., Kowey, P. R., Naccarelli, G. V., Freeman, J. V., Singer, D. E., Washam, J. B., Peterson, et al
2019; 220: 145–54
- **The Association of Health-Related Quality-of-Life Scores With Cardiovascular and Limb Outcomes in Patients With Symptomatic Peripheral Artery Disease: Insights From the EUCLID Trial**
Rymer, J., Mulder, H., Smolderen, K., Hiatt, W., Conte, M., Berger, J., Katona, B., Norgren, L., Mahaffey, K., Rockhold, F., Fowkes, F., Jones, S., Patel, et al
ELSEVIER SCIENCE INC.2019: B547
- **Effect of Canagliflozin on Renal and Cardiovascular Outcomes across Different Levels of Albuminuria: Data from the CANVAS Program.** *Journal of the American Society of Nephrology : JASN*
Neuen, B. L., Ohkuma, T., Neal, B., Matthews, D. R., de Zeeuw, D., Mahaffey, K. W., Fulcher, G., Li, Q., Jardine, M., Oh, R., Heerspink, H. L., Perkovic, V.
2019
- **Open versus Endovascular Repair of Abdominal Aortic Aneurysm REPLY** *NEW ENGLAND JOURNAL OF MEDICINE*
Jardine, M. J., Mahaffey, K. W., Perkovic, V.
2019; 381 (11): 1089–90
- **SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis.** *The lancet. Diabetes & endocrinology*
Neuen, B. L., Young, T., Heerspink, H. J., Neal, B., Perkovic, V., Billot, L., Mahaffey, K. W., Charytan, D. M., Wheeler, D. C., Arnott, C., Bompont, S., Levin, A., Jardine, et al
2019
- **Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome ODYSSEY OUTCOMES Trial** *JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY*
Jukema, J., Szarek, M., Zijlstra, L. E., de Silva, H., Bhatt, D. L., Bittner, V. A., Diaz, R., Edelberg, J. M., Goodman, S. G., Hanotin, C., Harrington, R. A., Karpov, Y., Moryusef, et al
2019; 74 (9): 1167–76
- **Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes.** *Circulation*
Roe, M. T., Li, Q. H., Bhatt, D. L., Bittner, V. A., Diaz, R., Goodman, S. G., Harrington, R. A., Jukema, J. W., Lopez-Jaramillo, P., Lopes, R. D., Louie, M. J., Moriarty, P. M., Szarek, et al
2019
- **Cardiovascular Risk Factors and Secondary Events Among Acute and Chronic Stable Myocardial Infarction Patients: Findings from a Managed Care Database.** *Cardiology and therapy*

Bash, L. D., White, K., Patel, M. D., Liu, J., Mavros, P., Mahaffey, K. W.
2019

- **Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS Program.** *Diabetologia*
Zhou, Z., Jardine, M., Perkovic, V., Matthews, D. R., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Desai, M., Oh, R., Simpson, R., Watts, N. B., Neal, B.
2019
- **Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups: Results from the Randomized CREDENCE Trial.** *Circulation*
Mahaffey, K. W., Jardine, M. J., Bompont, S., Cannon, C. P., Neal, B., Heerspink, H. J., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., Capuano, G., de Zeeuw, et al
2019
- **Association Between Warfarin Control Metrics and Atrial Fibrillation Outcomes in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation.** *JAMA cardiology*
Pokorney, S. D., Holmes, D. N., Thomas, L., Fonarow, G. C., Kowey, P. R., Reiffel, J. A., Singer, D. E., Freeman, J. V., Gersh, B. J., Mahaffey, K. W., Hylek, E. M., Naccarelli, G. V., Ezekowitz, et al
2019
- **Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial.** *The lancet. Diabetes & endocrinology*
Ray, K. K., Colhoun, H. M., Szarek, M., Baccara-Dinet, M., Bhatt, D. L., Bittner, V. A., Budaj, A. J., Diaz, R., Goodman, S. G., Hanotin, C., Harrington, R. A., Jukema, J. W., Loizeau, et al
2019
- **Acute Limb Ischemia in Peripheral Artery Disease: Insights from EUCLID.** *Circulation*
Hess, C. N., Huang, Z., Patel, M. R., Baumgartner, I., Berger, J. S., Blomster, J. I., Fowkes, F. G., Held, P., Jones, W. S., Katona, B., Mahaffey, K. W., Norgren, L., Rockhold, et al
2019
- **Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy** *NEW ENGLAND JOURNAL OF MEDICINE*
Perkovic, V., Jardine, M. J., Neal, B., Bompont, S., Heerspink, H. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., Cannon, C. P., Capuano, G., Chu, et al
2019; 380 (24): 2295–2306
- **EGFR LOSS WITH GLUCAGON-LIKE PEPTIDE-1 (GLP-1) ANALOGUE TREATMENT: DATA FROM SUSTAIN 6 AND LEADER**
Perkovic, V., Bain, S., Bakris, G., Buse, J., Gondolf, T., Idorn, T., Lausvig, N., Mahaffey, K., Marso, S., Nauck, M., Pratley, R., Rossing, P., Zinman, et al
OXFORD UNIV PRESS.2019
- **Stroke in Patients With Peripheral Artery Disease: Insights From the EUCLID Study** *STROKE*
Kolls, B. J., Sapp, S., Rockhold, F. W., Jordan, J., Dombrowski, K. E., Fowkes, F. R., Mahaffey, K. W., Berger, J. S., Katona, B. G., Blomster, J. I., Norgren, L., Abramson, B. L., Leiva-Pons, et al
2019; 50 (6): 1356–63
- **Effects of canagliflozin on amputation risk in type 2 diabetes: the CANVAS Program** *DIABETOLOGIA*
Matthews, D. R., Li, Q., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Desai, M., Hiatt, W. R., Nehler, M., Fabbrini, E., Kavalam, M., Lee, M., Neal, et al
2019; 62 (6): 926–38
- **Characteristics of Digital Health Studies Registered in ClinicalTrials.gov** *JAMA INTERNAL MEDICINE*
Chen, C. E., Harrington, R. A., Desai, S. A., Mahaffey, K. W., Turakhia, M. P.
2019; 179 (6): 838–40
- **DIFFERENT EGFR THRESHOLDS AND THE RENAL EFFECTS OF CANAGLIFLOZIN: DATA FROM THE CANVAS PROGRAM**
Oshima, M., Ohkuma, T., Neal, B., Li, Q., De Zeeuw, D., Mahaffey, K. W., Fulcher, G., Canovatchel, W., Matthews, D. R., Perkovic, V.
OXFORD UNIV PRESS.2019: 206
- **EFFECTS OF SEMAGLUTIDE AND LIRAGLUTIDE ON URINARY ALBUMIN-TO-CREATININE RATIO (UACR) - A POOLED ANALYSIS OF SUSTAIN 6 AND LEADER**

- Perkovic, V., Bain, S., Bakris, G., Buse, J., Idorn, T., Mahaffey, K., Marso, S., Nauck, M., Pratley, R., Rasmussen, S., Rossing, P., Tornoe, K., Zinman, et al
OXFORD UNIV PRESS.2019: 205–U715
- **EFFECTS OF THE GLUCAGON-LIKE PEPTIDE-1 (GLP-1) ANALOGUES SEMAGLUTIDE AND LIRAGLUTIDE ON RENAL OUTCOMES - A POOLED ANALYSIS OF THE SUSTAIN 6 AND LEADER TRIALS**
Perkovic, V., Bain, S., Bakris, G., Buse, J., Idorn, T., Mahaffey, K., Marso, S., Nauck, M., Pratley, R., Rasmussen, S., Rossing, P., Tornoe, K., Zinman, et al
OXFORD UNIV PRESS.2019: 338
 - **Effects of Canagliflozin on Heart Failure Outcomes Associated With Preserved and Reduced Ejection Fraction in Type 2 Diabetes Mellitus Results From the CANVAS Program** *CIRCULATION*
Figtree, G. A., Radholm, K., Barrett, T. D., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Matthews, D. R., Shaw, W., Neal, B.
2019; 139 (22): 2591–93
 - **Stroke in Patients With Peripheral Artery Disease.** *Stroke*
Kolls, B. J., Sapp, S., Rockhold, F. W., Jordan, J. D., Dombrowski, K. E., Fowkes, F. G., Mahaffey, K. W., Berger, J. S., Katona, B. G., Blomster, J. I., Norgren, L., Abramson, B. L., Leiva-Pons, et al
2019: STROKEAHA118023534
 - **Blood Pressure Control and Cardiovascular Outcomes in Patients With Atrial Fibrillation (From the ORBIT-AF Registry)** *AMERICAN JOURNAL OF CARDIOLOGY*
Vemulapalli, S., Inohara, T., Kim, S., Thomas, L., Piccini, J. P., Patel, M. R., Chang, P., Fonarow, G. C., Ezekowitz, M. D., Hylek, E., Go, A. S., Kowey, P. R., Mahaffey, et al
2019; 123 (10): 1628–36
 - **Comparison of Patient-Reported Care Satisfaction, Quality of Warfarin Therapy, and Outcomes of Atrial Fibrillation: Findings From the ORBIT-AF Registry** *JOURNAL OF THE AMERICAN HEART ASSOCIATION*
Perino, A. C., Shrader, P., Turakhia, M. P., Ansell, J. E., Gersh, B. J., Fonarow, G. C., Go, A. S., Kaiser, D. W., Hylek, E. M., Kowey, P. R., Singer, D. E., Thomas, L., Steinberg, et al
2019; 8 (9)
 - **Association of frailty and cognitive impairment with benefits of oral anticoagulation in patients with atrial fibrillation** *AMERICAN HEART JOURNAL*
Madhavan, M., Holmes, D. N., Piccini, J. P., Ansell, J. E., Fonarow, G. C., Hylek, E. M., Kowey, P. R., Mahaffey, K. W., Thomas, L., Peterson, E. D., Chan, P., Allen, L. A., Gersh, et al
2019; 211: 77–89
 - **Treatment of atrial fibrillation with concomitant coronary or peripheral artery disease: Results from the outcomes registry for better informed treatment of atrial fibrillation II.** *American heart journal*
Inohara, T., Shrader, P., Pieper, K., Blanco, R. G., Allen, L. A., Fonarow, G. C., Gersh, B. J., Go, A. S., Ezekowitz, M. D., Kowey, P. R., Reiffel, J. A., Naccarelli, G. V., Chan, et al
2019; 213: 81–90
 - **Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.** *The New England journal of medicine*
Perkovic, V., Jardine, M. J., Neal, B., Bompont, S., Heerspink, H. J., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., Cannon, C. P., Capuano, G., Chu, et al
2019
 - **Efficacy and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and a history of cancer: observations from ROCKETAF** *EUROPEAN HEART JOURNAL-QUALITY OF CARE AND CLINICAL OUTCOMES*
Chen, S. T., Hellkamp, A. S., Becker, R. C., Berkowitz, S. D., Breithardt, G., Fox, K. A. A., Hacke, W., Halperin, J. L., Hankey, G. J., Mahaffey, K., Nessel, C. C., Piccini, J. P., Singer, et al
2019; 5 (2): 145–52
 - **Effects of Canagliflozin on Heart Failure Outcomes Associated with Preserved and Reduced Ejection Fraction in Type 2 Diabetes: Results from the CANVAS Program.** *Circulation*
Figtree, G. A., Radholm, K., Barrett, T. D., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Matthews, D. R., Shaw, W., Neal, B.
2019
 - **EFFICACY OF A CENTRALIZED, BLENDED ELECTRONIC, AND HUMAN INTERVENTION TO IMPROVE DOAC ADHERENCE: THE SMARTADHERE TRIAL**

Turakhia, M. P., Sundaram, V., Smith, S., Ding, V., Ho, P., Kowey, P. R., Piccini, J., Foody, J., Birmingham, M., Ianus, J., Rajmane, A., Mahaffey, K.
ELSEVIER SCIENCE INC.2019: 510

- **Effects of canagliflozin on amputation risk in type 2 diabetes: the CANVAS Program.** *Diabetologia*
Matthews, D. R., Li, Q., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Desai, M., Hiatt, W. R., Nehler, M., Fabbrini, E., Kavalam, M., Lee, M., Neal, et al
2019
- **B-type natriuretic peptide, disease progression and clinical outcomes in atrial fibrillation** *HEART*
Inohara, T., Kim, S., Pieper, K., Blanco, R. G., Allen, L. A., Fonarow, G. C., Gersh, B. J., Ezekowitz, M. D., Kowey, P. R., Reiffel, J. A., Naccarelli, G. V., Chan, P. S., Mahaffey, et al
2019; 105 (5): 370–77
- **Periprocedural Outcomes According to Timing of Clopidogrel Loading Dose in Patients Who Did Not Receive P2Y12 Inhibitor Pretreatment.** *Circulation. Cardiovascular interventions*
Abtan, J., Ducrocq, G., Steg, P. G., Stone, G. W., Mahaffey, K. W., Gibson, C. M., Hamm, C. W., Price, M. J., Prats, J., Deliargyris, E. N., White, H. D., Harrington, R. A., Bhatt, et al
2019; 12 (3): e007445
- **Characteristics of Digital Health Studies Registered in ClinicalTrials.gov.** *JAMA internal medicine*
Chen, C. E., Harrington, R. A., Desai, S. A., Mahaffey, K. W., Turakhia, M. P.
2019
- **Blood Pressure Control and Cardiovascular Outcomes in Patients With Atrial Fibrillation (From the ORBIT-AF Registry).** *The American journal of cardiology*
Vemulapalli, S., Inohara, T., Kim, S., Thomas, L., Piccini, J. P., Patel, M. R., Chang, P., Fonarow, G. C., Ezekowitz, M. D., Hylek, E., Go, A. S., Kowey, P. R., Mahaffey, et al
2019
- **Appropriateness of Direct Oral Anticoagulant Dosing in Patients With Atrial Fibrillation: Insights From the Veterans Health Administration.** *Journal of pharmacy practice*
Leef, G. C., Perino, A. C., Askari, M., Fan, J., Ho, P. M., Olivier, C. B., Longo, L., Mahaffey, K. W., Turakhia, M. P.
2019: 897190019828270
- **Frequency, Regional Variation, and Predictors of Undetermined Cause of Death in Cardiometabolic Clinical Trials: A Pooled Analysis of 9259 Deaths in 9 Trials** *CIRCULATION*
Fanaroff, A. C., Clare, R., Pieper, K. S., Mahaffey, K. W., Melloni, C., Green, J. B., Alexander, J. H., Jones, W., Harrison, R. W., Mehta, R. H., Povsic, T. J., Moreira, H. G., Ai-Khatib, et al
2019; 139 (7): 863–73
- **Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events The ODYSSEY OUTCOMES Trial** *JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY*
Szarek, M., White, H. D., Schwartz, G. G., Alings, M., Bhatt, D. L., Bittner, V. A., Chiang, C., Diaz, R., Edelberg, J. M., Goodman, S. G., Hanotin, C., Harrington, R. A., Jukema, et al
2019; 73 (4): 387–96
- **Canagliflozin and Stroke in Type 2 Diabetes Mellitus Results From the Randomized CANVAS Program Trials** *STROKE*
Zhou, Z., Lindley, R. I., Radholm, K., Jenkins, B., Watson, J., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Shaw, W., Oh, R., Desai, M., Matthews, et al
2019; 50 (2): 396–404
- **Factors Associated With Patient-Reported Shared Decision-Making for Stroke Prevention in Atrial Fibrillation**
O'Brien, E. C., Pieper, K., Thiem, R., Fonarow, G. C., Kowey, P. R., Chan, P. S., Freeman, J., Naccarelli, G., Mahaffey, K. W., Ezekowitz, M. D., Go, A. S., Gersh, B. J., Singer, et al
LIPPINCOTT WILLIAMS & WILKINS.2019
- **Characterization of cardiovascular clinical events and impact of event adjudication on the treatment effect of darapladib versus placebo in patients with stable coronary heart disease: Insights from the STABILITY trial** *AMERICAN HEART JOURNAL*
Held, C., White, H. D., Stewart, R. A. H., Davies, R., Sampson, S., Chiswell, K., Silverstein, A., Lopes, R. D., Heldestad, U., Budaj, A., Mahaffey, K. W., Wallentin, L., STABILITY Investigators
2019; 208: 65–73

- **Canagliflozin review - safety and efficacy profile in patients with T2DM.** *Diabetes, metabolic syndrome and obesity : targets and therapy*
Jakher, H., Chang, T. I., Tan, M., Mahaffey, K. W.
2019; 12: 209-215
- **Association of frailty and cognitive impairment with benefits of oral anticoagulation in patients with atrial fibrillation.** *American heart journal*
Madhavan, M., Holmes, D. N., Piccini, J. P., Ansell, J. E., Fonarow, G. C., Hylek, E. M., Kowey, P. R., Mahaffey, K. W., Thomas, L., Peterson, E. D., Chan, P., Allen, L. A., Gersh, et al
2019; 211: 77-89
- **Cohort profile: patient characteristics and quality-of-life measurements for newly-referred patients with atrial fibrillation-Keio interhospital Cardiovascular Studies-atrial fibrillation (KiCS-AF).** *BMJ open*
Ikemura, N. n., Spertus, J. A., Kimura, T. n., Mahaffey, K. n., Piccini, J. P., Inohara, T. n., Ueda, I. n., Tanimoto, K. n., Suzuki, M. n., Nakamura, I. n., Akaishi, M. n., Mitamura, H. n., Fukuda, et al
2019; 9 (12): e032746
- **Comparison of Patient-Reported Care Satisfaction, Quality of Warfarin Therapy, and Outcomes of Atrial Fibrillation: Findings From the ORBIT - AF Registry.** *Journal of the American Heart Association*
Perino, A. C., Shrader, P. n., Turakhia, M. P., Ansell, J. E., Gersh, B. J., Fonarow, G. C., Go, A. S., Kaiser, D. W., Hylek, E. M., Kowey, P. R., Singer, D. E., Thomas, L. n., Steinberg, et al
2019; 8 (9): e011205
- **Canagliflozin review - safety and efficacy profile in patients with T2DM** *DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY*
Jakher, H., Chang, T. I., Tan, M., Mahaffey, K. W.
2019; 12: 209-15
- **Impact of Procedural Bleeding in Peripheral Artery Disease: An Analysis From EUCLID Trial.** *Circulation. Cardiovascular interventions*
Kansal, A. n., Huang, Z. n., Rockhold, F. W., Baumgartner, I. n., Berger, J. S., Blomster, J. I., Fowkes, F. G., Katona, B. n., Mahaffey, K. W., Norgren, L. n., Hiatt, W. R., Patel, M. R., Jones, et al
2019; 12 (10): e008069
- **Effect of Alirocumab on Mortality After Acute Coronary Syndromes: An Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial.** *Circulation*
Steg, P. G., Szarek, M. n., Bhatt, D. L., Bittner, V. A., Brégeault, M. F., Dalby, A. J., Diaz, R. n., Edelberg, J. M., Goodman, S. G., Hanotin, C. n., Harrington, R. A., Jukema, J. W., Lecorps, et al
2019
- **Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial.** *European heart journal*
White, H. D., Steg, P. G., Szarek, M. n., Bhatt, D. L., Bittner, V. A., Diaz, R. n., Edelberg, J. M., Erglis, A. n., Goodman, S. G., Hanotin, C. n., Harrington, R. A., Jukema, J. W., Lopes, et al
2019
- **Incremental prognostic value of renal function for stroke prediction in atrial fibrillation** *INTERNATIONAL JOURNAL OF CARDIOLOGY*
O'Brien, E. C., Holmes, D. N., Thomas, L., Singer, D. E., Fonarow, G. C., Mahaffey, K. W., Kowey, P. R., Hylek, E. M., Pokorney, S. D., Ansell, J. E., Pencina, M. J., Peterson, E. D., Piccini, et al
2019; 274: 152-57
- **Major bleeding in patients with peripheral artery disease: Insights from the EUCLID trial.** *American heart journal*
Ward, R. n., Huang, Z. n., Rockhold, F. W., Baumgartner, I. n., Berger, J. S., Blomster, J. I., Fowkes, F. G., Katona, B. G., Mahaffey, K. W., Norgren, L. n., Vemulapalli, S. n., Povsic, T. J., Mehta, et al
2019; 220: 51-58
- **A Cluster Analysis of the Japanese Multicenter Outpatient Registry of Patients With Atrial Fibrillation.** *The American journal of cardiology*
Inohara, T. n., Piccini, J. P., Mahaffey, K. W., Kimura, T. n., Katsumata, Y. n., Tanimoto, K. n., Inagawa, K. n., Ikemura, N. n., Ueda, I. n., Fukuda, K. n., Takatsuki, S. n., Kohsaka, S. n.
2019
- **Chronic kidney disease and risk for cardiovascular and limb outcomes in patients with symptomatic peripheral artery disease: The EUCLID trial.** *Vascular medicine (London, England)*
Hopley, C. W., Kavanagh, S. n., Patel, M. R., Ostrom, C. n., Baumgartner, I. n., Berger, J. S., Blomster, J. I., Fowkes, F. G., Jones, W. S., Katona, B. G., Mahaffey, K. W., Norgren, L. n., Rockhold, et al

2019: 1358863X19864172

- **Patient-Reported Satisfaction and Study Drug Discontinuation: Post-Hoc Analysis of Findings from ROCKET AF.** *Cardiology and therapy*
Ungar, L. n., Rodriguez, F. n., Hellkamp, A. S., Becker, R. C., Berkowitz, S. D., Breithardt, G. n., Fox, K. A., Hacke, W. n., Halperin, J. L., Hankey, G. J., Nessel, C. C., Singer, D. E., Patel, et al
2019
- **The efficacy and safety of cangrelor in single vessel vs multi vessel percutaneous coronary intervention: Insights from CHAMPION PHOENIX.** *Clinical cardiology*
Yong, C. M., Sundaram, V. n., Abnoui, F. n., Olivier, C. B., Yang, J. n., Stone, G. W., Steg, P. G., Michael Gibson, C. n., Hamm, C. W., Price, M. J., Deliargyris, E. N., Prats, J. n., White, et al
2019
- **Central Adjudication Identified Additional and Prognostically Important Myocardial Infarctions in Patients Undergoing Percutaneous Coronary Intervention.** *Circulation. Cardiovascular interventions*
Olivier, C. B., Bhatt, D. L., Leonardi, S. n., Stone, G. W., Gibson, C. M., Steg, P. G., Hamm, C. W., Wilson, M. D., Mangum, S. n., Price, M. J., Prats, J. n., White, H. D., Lopes, et al
2019; 12 (7): e007342
- **Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial.** *European heart journal*
White, H. D., Steg, P. G., Szarek, M. n., Bhatt, D. L., Bittner, V. A., Diaz, R. n., Edelberg, J. M., Erglis, A. n., Goodman, S. G., Hanotin, C. n., Harrington, R. A., Jukema, J. W., Lopes, et al
2019
- **Incremental prognostic value of renal function for stroke prediction in atrial fibrillation** *INTERNATIONAL JOURNAL OF CARDIOLOGY*
O'Brien, E. C., Holmes, D. N., Thomas, L., Singer, D. E., Fonarow, G. C., Mahaffey, K. W., Kowey, P. R., Hylek, E. M., Pokorney, S. D., Ansell, J. E., Pencina, M. J., Peterson, E. D., Piccini, et al
2019; 274: 152–57
- **Major bleeding in patients with peripheral artery disease: Insights from the EUCLID trial.** *American heart journal*
Ward, R. n., Huang, Z. n., Rockhold, F. W., Baumgartner, I. n., Berger, J. S., Blomster, J. I., Fowkes, F. G., Katona, B. G., Mahaffey, K. W., Norgren, L. n., Vemulapalli, S. n., Povsic, T. J., Mehta, et al
2019; 220: 51–58
- **A Cluster Analysis of the Japanese Multicenter Outpatient Registry of Patients With Atrial Fibrillation.** *The American journal of cardiology*
Inohara, T. n., Piccini, J. P., Mahaffey, K. W., Kimura, T. n., Katsumata, Y. n., Tanimoto, K. n., Inagawa, K. n., Ikemura, N. n., Ueda, I. n., Fukuda, K. n., Takatsuki, S. n., Kohsaka, S. n.
2019
- **Chronic kidney disease and risk for cardiovascular and limb outcomes in patients with symptomatic peripheral artery disease: The EUCLID trial.** *Vascular medicine (London, England)*
Hopley, C. W., Kavanagh, S. n., Patel, M. R., Ostrom, C. n., Baumgartner, I. n., Berger, J. S., Blomster, J. I., Fowkes, F. G., Jones, W. S., Katona, B. G., Mahaffey, K. W., Norgren, L. n., Rockhold, et al
2019: 1358863X19864172
- **Patient-Reported Satisfaction and Study Drug Discontinuation: Post-Hoc Analysis of Findings from ROCKET AF.** *Cardiology and therapy*
Ungar, L. n., Rodriguez, F. n., Hellkamp, A. S., Becker, R. C., Berkowitz, S. D., Breithardt, G. n., Fox, K. A., Hacke, W. n., Halperin, J. L., Hankey, G. J., Nessel, C. C., Singer, D. E., Patel, et al
2019
- **The efficacy and safety of cangrelor in single vessel vs multi vessel percutaneous coronary intervention: Insights from CHAMPION PHOENIX.** *Clinical cardiology*
Yong, C. M., Sundaram, V. n., Abnoui, F. n., Olivier, C. B., Yang, J. n., Stone, G. W., Steg, P. G., Michael Gibson, C. n., Hamm, C. W., Price, M. J., Deliargyris, E. N., Prats, J. n., White, et al
2019
- **Central Adjudication Identified Additional and Prognostically Important Myocardial Infarctions in Patients Undergoing Percutaneous Coronary Intervention.** *Circulation. Cardiovascular interventions*
Olivier, C. B., Bhatt, D. L., Leonardi, S. n., Stone, G. W., Gibson, C. M., Steg, P. G., Hamm, C. W., Wilson, M. D., Mangum, S. n., Price, M. J., Prats, J. n., White, H. D., Lopes, et al
2019; 12 (7): e007342

- **Canagliflozin and Stroke in Type 2 Diabetes Mellitus.** *Stroke*
Zhou, Z., Lindley, R. I., Radholm, K., Jenkins, B., Watson, J., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Shaw, W., Oh, R., Desai, M., Matthews, et al
2018: STROKEAHA118023009
- **Cardiovascular and Limb Outcomes in Patients With Diabetes and Peripheral Artery Disease: The EUCLID Trial.** *Journal of the American College of Cardiology*
Low Wang, C. C., Blomster, J. I., Heizer, G., Berger, J. S., Baumgartner, I., Fowkes, F. G., Held, P., Katona, B. G., Norgren, L., Jones, W. S., Lopes, R. D., Olin, J. W., Rockhold, et al
2018; 72 (25): 3274–84
- **Cardiovascular and Limb Outcomes in Patients With Diabetes and Peripheral Artery Disease The EUCLID Trial** *JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY*
Wang, C., Blomster, J. I., Heizer, G., Berger, J. S., Baumgartner, I., Fowkes, F. R., Held, P., Katona, B. G., Norgren, L., Jones, W., Lopes, R. D., Olin, J. W., Rockhold, et al
2018; 72 (25): 3274–84
- **Stroke Outcomes With Vorapaxar Versus Placebo in Patients With Acute Coronary Syndromes: Insights From the TRACER Trial.** *Journal of the American Heart Association*
Ungar, L., Clare, R. M., Rodriguez, F., Kolls, B. J., Armstrong, P. W., Aylward, P., Held, C., Moliterno, D. J., Strony, J., Van de Werf, F., Wallentin, L., White, H. D., Tricoci, et al
2018; 7 (24): e009609
- **Stroke Outcomes With Vorapaxar Versus Placebo in Patients With Acute Coronary Syndromes: Insights From the TRACER Trial** *JOURNAL OF THE AMERICAN HEART ASSOCIATION*
Ungar, L., Clare, R. M., Rodriguez, F., Kolls, B. J., Armstrong, P. W., Aylward, P., Held, C., Moliterno, D. J., Strony, J., Van de Werf, F., Wallentin, L., White, H. D., Tricoci, et al
2018; 7 (24)
- **Cost-Effectiveness of Alirocumab Based on Evidence From a Large Multinational Outcome Trial: The ODYSSEY OUTCOMES Economics Study**
Bhatt, D. L., Briggs, A., Reed, S. D., Annemans, L., Szarek, M., Bittner, V. A., Diaz, R., Edelberg, J. M., Goodman, S. G., Hanotin, C., Harrington, R. A., Jukema, J., Mahaffey, et al
LIPPINCOTT WILLIAMS & WILKINS.2018: E753–E754
- **Alirocumab Reduces Risk of Death after Acute Coronary Syndrome in Patients with Persistently Elevated Atherogenic Lipoproteins on Intensive Statin Treatment**
Schwartz, G. G., Szarek, M. M., Bhatt, D. L., Bittner, V. A., Bregeault, M., Dalby, A. J., Diaz, R., Edelberg, J. M., Goodman, S. G., Hanotin, C., Harrington, R. A., Jukema, J. W., Lecorps, et al
LIPPINCOTT WILLIAMS & WILKINS.2018: E772–E773
- **Incidence, Characteristics, and Outcomes of Myocardial Infarction in Patients With Peripheral Artery Disease: Insights From the EUCLID Trial.** *JAMA cardiology*
Olivier, C. B., Mulder, H., Hiatt, W. R., Jones, W. S., Fowkes, F. G., Rockhold, F. W., Berger, J. S., Baumgartner, I., Held, P., Katona, B. G., Norgren, L., Blomster, J., Patel, et al
2018
- **Impact of lesion complexity on peri-procedural adverse events and the benefit of potent intravenous platelet adenosine diphosphate receptor inhibition after percutaneous coronary intervention: core laboratory analysis from 10854 patients from the CHAMPION PHOENIX trial.** *European heart journal*
Stone, G. W., Genereux, P., Harrington, R. A., White, H. D., Gibson, C. M., Steg, P. G., Hamm, C. W., Mahaffey, K. W., Price, M. J., Prats, J., Deliargyris, E. N., Bhatt, D. L.
2018; 39 (46): 4112–21
- **Impact of lesion complexity on peri-procedural adverse events and the benefit of potent intravenous platelet adenosine diphosphate receptor inhibition after percutaneous coronary intervention: core laboratory analysis from 10 854 patients from the CHAMPIONPHOENIX trial** *EUROPEAN HEART JOURNAL*
Stone, G. W., Genereux, P., Harrington, R. A., White, H. D., Gibson, C., Steg, P., Hamm, C. W., Mahaffey, K. W., Price, M. J., Prats, J., Deliargyris, E. N., Bhatt, D. L.
2018; 39 (46): 4112–21
- **Reviewing the role of healthy volunteer studies in drug development.** *Journal of translational medicine*

- Karakunnel, J. J., Bui, N., Palaniappan, L., Schmidt, K. T., Mahaffey, K. W., Morrison, B., Figg, W. D., Kummar, S.
2018; 16 (1): 336
- **Reviewing the role of healthy volunteer studies in drug development** *JOURNAL OF TRANSLATIONAL MEDICINE*
Karakunnel, J. J., Bui, N., Palaniappan, L., Schmidt, K. T., Mahaffey, K. W., Morrison, B., Figg, W. D., Kummar, S.
2018; 16
 - **Ticagrelor versus clopidogrel in patients with symptomatic peripheral artery disease and prior coronary artery disease: Insights from the EUCLID trial** *VASCULAR MEDICINE*
Berger, J. S., Abramson, B. L., Lopes, R. D., Heizer, G., Rockhold, F. W., Baumgartner, I., Fowkes, F. R., Held, P., Katona, B. G., Norgren, L., Jones, W., Millegard, M., Blomster, et al
2018; 23 (6): 523–30
 - **Association of Race/Ethnicity With Oral Anticoagulant Use in Patients With Atrial Fibrillation Findings From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II** *JAMA CARDIOLOGY*
Essien, U. R., Holmes, D. N., Jackson, L. R., Fonarow, G. C., Mahaffey, K. W., Reiffel, J. A., Steinberg, B. A., Allen, L. A., Chan, P. S., Freeman, J., Blanco, R. G., Pieper, K. S., Piccini, et al
2018; 3 (12): 1174–82
 - **Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome** *NEW ENGLAND JOURNAL OF MEDICINE*
Schwartz, G. G., Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Diaz, R., Edelberg, J. M., Goodman, S. G., Hanotin, C., Harrington, R. A., Jukema, J. W., Lecorps, G., Mahaffey, et al
2018; 379 (22): 2097–2107
 - **Association of Race/Ethnicity With Oral Anticoagulant Use in Patients With Atrial Fibrillation: Findings From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II.** *JAMA cardiology*
Essien, U. R., Holmes, D. N., Jackson, L. R., Fonarow, G. C., Mahaffey, K. W., Reiffel, J. A., Steinberg, B. A., Allen, L. A., Chan, P. S., Freeman, J. V., Blanco, R. G., Pieper, K. S., Piccini, et al
2018
 - **Frequency, Regional Variation, and Predictors of Undetermined Cause of Death in Cardiometabolic Clinical Trials: A Pooled Analysis of 9,259 Deaths in 9 Trials.** *Circulation*
Fanaroff, A. C., Clare, R., Pieper, K. S., Mahaffey, K. W., Melloni, C., Green, J., Alexander, J. H., Jones, W. S., Harrison, R. W., Mehta, R. H., Povsic, T. J., Moreira, H. G., Al-Khatib, et al
2018
 - **Characteristics and outcomes of patients requiring bailout use of glycoprotein IIb/IIIa inhibitors for thrombotic complications of percutaneous coronary intervention: An analysis from the CHAMPION PHOENIX trial.** *International journal of cardiology*
Abtan, J., Ducrocq, G., Steg, P. G., Stone, G. W., Mahaffey, K. W., Gibson, C. M., Hamm, C., Price, M. J., Prats, J., Elkin, S., Deliargyris, E. N., White, H. D., Menozzi, et al
2018
 - **Embolic and Other Adverse Outcomes in Symptomatic Versus Asymptomatic Patients With Atrial Fibrillation (from the ORBIT-AF Registry)** *AMERICAN JOURNAL OF CARDIOLOGY*
Thind, M., Holmes, D. N., Badri, M., Pieper, K. S., Singh, A., Blanco, R. G., Steinberg, B. A., Fonarow, G. C., Gersh, B. J., Mahaffey, K. W., Peterson, E. D., Reiffel, J. A., Piccini, et al
2018; 122 (10): 1677–83
 - **Association of Multiple Biomarkers With Risk of All-Cause and Cause-Specific Mortality After Acute Coronary Syndromes: A Secondary Analysis of the PLATO Biomarker Study.** *JAMA cardiology*
Lindholm, D., James, S. K., Gabrysch, K., Storey, R. F., Himmelmann, A., Cannon, C. P., Mahaffey, K. W., Steg, P. G., Held, C., Siegbahn, A., Wallentin, L.
2018
 - **Characterization of cardiovascular clinical events and impact of event adjudication on the treatment effect of darapladib versus placebo in patients with stable coronary heart disease: Insights from the STABILITY trial.** *American heart journal*
Held, C., White, H. D., Stewart, R. A., Davies, R., Sampson, S., Chiswell, K., Silverstein, A., Lopes, R. D., Heldestad, U., Budaj, A., Mahaffey, K. W., Wallentin, L., STABILITY Investigators
2018; 208: 65–73
 - **Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.** *The New England journal of medicine*

Schwartz, G. G., Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Diaz, R., Edelberg, J. M., Goodman, S. G., Hanotin, C., Harrington, R. A., Jukema, J. W., Lecorps, G., Mahaffey, et al
2018

- **Estimation of Stroke Outcomes in Atrial Fibrillation Using Continuous Clinical and Implantable Device Data From the Treat-AF Study: A Comparison With CHA2DS2-VASc Score**
Bentley, J. P., Askari, M., Fan Jun, Heidenreich, P. A., Mahaffey, K. W., Desai, M., Scheinker, D., Turakhia, M. P.
LIPPINCOTT WILLIAMS & WILKINS.2018
- **Acute Limb Ischemia in Peripheral Artery Disease: Insights From EUCLID**
Hess, C. N., Huang, Z., Patel, M. R., Baumgartner, I., Berger, J. S., Blomster, J., Fowkes, F. R., Held, P., Jones, W., Katona, B. G., Mahaffey, K. W., Norgren, L., Rockhold, et al
LIPPINCOTT WILLIAMS & WILKINS.2018
- **The TIMI Risk Score for Secondary Prevention for Myocardial Infarction Applied to Patients With Peripheral Artery Disease: A Collaborative Analysis for the Chronic Kidney Disease Prognosis Consortium and the Risk Validation Scientific Committee**
Mok, Y., Ballew, S. H., Bash, L. D., Bhatt, D. L., Bonaca, M. P., Carrero, J., Coresh, J., D'Agostino, R. B., Fowkes, F. R., Jee, S., Kenealy, T., Kovesdy, C. P., Mahaffey, et al
LIPPINCOTT WILLIAMS & WILKINS.2018
- **Stroke Outcomes With Vorapaxar versus Placebo in Patients With Acute Coronary Syndromes: Insights From the TRACER Trial**
Ungar, L., Clare, R., Rodriguez, F., Kolls, B., Armstrong, P., Aylward, P., Held, C., Moliterno, D., Strony, J., Van de Werf, F., Wallentin, L., White, H., Tricoci, et al
LIPPINCOTT WILLIAMS & WILKINS.2018
- **Comparison of Patient Reported Care Satisfaction, Quality of Warfarin Therapy, and Outcomes of Atrial Fibrillation: Findings From the ORBIT-AF Registry**
Perino, A. C., Shrader, P., Turakhia, M. P., Ansell, J. E., Gersh, B. J., Fonarow, G. C., Go, A. S., Kaiser, D. W., Hylek, E. M., Kowey, P. R., Singer, D. E., Thomas, L., Steinberg, et al
LIPPINCOTT WILLIAMS & WILKINS.2018
- **Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events in the ODYSSEY OUTCOMES Trial**
Szarek, M., White, H. D., Schwartz, G. G., Alings, M., Bhatt, D. L., Bittner, V. A., Chiang, C., Diaz, R., Edelberg, J. M., Goodman, S. G., Hanotin, C., Harrington, R. A., Jukema, et al
LIPPINCOTT WILLIAMS & WILKINS.2018
- **Treatment Patterns and Clinical Outcomes in Adults With Concomitant Atrial Fibrillation and Vascular Disease**
Inohara, T., Shrader, P., Pieper, K., Blanco, R. G., Fonarow, G. C., Mahaffey, K. W., Gersh, B. J., Go, A. S., Kowey, P. R., Peterson, E., Piccini, J. P.
LIPPINCOTT WILLIAMS & WILKINS.2018
- **Comparing Treatments and Outcomes Across the Spectrum of Stroke and Bleeding Risks in Non-Valvular Atrial Fibrillation: Results From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry.**
Marzec, L. N., Piccini, J. P., Shrader, P., Pieper, K., Blanco, R. G., Fonarow, G. C., Gersh, B. J., Ho, P., Hylek, E., Kowey, P. R., Mahaffey, K. W., Steinberg, B. A., Peterson, et al
LIPPINCOTT WILLIAMS & WILKINS.2018
- **Polyvascular Disease and Risk of Major Adverse Cardiovascular Events in Peripheral Artery Disease: A Secondary Analysis of the EUCLID Trial. JAMA network open**
Gutierrez, J. A., Mulder, H., Jones, W. S., Rockhold, F. W., Baumgartner, I., Berger, J. S., Blomster, J. I., Fowkes, F. G., Held, P., Katona, B. G., Mahaffey, K. W., Norgren, L., Hiatt, et al
2018; 1 (7): e185239
- **Characteristics and outcomes of adults with chronic obstructive pulmonary disease and atrial fibrillation HEART**
Durheim, M. T., Holmes, D. N., Blanco, R. G., Allen, L. A., Chan, P. S., Freeman, J. V., Fonarow, G. C., Go, A. S., Hylek, E. M., Mahaffey, K. W., Pokorney, S. D., Reiffel, J. A., Singer, et al
2018; 104 (22): 1850–58
- **Definitions of peri-procedural myocardial infarction and the association with one-year mortality: Insights from CHAMPION trials INTERNATIONAL JOURNAL OF CARDIOLOGY**
Olivier, C. B., Sundaram, V., Bhatt, D. L., Leonardi, S., Lopes, R. D., Ding, V. Y., Yang, L., Stone, G. W., Steg, P., Gibson, C., Hamm, C. W., Price, M. J., White, et al
2018; 270: 96–101

- **Early therapeutic persistence on dabigatran versus warfarin therapy in patients with atrial fibrillation: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry** *JOURNAL OF THROMBOSIS AND THROMBOLYSIS*
Jackson, L. R., Kim, S., Shrader, P., Blanco, R., Thomas, L., Ezekowitz, M. D., Ansell, J., Fonarow, G. C., Gersh, B. J., Go, A. S., Kowey, P. R., Mahaffey, K. W., Hylek, et al
2018; 46 (4): 435–39
- **Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events in the ODYSSEY OUTCOMES Trial.** *Journal of the American College of Cardiology*
Szarek, M., White, H. D., Schwartz, G. G., Alings, M., Bhatt, D. L., Bittner, V. A., Chiang, C., Diaz, R., Edelberg, J. M., Goodman, S. G., Hanotin, C., Harrington, R. A., Jukema, et al
2018
- **Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function: Data From the CANVAS Program** *CIRCULATION*
Neuen, B. L., Ohkuma, T., Neal, B., Matthews, D. R., de Zeeuw, D., Mahaffey, K. W., Fulcher, G., Desai, M., Li, Q., Deng, H., Rosenthal, N., Jardine, M. J., Bakris, et al
2018; 138 (15): 1537–50
- **Cardiovascular Outcomes After Lower Extremity Endovascular or Surgical Revascularization** *JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY*
Baumgartner, I., Norgren, L., Fowkes, F. R., Mulder, H., Patel, M. R., Berger, J. S., Jones, W., Rockhold, F. W., Katona, B. G., Mahaffey, K., Hiatt, W. R., Executive Comm Investigators EUCLI
2018; 72 (14): 1563–72
- **Academic health centers: integration of clinical research with healthcare and education. Comments on a workshop.** *Clinics (Sao Paulo, Brazil)*
Arai, R. J., Noronha, I. d., Nicolau, J. C., Schmidt, C., de Albuquerque, G. M., Mahaffey, K. W., Krieger, E. M., Auler Junior, J. O.
2018; 73 (suppl 1): e515s
- **B-type natriuretic peptide, disease progression and clinical outcomes in atrial fibrillation.** *Heart (British Cardiac Society)*
Inohara, T., Kim, S., Pieper, K., Blanco, R. G., Allen, L. A., Fonarow, G. C., Gersh, B. J., Ezekowitz, M. D., Kowey, P. R., Reiffel, J. A., Naccarelli, G. V., Chan, P. S., Mahaffey, et al
2018
- **Pharmacotherapy for Atrial Fibrillation in Patients With Chronic Kidney Disease: Insights From ORBIT-AF** *JOURNAL OF THE AMERICAN HEART ASSOCIATION*
Washam, J. B., Holmes, D. N., Thomas, L. E., Pokorney, S. D., Hylek, E. M., Fonarow, G. C., Mahaffey, K. W., Gersh, B. J., Kowey, P. R., Ansell, J. E., Go, A. S., Reiffel, J. A., Freeman, et al
2018; 7 (18)
- **Pharmacotherapy for Atrial Fibrillation in Patients With Chronic Kidney Disease: Insights From ORBIT-AF.** *Journal of the American Heart Association*
Washam, J. B., Holmes, D. N., Thomas, L. E., Pokorney, S. D., Hylek, E. M., Fonarow, G. C., Mahaffey, K. W., Gersh, B. J., Kowey, P. R., Ansell, J. E., Go, A. S., Reiffel, J. A., Freeman, et al
2018; 7 (18): e008928
- **Efficacy and Safety of Rivaroxaban versus Warfarin in Patients with Nonvalvular Atrial Fibrillation and a History of Cancer: Observations from ROCKET AF.** *European heart journal. Quality of care & clinical outcomes*
Chen, S. T., Hellkamp, A. S., Becker, R. C., Berkowitz, S. D., Breithardt, G., Fox, K. A., Hacke, W., Halperin, J. L., Hankey, G. J., Mahaffey, K. W., Nessel, C. C., Piccini, J. P., Singer, et al
2018
- **Rationale and design of a large-scale, app-based study to identify cardiac arrhythmias using a smartwatch: The Apple Heart Study.** *American heart journal*
Turakhia, M. P., Desai, M., Hedlin, H., Rajmane, A., Talati, N., Ferris, T., Desai, S., Nag, D., Patel, M., Kowey, P., Rumsfeld, J. S., Russo, A. M., Hills, et al
2018
- **Effects of genetic variation in protease activated receptor 4 after an acute coronary syndrome: Analysis from the TRACER trial** *BLOOD CELLS MOLECULES AND DISEASES*
Tricoci, P., Neely, M., Whitley, M. J., Edelstein, L. C., Simon, L. M., Shaw, C., Fortina, P., Moliterno, D. J., Armstrong, P. W., Aylward, P., White, H., Van de Werf, F., Jennings, et al

2018; 72: 37–43

- **Association of Healthcare Plan with atrial fibrillation prescription patterns** *CLINICAL CARDIOLOGY*
Chang, A., Askari, M., Fan, J., Heidenreich, P. A., Ho, P., Mahaffey, K. W., Ullal, A., Perino, A., Turakhia, M. P.
2018; 41 (9): 1136–43
- **Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials** *LANCET DIABETES & ENDOCRINOLOGY*
Perkovic, V., de Zeeuw, D., Mahaffey, K. W., Fulcher, G., Erondou, N., Shaw, W., Barrett, T. D., Weidner-Wells, M., Deng, H., Matthews, D. R., Neal, B.
2018; 6 (9): 691–704
- **Prognostic Significance of Nuisance Bleeding in Anticoagulated Patients With Atrial Fibrillation** *CIRCULATION*
O'Brien, E. C., Holmes, D. N., Thomas, L. E., Fonarow, G. C., Allen, L. A., Gersh, B. J., Kowey, P. R., Singer, D. E., Ezekowitz, M. D., Naccarelli, G. V., Ansell, J. E., Chan, P. S., Mahaffey, et al
2018; 138 (9): 889–97
- **Stroke Risk and Treatment in Patients with Atrial Fibrillation and Low CHA2DS2-VASc Scores: Findings From the ORBIT-AF I and II Registries.** *Journal of the American Heart Association*
Jackson, L. R., Kim, S., Fonarow, G. C., Freeman, J. V., Gersh, B. J., Go, A. S., Hylek, E. M., Kowey, P. R., Mahaffey, K. W., Singer, D., Thomas, L., Blanco, R., Peterson, et al
2018; 7 (16): e008764
- **Initiating anticoagulation with the intention of cardioverting: does drug choice matter?** *EUROPEAN HEART JOURNAL*
Mahaffey, K. W., Turakhia, M. P.
2018; 39 (32): 2972–74
- **Stroke Risk and Treatment in Patients with Atrial Fibrillation and Low CHA(2)DS(2)-VASc Scores: Findings From the ORBIT-AF I and II Registries** *JOURNAL OF THE AMERICAN HEART ASSOCIATION*
Jackson, L. R., Kim, S., Fonarow, G. C., Freeman, J. V., Gersh, B. J., Go, A. S., Hylek, E. M., Kowey, P. R., Mahaffey, K. W., Singer, D., Thomas, L., Blanco, R., Peterson, et al
2018; 7 (16)
- **Letter by Matthews et al Regarding Article, "Class Effect for Sodium Glucose-Cotransporter-2 Inhibitors in Cardiovascular Outcomes: Implications for the Cardiovascular Disease Specialist"** *CIRCULATION*
Matthews, D. R., Perkovic, V., Mahaffey, K. W.
2018; 138 (6): 660–61
- **Selective Serotonin Reuptake Inhibitors and Bleeding Risk in Anticoagulated Patients With Atrial Fibrillation: An Analysis From the ROCKET AF Trial** *JOURNAL OF THE AMERICAN HEART ASSOCIATION*
Quinn, G. R., Hellkamp, A. S., Hankey, G. J., Becker, R. C., Berkowitz, S. D., Breithardt, G., Fava, M., Fox, K. A. A., Halperin, J. L., Mahaffey, K. W., Nessel, C. C., Patel, M. R., Piccini, et al
2018; 7 (15)
- **Selective Serotonin Reuptake Inhibitors and Bleeding Risk in Anticoagulated Patients With Atrial Fibrillation: An Analysis From the ROCKET AF Trial.** *Journal of the American Heart Association*
Quinn, G. R., Hellkamp, A. S., Hankey, G. J., Becker, R. C., Berkowitz, S. D., Breithardt, G., Fava, M., Fox, K. A., Halperin, J. L., Mahaffey, K. W., Nessel, C. C., Patel, M. R., Piccini, et al
2018; 7 (15): e008755
- **Letter by Matthews et al Regarding Article, "Class Effect for Sodium Glucose-Cotransporter-2 Inhibitors in Cardiovascular Outcomes: Implications for the Cardiovascular Disease Specialist".** *Circulation*
Matthews, D. R., Perkovic, V., Mahaffey, K. W.
2018; 138 (6): 660-661
- **Safety of ticagrelor in patients with baseline conduction abnormalities: A PLATO (Study of Platelet Inhibition and Patient Outcomes) analysis** *AMERICAN HEART JOURNAL*
Scirica, B. M., Bansilal, S., Davoudi, F., Armstrong, P. W., Clare, R. M., Schulte, P. J., Pieper, K. S., Becker, R. C., James, S. K., Storey, R. F., Steg, P., Held, C., Himmelmann, et al
2018; 202: 54–60
- **Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program** *CIRCULATION*

- Radholm, K., Figtree, G., Perkovic, V., Solomon, S. D., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Barrett, T. D., Shaw, W., Desai, M., Matthews, D. R., Neal, B.
2018; 138 (5): 458–68
- **International Validation of the Thrombolysis in Myocardial Infarction (TIMI) Risk Score for Secondary Prevention in Post-MI Patients: A Collaborative Analysis of the Chronic Kidney Disease Prognosis Consortium and the Risk Validation Scientific Committee** *JOURNAL OF THE AMERICAN HEART ASSOCIATION*
Mok, Y., Ballew, S. H., Bash, L. D., Bhatt, D. L., Boden, W. E., Bonaca, M. P., Carrero, J., Coresh, J., D'Agostino, R. B., Elley, C., Fowkes, F. R., Jee, S., Kovesdy, et al
2018; 7 (14)
 - **Discharge timing and outcomes after uncomplicated non-ST-segment elevation acute myocardial infarction** *AMERICAN HEART JOURNAL*
Rymer, J. A., Tempelhof, M. W., Clare, R. M., Pieper, K. S., Granger, C. B., Van de Werf, F., Moliterno, D. J., Harrington, R. A., White, H. D., Armstrong, P. W., Lopes, R. D., Mahaffey, K. W., Newby, et al
2018; 201: 103–10
 - **Incidence, timing, and type of first and recurrent ischemic events in patients with and without peripheral artery disease after an acute coronary syndrome** *AMERICAN HEART JOURNAL*
Inohara, T., Pieper, K., Wojdyla, D. M., Patel, M. R., Jones, W., Tricoci, P., Mahaffey, K. W., James, S. K., Alexander, J. H., Lopes, R. D., Wallentin, L., Oilman, E., Roe, et al
2018; 201: 25–32
 - **Therapeutic Strategies Following Major, Clinically Relevant Nonmajor, and Nuisance Bleeding in Atrial Fibrillation: Findings From ORBIT-AF** *JOURNAL OF THE AMERICAN HEART ASSOCIATION*
O'Brien, E. C., Holmes, D. N., Thomas, L., Fonarow, G. C., Kowey, P. R., Ansell, J. E., Mahaffey, K. W., Gersh, B. J., Peterson, E. D., Piccini, J. P., Hylek, E. M.
2018; 7 (12)
 - **Definitions of peri-procedural myocardial infarction and the association with one-year mortality: Insights from CHAMPION trials.** *International journal of cardiology*
Olivier, C. B., Sundaram, V., Bhatt, D. L., Leonardi, S., Lopes, R. D., Ding, V. Y., Yang, L., Stone, G. W., Steg, P. G., Gibson, C. M., Hamm, C. W., Price, M. J., White, et al
2018
 - **Initiating anticoagulation with the intention of cardioverting: does drug choice matter?** *European heart journal*
Mahaffey, K. W., Turakhia, M. P.
2018
 - **Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular disease, death and safety outcomes in type 2 diabetes - A systematic review** *DIABETES RESEARCH AND CLINICAL PRACTICE*
Radholm, K., Wu, J. H. Y., Wong, M., Foote, C., Fulcher, G., Mahaffey, K. W., Perkovic, V., Neal, B.
2018; 140: 118–28
 - **Impact of polyvascular disease on patients with atrial fibrillation: Insights from ROCKET AF** *AMERICAN HEART JOURNAL*
Chen, S. T., Hellkamp, A. S., Becker, R. C., Berkowitz, S. D., Breithardt, G., Fox, K. A. A., Hacke, W., Halperin, J. L., Hankey, G. J., Mahaffey, K. W., Nessel, C. C., Piccini, J. P., Singer, et al
2018; 200: 102–9
 - **Prognostic and Practical Validation of Current Definitions of Myocardial Infarction Associated With Percutaneous Coronary Intervention** *JACC-CARDIOVASCULAR INTERVENTIONS*
Tricoci, P., Newby, L., Clare, R. M., Leonardi, S., Gibson, C., Giugliano, R. P., Armstrong, P. W., Van de Werf, F., Montalescot, G., Moliterno, D. J., Held, C., Aylward, P. E., Wallentin, et al
2018; 11 (9): 856+
 - **External validation of the TIMI risk score for secondary cardiovascular events among patients with recent myocardial infarction** *ATHEROSCLEROSIS*
Williams, B. A., Chagin, K. M., Bash, L. D., Boden, W. E., Duval, S., Fowkes, F. R., Mahaffey, K. W., Patel, M. D., D'Agostino, R. B., Peterson, E. D., Kattan, M. W., Bhatt, D. L., Bonaca, et al
2018; 272: 80–86
 - **Mineralocorticoid Receptor Antagonism in Patients With Atrial Fibrillation: Findings From the ORBIT-AF (Outcomes Registry for Better Informed Treatment of Atrial Fibrillation) Registry** *JOURNAL OF THE AMERICAN HEART ASSOCIATION*

- Fudim, M., Liu, P. R., Shrader, P., Blanco, R. G., Allen, L. A., Fonarow, G. C., Gersh, B. J., Kowey, P. R., Mahaffey, K. W., Hylek, E., Go, A. S., Thomas, L., Peterson, et al
2018; 7 (8)
- **Net clinical benefit of rivaroxaban compared with warfarin in atrial fibrillation: Results from ROCKET AF** *INTERNATIONAL JOURNAL OF CARDIOLOGY*
Barnett, A. S., Cyr, D. D., Goodman, S. G., Levitan, B. S., Yuan, Z., Hankey, G. J., Singer, D. E., Becker, R. C., Breithardt, G., Berkowitz, S. D., Halperin, J. L., Hacke, W., Mahaffey, et al
2018; 257: 78–83
 - **Incidence, Predictors, and Outcomes of Acquired Thrombocytopenia After Percutaneous Coronary Intervention: A Pooled, Patient-Level Analysis of the CHAMPION Trials (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition).** *Circulation. Cardiovascular interventions*
Groves, E. M., Bhatt, D. L., Steg, P. G., Deliargyris, E. N., Stone, G. W., Gibson, C. M., Hamm, C. W., Mahaffey, K. W., White, H. D., Angiolillo, D., Prats, J., Harrington, R. A., Price, et al
2018; 11 (4): e005635
 - **Incidence, Predictors, and Outcomes of Acquired Thrombocytopenia After Percutaneous Coronary Intervention A Pooled, Patient-Level Analysis of the CHAMPION Trials (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition)** *CIRCULATION-CARDIOVASCULAR INTERVENTIONS*
Groves, E. M., Bhatt, D. L., Steg, P., Deliargyris, E. N., Stone, G. W., Gibson, C., Hamm, C. W., Mahaffey, K. W., White, H. D., Angiolillo, D., Prats, J., Harrington, R. A., Price, et al
2018; 11 (4)
 - **Optimised care of elderly patients with acute coronary syndrome** *EUROPEAN HEART JOURNAL-ACUTE CARDIOVASCULAR CARE*
Leonardi, S., Bueno, H., Ahrens, I., Hassager, C., Bonnefoy, E., Lettino, M.
2018; 7 (3): 287–95
 - **THE EFFICACY AND SAFETY OF CANGRELOR FOR PATIENTS UNDERGOING SINGLE VESSEL VERSUS MULTI VESSEL PERCUTANEOUS CORONARY INTERVENTION: INSIGHTS FROM THE CHAMPION PHOENIX TRIAL**
Olivier, C., Abnoui, F., Sundaram, V., Yang, J., Stone, G., Steg, P., Gibson, C., Hamm, C., Price, M., Deliargyris, E., Prats, J., White, H., Harrington, et al
ELSEVIER SCIENCE INC.2018: 29
 - **2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials** *JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY*
Hicks, K. A., Mahaffey, K. W., Mehran, R., Nissen, S. E., Wiviott, S. D., Dunn, B., Solomon, S. D., Marler, J. R., Teerlink, J. R., Farb, A., Morrow, D. A., Targum, S. L., Sila, et al
2018; 71 (9): 1021–34
 - **Disease understanding in patients newly diagnosed with atrial fibrillation** *HEART*
Kaufman, B. G., Kim, S., Pieper, K., Allen, L. A., Gersh, B. J., Naccarelli, G. V., Ezekowitz, M. D., Fonarow, G. C., Mahaffey, K. W., Singer, D. E., Chan, P. S., Freeman, J. V., Ansell, et al
2018; 104 (6): 494–501
 - **2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials** *CIRCULATION*
Hicks, K. A., Mahaffey, K. W., Mehran, R., Nissen, S. E., Wiviott, S. D., Dunn, B., Solomon, S. D., Mar-Ler, J. R., Teerlink, J. R., Farb, A., Morrow, D. A., Targum, S. L., Sila, et al
2018; 137 (9): 961–72
 - **Frequency and Outcomes of Reduced Dose Non-Vitamin K Antagonist Anticoagulants: Results From ORBIT-AF II (The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II)** *JOURNAL OF THE AMERICAN HEART ASSOCIATION*
Steinberg, B. A., Shrader, P., Pieper, K., Thomas, L., Allen, L. A., Ansell, J., Chan, P. S., Ezekowitz, M. D., Fonarow, G. C., Freeman, J. V., Gersh, B. J., Kowey, P. R., Mahaffey, et al
2018; 7 (4)
 - **Short- and long-term mortality following bleeding events in patients undergoing percutaneous coronary intervention: insights from four validated bleeding scales in the CHAMPION trials** *EUROINTERVENTION*
Vaduganathan, M., Harrington, R. A., Stone, G. W., Steg, P., Gibson, C., Hamm, C. W., Price, M. J., Lopes, R. D., Leonardi, S., Deliargyris, E. N., Prats, J., Mahaffey, K. W., White, et al
2018; 13 (15): 1841–49
 - **Ischaemic Events and Stent Thrombosis following Planned Discontinuation of Study Treatment with Ticagrelor or Clopidogrel in the PLATO Study** *THROMBOSIS AND HAEMOSTASIS*

- Storey, R. F., Ardissino, D., Vignali, L., Cairns, R., Becker, R. C., Cannon, C. P., Mahaffey, K. W., Himmelmann, A., Katus, H. A., James, S. K., Wallentin, L., PLATO Investigators
2018; 118 (2): 427–29
- **Clinical features and outcomes of patients with type 2 myocardial infarction: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial** *AMERICAN HEART JOURNAL*
Guimaraes, P. O., Leonardi, S., Huang, Z., Wallentin, L., Van de Werf, F., Aylward, P. E., Held, C., Harrington, R. A., Moliterno, D. J., Armstrong, P. W., White, H. D., Alexander, K. P., Lopes, et al
2018; 196: 28–35
 - **Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)** *CIRCULATION*
Mahaffey, K. W., Neal, B., Perkovic, V., de Zeeuw, D., Fulcher, G., Erondou, N., Shaw, W., Fabbrini, E., Sun, T., Li, Q., Desai, M., Matthews, D. R., CANVAS Program Collaborative Grp
2018; 137 (4): 323–34
 - **Cangrelor compared with clopidogrel in patients with prior myocardial infarction - Insights from the CHAMPION trials** *INTERNATIONAL JOURNAL OF CARDIOLOGY*
Eisen, A., Harrington, R. A., Stone, G. W., Steg, P., Gibson, C., Hamm, C. W., Price, M. J., Prats, J., Deliargyris, E. N., Mahaffey, K. W., White, H. D., Bhatt, D. L., CHAMPION Investigators
2018; 250: 49–55
 - **Academic health centers: integration of clinical research with healthcare and education. Comments on a workshop** *CLINICS*
Arai, R., Noronha, I., Nicolau, J., Schmidt, C., de Albuquerque, G., Mahaffey, K. W., Krieger, E., Costa Auler Junior, J.
2018; 73
 - **Association of Healthcare Plan with Atrial Fibrillation Prescription Patterns.** *Clinical cardiology*
Chang, A. Y., Askari, M. n., Fan, J. n., Heidenreich, P. A., Ho, P. M., Mahaffey, K. W., Ullal, A. J., Perino, A. C., Turakhia, M. P.
2018
 - **Outcomes of Patients with Critical Limb Ischaemia in the EUCLID Trial** *EUROPEAN JOURNAL OF VASCULAR AND ENDOVASCULAR SURGERY*
Norgren, L., Patel, M. R., Hiatt, W. R., Wojdyla, D. M., Fowkes, F. R., Baumgartner, I., Mahaffey, K. W., Berger, J. S., Jones, W., Katona, B. G., Held, P., Blomster, J. I., Rockhold, et al
2018; 55 (1): 109–17
 - **Efficacy and safety of rivaroxaban compared with warfarin in patients with carotid artery disease and nonvalvular atrial fibrillation: Insights from the ROCKET AF trial** *CLINICAL CARDIOLOGY*
Kochar, A., Hellkamp, A. S., Lokhnygina, Y., Jones, W., Becker, R. C., Berkowitz, S. D., Breithardt, G., Fox, K. A. A., Halperin, J. L., Hankey, G. J., Mahaffey, K. W., Nessel, C. C., Singer, et al
2018; 41 (1): 39–45
 - **Anticoagulant and antiplatelet therapy choices for patients with atrial fibrillation one year after coronary stenting or acute coronary syndrome** *EXPERT OPINION ON DRUG SAFETY*
Olivier, C. B., Turakhia, M. P., Mahaffey, K. W.
2018; 17 (3): 251–58
 - **Prevalence, Characteristics, and Outcomes of Valvular Heart Disease in Patients With Atrial Fibrillation: Insights From the ORBIT-AF (Outcomes Registry for Better Informed Treatment for Atrial Fibrillation).** *Journal of the American Heart Association*
Thomas, K. L., Jackson, L. R., Shrader, P., Ansell, J., Fonarow, G. C., Gersh, B., Kowey, P. R., Mahaffey, K. W., Singer, D. E., Thomas, L., Piccini, J. P., Peterson, E. D.
2017; 6 (12)
 - **Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events in Type 2 Diabetes: Results From the CANVAS Program**
Mahaffey, K. W., Neal, B., Perkovic, V., de Zeeuw, D., Fulcher, G., Erondou, N., Shaw, W., Sun, T., Desai, M., Matthews, D. R., CANVAS Program Collaborative Grp
LIPPINCOTT WILLIAMS & WILKINS.2017: E454–E455
 - **International trends in clinical characteristics and oral anticoagulation treatment for patients with atrial fibrillation: Results from the GARFIELD-AF, ORBIT-AF I, and ORBIT-AF II registries** *AMERICAN HEART JOURNAL*
Steinberg, B. A., Gao, H., Shrader, P., Pieper, K., Thomas, L., Camm, A., Ezekowitz, M. D., Fonarow, G. C., Gersh, B. J., Goldhaber, S., Haas, S., Hacke, W., Kowey, et al

2017; 194: 132–40

- **International trends in clinical characteristics and oral anticoagulation treatment for patients with atrial fibrillation: Results from the GARFIELD-AF, ORBIT-AF I, and ORBIT-AF II registries.** *American heart journal*
Steinberg, B. A., Gao, H., Shrader, P., Pieper, K., Thomas, L., Camm, A. J., Ezekowitz, M. D., Fonarow, G. C., Gersh, B. J., Goldhaber, S., Haas, S., Hacke, W., Kowey, et al
2017; 194: 132-140
- **Prevalence, Characteristics, and Outcomes of Valvular Heart Disease in Patients With Atrial Fibrillation: Insights From the ORBIT-AF (Outcomes Registry for Better Informed Treatment for Atrial Fibrillation)** *JOURNAL OF THE AMERICAN HEART ASSOCIATION*
Thomas, K. L., Jackson, L. R., Shrader, P., Ansell, J., Fonarow, G. C., Gersh, B., Kowey, P. R., Mahaffey, K. W., Singer, D. E., Thomas, L., Piccini, J. P., Peterson, E. D.
2017; 6 (12)
- **Outcome of Patients Receiving Thrombolytic Therapy While on Rivaroxaban for Nonvalvular Atrial Fibrillation (from Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation)** *AMERICAN JOURNAL OF CARDIOLOGY*
Chen, S. T., Hellkamp, A. S., Becker, R. C., Berkowitz, S. D., Breithardt, G., Fox, K. A. A., Hacke, W., Halperin, J. L., Hankey, G. J., Mahaffey, K. W., Nessel, C. C., Piccini, J. P., Singer, et al
2017; 120 (10): 1837–40
- **Treatment of Atrial Fibrillation and Concordance With the American Heart Association/American College of Cardiology/Heart Rhythm Society Guidelines: Findings From ORBIT-AF (Outcomes Registry for Better Informed Treatment of Atrial Fibrillation).** *Circulation. Arrhythmia and electrophysiology*
Barnett, A. S., Kim, S., Fonarow, G. C., Thomas, L. E., Reiffel, J. A., Allen, L. A., Freeman, J. V., Naccarelli, G., Mahaffey, K. W., Go, A. S., Kowey, P. R., Ansell, J. E., Gersh, et al
2017; 10 (11)
- **Treatment of Atrial Fibrillation and Concordance With the American Heart Association/American College of Cardiology/Heart Rhythm Society Guidelines Findings From ORBIT-AF (Outcomes Registry for Better Informed Treatment of Atrial Fibrillation)** *CIRCULATION-ARRHYTHMIA AND ELECTROPHYSIOLOGY*
Barnett, A. S., Kim, S., Fonarow, G. C., Thomas, L. E., Reiffel, J. A., Allen, L. A., Freeman, J. V., Naccarelli, G., Mahaffey, K. W., Go, A. S., Kowey, P. R., Ansell, J. E., Gersh, et al
2017; 10 (11)
- **Cardiovascular adverse events in the drug-development program of bupropion for smoking cessation: A systematic retrospective adjudication effort.** *Clinical cardiology*
Kittle, J., Lopes, R. D., Huang, M., Marquess, M. L., Wilson, M. D., Ascher, J., Krishen, A., Hasselblad, V., Kolls, B. J., Roe, M. T., McGuire, D. K., Russell, S. D., Mahaffey, et al
2017; 40 (10): 899-906
- **Cangrelor Versus Clopidogrel on a Background of Unfractionated Heparin (from CHAMPION PHOENIX)** *AMERICAN JOURNAL OF CARDIOLOGY*
Vaduganathan, M., Harrington, R. A., Stone, G. W., Steg, P., Gibson, C., Hamm, C. W., Price, M. J., Deliargyris, E. N., Prats, J., Mahaffey, K. W., White, H. D., Bhatt, D. L., CHAMPION PHOENIX Investigators
2017; 120 (7): 1043–48
- **Care Patterns and Outcomes in Atrial Fibrillation Patients With and Without Diabetes ORBIT-AF Registry** *JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY*
Echouffo-Tcheugui, J. B., Shrader, P., Thomas, L., Gersh, B. J., Kowey, P. R., Mahaffey, K. W., Singer, D. E., Hylek, E. M., Go, A. S., Peterson, E. D., Piccini, J. P., Fonarow, G. C.
2017; 70 (11): 1325–35
- **Efficacy and Safety of Rivaroxaban Versus Warfarin in Patients Taking Nondihydropyridine Calcium Channel Blockers for Atrial Fibrillation (from the ROCKET AF Trial)** *AMERICAN JOURNAL OF CARDIOLOGY*
Washam, J. B., Hellkamp, A. S., Lokhnygina, Y., Piccini, J. P., Berkowitz, S. D., Nessel, C. C., Becker, R. C., Breithardt, G., Fox, K. A. A., Halperin, J. L., Hankey, G. J., Mahaffey, K. W., Singer, et al
2017; 120 (4): 588–94
- **Cangrelor in Older Patients Undergoing Percutaneous Coronary Intervention Findings From CHAMPION PHOENIX** *CIRCULATION-CARDIOVASCULAR INTERVENTIONS*
Cavender, M. A., Bhatt, D. L., Stone, G. W., Steg, P., Gibson, C., Hamm, C. W., Price, M. J., Prats, J., Elkin, S., Deliargyris, E. N., Mahaffey, K. W., White, H. D., Harrington, et al

2017; 10 (8)

- **Use of troponin assay 99th percentile as the decision level for myocardial infarction diagnosis** *AMERICAN HEART JOURNAL*
Bagai, A., Alexander, K. P., Berger, J. S., Senior, R., Sajeev, C., Pracon, R., Mavromatis, K., Luis Lopez-Sendon, J., Gosselin, G., Diaz, A., Perna, G., Drozd, J., Humen, et al
2017; 190: 135–39
- **Management and outcomes of patients with atrial fibrillation and a history of cancer: the ORBIT-AF registry** *EUROPEAN HEART JOURNAL-QUALITY OF CARE AND CLINICAL OUTCOMES*
Melloni, C., Shrader, P., Carver, J., Piccini, J. P., Thomas, L., Fonarow, G. C., Ansell, J., Gersh, B., Go, A. S., Hylek, E., Herling, I. M., Mahaffey, K. W., Yu, et al
2017; 3 (3): 192–97
- **Factors associated with non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II)** *AMERICAN HEART JOURNAL*
Steinberg, B. A., Shrader, P., Thomas, L., Ansell, J., Fonarow, G. C., Gersh, B. J., Hylek, E., Kowey, P. R., Mahaffey, K. W., O'Brien, E. C., Singer, D. E., Peterson, E. D., Piccini, et al
2017; 189: 40–47
- **Relation of Risk of Stroke in Patients With Atrial Fibrillation to Body Mass Index (from Patients Treated With Rivaroxaban and Warfarin in the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation Trial).** *American journal of cardiology*
Balla, S. R., Cyr, D. D., Lokhnygina, Y., Becker, R. C., Berkowitz, S. D., Breithardt, G., Fox, K. A., Hacke, W., Halperin, J. L., Hankey, G. J., Mahaffey, K. W., Nessel, C. C., Piccini, et al
2017; 119 (12): 1989–1996
- **Cangrelor reduces the risk of ischemic complications in patients with single-vessel and multi-vessel disease undergoing percutaneous coronary intervention: Insights from the CHAMPION PHOENIX trial.** *American heart journal*
Abnoui, F., Sundaram, V., Yong, C. M., Prats, J., Deliargyris, E. N., Stone, G. W., Hamm, C. W., Steg, P. G., Gibson, C. M., White, H. D., Price, M. J., Génèreux, P., Desai, et al
2017; 188: 147–155
- **Characteristics of dyspnoea and associated clinical outcomes in the CHAMPION PHOENIX study** *THROMBOSIS AND HAEMOSTASIS*
Parker, W. A., Bhatt, D. L., Prats, J., Day, J. R. S., Steg, P., Stone, G. W., Hamm, C. W., Mahaffey, K. W., Price, M. J., Gibson, C., White, H. D., Storey, R. F., CHAMPION PHOENIX Investigators
2017; 117 (6): 1093–1100
- **Safety and Efficacy of Rivaroxaban in Patients With Cardiac Implantable Electronic Devices: Observations From the ROCKET AF Trial** *JOURNAL OF THE AMERICAN HEART ASSOCIATION*
Leef, G. C., Hellkamp, A. S., Patel, M. R., Becker, R. C., Berkowitz, S. D., Breithardt, G., Halperin, J. L., Hankey, G. J., Hacke, W., Nessel, C. C., Singer, D. E., Fox, K. A. A., Mahaffey, et al
2017; 6 (6)
- **Effect of Atrial Fibrillation on Mortality, Stroke Risk, and Quality-of-Life Scores in Patients With Heart Failure (from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation [ORBIT-AF]).** *American journal of cardiology*
Cherian, T. S., Shrader, P., Fonarow, G. C., Allen, L. A., Piccini, J. P., Peterson, E. D., Thomas, L., Kowey, P. R., Gersh, B. J., Mahaffey, K. W.
2017; 119 (11): 1763–1769
- **Levosimendan in Patients with Left Ventricular Dysfunction Undergoing Cardiac Surgery** *NEW ENGLAND JOURNAL OF MEDICINE*
Mehta, R. H., Leimberger, J. D., van Diepen, S., Meza, J., Wang, A., Jankowich, R., Harrison, R. W., Hay, D., Fremes, S., Duncan, A., Soltesz, E. G., Luber, J., Park, et al
2017; 376 (21): 2032–42
- **Oral anticoagulation management in patients with atrial fibrillation undergoing cardiac implantable electronic device implantation.** *Clinical cardiology*
Black-Maier, E., Kim, S., Steinberg, B. A., Fonarow, G. C., Freeman, J. V., Kowey, P. R., Ansell, J., Gersh, B. J., Mahaffey, K. W., Naccarelli, G., Hylek, E. M., Go, A. S., Peterson, et al
2017
- **Management of Major Bleeding in Patients With Atrial Fibrillation Treated With Non-Vitamin K Antagonist Oral Anticoagulants Compared With Warfarin in Clinical Practice (from Phase II of the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation [ORBIT-AF II]).** *American journal of cardiology*
Steinberg, B. A., Simon, D. N., Thomas, L., Ansell, J., Fonarow, G. C., Gersh, B. J., Kowey, P. R., Mahaffey, K. W., Peterson, E. D., Piccini, J. P.

2017; 119 (10): 1590-1595

- **Adjuvant Antithrombotic Therapy in TAVR** *CURRENT CARDIOLOGY REPORTS*
O'Malley, R. G., Mahaffey, K. W., Fearon, W. F.
2017; 19 (5)
- **Noncentral Nervous System Systemic Embolism in Patients With Atrial Fibrillation Results From ROCKET AF (Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation)** *CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES*
Orgel, R., Wojdyla, D., Huberman, D., Halperin, J. L., Breithardt, G., Singer, D. E., Fox, K. A., Hankey, G. J., Mahaffey, K. W., Jones, W. S., Patel, M. R.
2017; 10 (5)
- **An examination of the relationship between serum uric acid level, a clinical history of gout, and cardiovascular outcomes among patients with acute coronary syndrome.** *American heart journal*
Pagidipati, N. J., Hess, C. N., Clare, R. M., Akerblom, A., Tricoci, P., Wojdyla, D., Keenan, R. T., James, S., Held, C., Mahaffey, K. W., Klein, A. B., Wallentin, L., Roe, et al
2017; 187: 53-61
- **Differential occurrence, profile, and impact of first recurrent cardiovascular events after an acute coronary syndrome.** *American heart journal*
Hess, C. N., Clare, R. M., Neely, M. L., Tricoci, P., Mahaffey, K. W., James, S. K., Alexander, J. H., Held, C., Lopes, R. D., Fox, K. A., White, H. D., Wallentin, L., Armstrong, et al
2017; 187: 194-203
- **Efficacy and safety of rivaroxaban versus warfarin in patients from mainland China with nonvalvular atrial fibrillation: A subgroup analysis from the ROCKET AF trial.** *Thrombosis research*
Sun, Y., Hu, D., Stevens, S., Lokhnygina, Y., Becker, R. C., Berkowitz, S. D., Breithardt, G., Hacke, W., Halperin, J. L., Hankey, G. J., Mahaffey, K. W., Nessel, C. C., Piccini, et al
2017
- **Obesity, Diabetes, and Acute Coronary Syndrome: Differences Between Asians and Whites.** *The American journal of medicine*
Koshizaka, M., Lopes, R. D., Newby, L. K., Clare, R. M., Schulte, P. J., Tricoci, P., Mahaffey, K. W., Ogawa, H., Moliterno, D. J., Giugliano, R. P., Huber, K., James, S., Harrington, et al
2017
- **Predicting the risk of bleeding during dual antiplatelet therapy after acute coronary syndromes.** *Heart (British Cardiac Society)*
Alfredsson, J., Neely, B., Neely, M. L., Bhatt, D. L., Goodman, S. G., Tricoci, P., Mahaffey, K. W., Cornel, J. H., White, H. D., Fox, K. A., Prabhakaran, D., Winters, K. J., Armstrong, et al
2017
- **Data monitoring committees: Promoting best practices to address emerging challenges** *CLINICAL TRIALS*
Fleming, T. R., DeMets, D. L., Roe, M. T., Wittes, J., Calis, K. A., Vora, A. N., Meisel, A., Bain, R. P., Konstam, M. A., Pencina, M. J., Gordon, D. J., Mahaffey, K. W., Hennekens, et al
2017; 14 (2): 115-123
- **Absence of Oral Anticoagulation and Subsequent Outcomes Among Outpatients with Atrial Fibrillation** *AMERICAN JOURNAL OF MEDICINE*
Hess, P. L., Kim, S., Fonarow, G. C., Thomas, L., Singer, D. E., Freeman, J. V., Gersh, B. J., Ansell, J., Kowey, P. R., Mahaffey, K. W., Chan, P. S., Steinberg, B. A., Peterson, et al
2017; 130 (4): 449-456
- **CANGRELOR VERSUS CLOPIDOGREL ON A BACKGROUND OF UNFRACTIONATED HEPARIN INSIGHTS FROM CHAMPION PHOENIX**
Vaduganathan, M., Harrington, R., Stone, G., Steg, P., Gibson, C., Hamm, C., Price, M., Deliangyris, E., Prats, J., Mahaffey, K., White, H., Bhatt, D.
ELSEVIER SCIENCE INC.2017: 1345
- **ONE-YEAR MORTALITY INCREASED IN PATIENTS WITH PERI-PROCEDURAL MYOCARDIAL INFARCTION: INSIGHTS FROM THE CHAMPION TRIALS**
Olivier, C., Sundaram, V., Ding, V., Yang, L., Leonardi, S., Lopes, R., Bhatt, D., Stone, G., Steg, P., Gibson, C., Hamm, C., Price, M., White, et al
ELSEVIER SCIENCE INC.2017: 7

- **IMPACT OF PERIPROCEDURAL MYOCARDIAL INFARCTION IN CONTEMPORARY PCI: POOLED PATIENT-LEVEL DATA FROM THE CHAMPION TRIALS**
Vaduganathan, M., Harrington, R., Stone, G., Steg, P., Gibson, C., Hamm, C., Price, M., Deliargyris, E., Prats, J., Mahaffey, K., White, H., Bhatt, D.
ELSEVIER SCIENCE INC.2017: 112
- **Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial** *EUROPEAN HEART JOURNAL*
Valgimigli, M., Costa, F., Lokhnygina, Y., Clare, R. M., Wallentin, L., Moliterno, D. J., Armstrong, P. W., White, H. D., Held, C., Aylward, P. E., Van de Werf, F., Harrington, R. A., Mahaffey, et al
2017; 38 (11): 804-?
- **Treatment Consistency Across Levels of Baseline Renal Function With Rivaroxaban or Warfarin A ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) Analysis** *CIRCULATION*
Lindner, S. M., Fordyce, C. B., Hellkamp, A. S., Lokhnygina, Y., Piccini, J. P., Breithardt, G., Mahaffey, K. W., Singer, D. E., Hacke, W., Halperin, J. L., Hankey, G. J., Berkowitz, S. D., Nessel, et al
2017; 135 (10): 1001-3
- **Results of a curtailed randomized controlled trial, evaluating the efficacy and safety of azimilide in patients with implantable cardioverter-defibrillators: The SHIELD-2 trial.** *American heart journal*
Robinson, V. M., Bharucha, D. B., Mahaffey, K. W., Dorian, P., Kowey, P. R.
2017; 185: 43-51
- **Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): A randomized, placebo-controlled trial.** *Diabetes, obesity & metabolism*
Neal, B., Perkovic, V., Matthews, D. R., Mahaffey, K. W., Fulcher, G., Meininger, G., Erondy, N., Desai, M., Shaw, W., Vercruyse, F., Yee, J., Deng, H., de Zeeuw, et al
2017; 19 (3): 387-393
- **Cardioversion and subsequent quality of life and natural history of atrial fibrillation.** *American heart journal*
Pokorney, S. D., Kim, S., Thomas, L., Fonarow, G. C., Kowey, P. R., Gersh, B. J., Mahaffey, K. W., Peterson, E. D., Piccini, J. P.
2017; 185: 59-66
- **Optimising the analysis strategy for the CANVAS Program - a pre-specified plan for the integrated analyses of the CANVAS and CANVAS-R trials.** *Diabetes, obesity & metabolism*
Neal, B., Perkovic, V., Mahaffey, K. W., Fulcher, G., Erondy, N., Desai, M., Shaw, W., Law, G., Walton, M. K., Rosenthal, N., Zeeuw, D. d., Matthews, D. R.
2017
- **Evaluation of Ischemic and Bleeding Risks Associated With 2 Parenteral Antiplatelet Strategies Comparing Cangrelor With Glycoprotein IIb/IIIa Inhibitors: An Exploratory Analysis From the CHAMPION Trials.** *JAMA cardiology*
Vaduganathan, M., Harrington, R. A., Stone, G. W., Deliargyris, E. N., Steg, P. G., Gibson, C. M., Hamm, C. W., Price, M. J., Menozzi, A., Prats, J., Elkin, S., Mahaffey, K. W., White, et al
2017; 2 (2): 127-135
- **Cangrelor With and Without Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Percutaneous Coronary Intervention** *JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY*
Vaduganathan, M., Harrington, R. A., Stone, G. W., Deliargyris, E. N., Steg, P. G., Gibson, C. M., Hamm, C. W., Price, M. J., Menozzi, A., Prats, J., Elkin, S., Mahaffey, K. W., White, et al
2017; 69 (2): 176-185
- **Ticagrelor Compared With Clopidogrel in Patients With Prior Lower Extremity Revascularization for Peripheral Artery Disease** *CIRCULATION*
Jones, W. S., Baumgartner, I., Hiatt, W. R., Heizer, G., Conte, M. S., White, C. J., Berger, J. S., Held, P., Katona, B. G., Mahaffey, K. W., Norgren, L., Blomster, J., Millegard, et al
2017; 135 (3): 241-?
- **Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease** *NEW ENGLAND JOURNAL OF MEDICINE*
Hiatt, W. R., Fowkes, F. G., Heizer, G., Berger, J. S., Baumgartner, I., Held, P., Katona, B. G., Mahaffey, K. W., Norgren, L., Jones, W. S., Blomster, J., Millegard, M., Reist, et al
2017; 376 (1): 32-40

- **Impact of Cerebrovascular Events Older Than One Year on Ischemic and Bleeding Outcomes With Cangrelor in Percutaneous Coronary Intervention** *CIRCULATION-CARDIOVASCULAR INTERVENTIONS*
Sawhani, N. N., Harrington, R. A., Stone, G. W., Steg, P. G., Gibson, C. M., Hamm, C. W., Price, M. J., Prats, J., Deliangryis, E. N., Mahaffey, K. W., White, H. D., Bhatt, D. L.
2017; 10 (1)
- **Navigating the Future of Cardiovascular Drug Development-Leveraging Novel Approaches to Drive Innovation and Drug Discovery: Summary of Findings from the Novel Cardiovascular Therapeutics Conference.** *Cardiovascular drugs and therapy*
Povsic, T. J., Scott, R. n., Mahaffey, K. W., Blaustein, R. n., Edelberg, J. M., Lefkowitz, M. P., Solomon, S. D., Fox, J. C., Healy, K. E., Khakoo, A. Y., Losordo, D. W., Malik, F. I., Monia, et al
2017; 31 (4): 445–58
- **Cardiovascular adverse events in the drug-development program of bupropion for smoking cessation: A systematic retrospective adjudication effort.** *Clin Cardiol.* 2017 Jun 12.
Kittle, J., et al
2017: 899–906
- **The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CRENDENCE) Study Rationale, Design, and Baseline Characteristics** *AMERICAN JOURNAL OF NEPHROLOGY*
Jardine, M. J., Mahaffey, K. W., Neal, B., Agarwal, R., Bakris, G. L., Brenner, B. M., Bull, S., Cannon, C. P., Charytan, D. M., de Zeeuw, D., Edwards, R., Greene, T., Heerspink, et al
2017; 46 (6): 462–72
- **Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.** *The New England journal of medicine*
Neal, B. n., Perkovic, V. n., Mahaffey, K. W., de Zeeuw, D. n., Fulcher, G. n., Erondu, N. n., Shaw, W. n., Law, G. n., Desai, M. n., Matthews, D. R.
2017; 377 (7): 644–57
- **A 15-year review of the Stanford Internal Medicine Residency Program: predictors of resident satisfaction and dissatisfaction** *ADVANCES IN MEDICAL EDUCATION AND PRACTICE*
Kahn, J. S., Witteles, R. M., Mahaffey, K. W., Desai, S. A., Ozdalga, E., Heidenreich, P. A.
2017; 8: 559–66
- **Rejoinder.** *Clinical trials*
Fleming, T. R., DeMets, D. L., Roe, M. T., Wittes, J., Calis, K. A., Vora, A. N., Meisel, A., Bain, R. P., Konstam, M. A., Pencina, M. J., Gordon, D. J., Mahaffey, K. W., Hennekens, et al
2017: 1740774516688917-?
- **Predictors and Prognostic Implications of Incident Heart Failure in Patients With Prevalent Atrial Fibrillation** *JACC-HEART FAILURE*
Pandey, A., Kim, S., Moore, C., Thomas, L., Gersh, B., Allen, L. A., Kowey, P. R., Mahaffey, K. W., Hylek, E., Peterson, E. D., Piccini, J. P., Fonarow, G. C.
2017; 5 (1): 44-52
- **Off-Label Dosing of Non-Vitamin K Antagonist Oral Anticoagulants and Adverse Outcomes The ORBIT-AF II Registry** *JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY*
Steinberg, B. A., Shrader, P., Thomas, L., Ansell, J., Fonarow, G. C., Gersh, B. J., Kowey, P. R., Mahaffey, K. W., Naccarelli, G., Reiffel, J., Singer, D. E., Peterson, E. D., Piccini, et al
2016; 68 (24): 2597-2604
- **Effects of Ticagrelor Compared With Clopidogrel in Patients With Peripheral Artery Disease (EUCLID)**
Patel, M. R., Fowkes, F. R., Berger, J. S., Norgren, L., Heizer, G., Baumgartner, I., Mahaffey, K. W., Katona, B. G., Held, P., Blomster, J., Jones, W., Reiser, C., Millegard, et al
LIPPINCOTT WILLIAMS & WILKINS.2016: E703
- **Relation of Post Coronary Artery Bypass Graft Creatine Kinase-MB Elevations and New Q Waves With Long-Term Cardiovascular Death in Patients With Diabetes Mellitus and Multivessel Coronary Artery Disease** *AMERICAN JOURNAL OF CARDIOLOGY*
Domanski, M., Farkouh, M. E., Zak, V., French, J., Alexander, J. H., Bochenek, A., Hamon, M., Mahaffey, K., Puskas, J., Smith, P., Shrader, P., Fuster, V.
2016; 118 (11): 1655-1660
- **Absence of Oral Anticoagulation and Subsequent Outcomes Among Outpatients with Atrial Fibrillation.** *American journal of medicine*
Hess, P. L., Kim, S., Fonarow, G. C., Thomas, L., Singer, D. E., Freeman, J. V., Gersh, B. J., Ansell, J., Kowey, P. R., Mahaffey, K. W., Chan, P. S., Steinberg, B. A., Peterson, et al

2016

- **Vorapaxar: emerging evidence and clinical questions in a new era of PAR-1 inhibition.** *Coronary artery disease*
Ungar, L., Rodriguez, F., Mahaffey, K. W.
2016; 27 (7): 604-615
- **How well does physician risk assessment predict stroke and bleeding in atrial fibrillation? Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF).** *American heart journal*
Steinberg, B. A., Shrader, P., Kim, S., Thomas, L., Fonarow, G. C., Ansell, J., Kowey, P. R., Singer, D. E., Gersh, B. J., Mahaffey, K. W., Peterson, E. D., Piccini, J. P.
2016; 181: 145-152
- **Influence of Kidney Function Estimation Methods on Eligibility for Edoxaban Population Impact of the US Food and Drug Administration's Approach for Its Product Labeling** *CIRCULATION*
Pokorney, S. D., Shrader, P., Thomas, L., Fonarow, G. C., Kowey, P. R., Singer, D. E., Ansell, J., Gersh, B. J., Mahaffey, K. W., Hylek, E. M., Go, A. S., Piccini, J. P., Peterson, et al
2016; 134 (15): 1122-24
- **Temporal changes in biomarkers and their relationships to reperfusion and to clinical outcomes among patients with ST segment elevation myocardial infarction.** *Journal of thrombosis and thrombolysis*
van Diepen, S., Alemayehu, W. G., Zheng, Y., Theroux, P., Newby, L. K., Mahaffey, K. W., Granger, C. B., Armstrong, P. W.
2016; 42 (3): 376-385
- **Efficacy and Safety of Cangrelor in Preventing Periprocedural Complications in Patients With Stable Angina and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention The CHAMPION PHOENIX Trial** *JACC-CARDIOVASCULAR INTERVENTIONS*
Abtan, J., Steg, P. G., Stone, G. W., Mahaffey, K. W., Gibson, C. M., Hamm, C. W., Price, M. J., Abnousi, F., Prats, J., Deliargyris, E. N., White, H. D., Harrington, R. A., Bhatt, et al
2016; 9 (18): 1905-1913
- **Consistent Reduction in Periprocedural Myocardial Infarction With Cangrelor as Assessed by Multiple Definitions: Findings From CHAMPION PHOENIX (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition).** *Circulation*
Cavender, M. A., Bhatt, D. L., Stone, G. W., White, H. D., Steg, P. G., Gibson, C. M., Hamm, C. W., Price, M. J., Leonardi, S., Prats, J., Deliargyris, E. N., Mahaffey, K. W., Harrington, et al
2016; 134 (10): 723-733
- **Use of concomitant aspirin in patients with atrial fibrillation: Findings from the ROCKET AF trial** *AMERICAN HEART JOURNAL*
Shah, R., Hellkamp, A., Lokhnygina, Y., Becker, R. C., Berkowitz, S. D., Breithardt, G., Backe, W., Halperin, J. L., Hankey, G. J., Fox, K. A., Nessel, C. C., Mahaffey, K. W., Piccini, et al
2016; 179: 77-86
- **Use of concomitant aspirin in patients with atrial fibrillation: Findings from the ROCKET AF trial.** *American heart journal*
Shah, R., Hellkamp, A., Lokhnygina, Y., Becker, R. C., Berkowitz, S. D., Breithardt, G., Hacke, W., Halperin, J. L., Hankey, G. J., Fox, K. A., Nessel, C. C., Mahaffey, K. W., Piccini, et al
2016; 179: 77-86
- **Use of Dual Antiplatelet Therapy and Patient Outcomes in Those Undergoing Percutaneous Coronary Intervention: The ROCKET AF Trial.** *JACC. Cardiovascular interventions*
Sherwood, M. W., Cyr, D. D., Jones, W. S., Becker, R. C., Berkowitz, S. D., Washam, J. B., Breithardt, G., Fox, K. A., Halperin, J. L., Hankey, G. J., Singer, D. E., Piccini, J. P., Nessel, et al
2016; 9 (16): 1694-1702
- **Implications of different criteria for percutaneous coronary intervention-related myocardial infarction on study results of three large phase III clinical trials: The CHAMPION experience.** *European heart journal. Acute cardiovascular care*
Leonardi, S., Lopes, R. D., Steg, P. G., Abnousi, F., Menozzi, A., Prats, J., Mangum, S., Wilson, M., Todd, M., Stone, G. W., Gibson, C. M., Hamm, C. W., Price, et al
2016
- **Blood pressure control and stroke or bleeding risk in anticoagulated patients with atrial fibrillation: Results from the ROCKET AF Trial.** *American heart journal*
Vemulapalli, S., Hellkamp, A. S., Jones, W. S., Piccini, J. P., Mahaffey, K. W., Becker, R. C., Hankey, G. J., Berkowitz, S. D., Nessel, C. C., Breithardt, G., Singer, D. E., Fox, K. A., Patel, et al
2016; 178: 74-84

- **Arterial access site and outcomes in patients undergoing percutaneous coronary intervention with and without vorapaxar.** *Catheterization and cardiovascular interventions*
Déry, J., Mahaffey, K. W., Tricoci, P., White, H. D., Podder, M., Westerhout, C. M., Moliterno, D. J., Harrington, R. A., Chen, E., Strony, J., Van de Werf, F., Ziada, K. M., Held, et al
2016; 88 (2): 163-173
- **Albuminuria and cardiovascular events in patients with acute coronary syndromes: Results from the TRACER trial.** *American heart journal*
Åkerblom, A., Clare, R. M., Lokhnygina, Y., Wallentin, L., Held, C., Van de Werf, F., Moliterno, D. J., Patel, U. D., Leonardi, S., Armstrong, P. W., Harrington, R. A., White, H. D., Aylward, et al
2016; 178: 1-8
- **Effect of age on efficacy and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial.** *American heart journal*
Armaganijan, L. V., Alexander, K. P., Huang, Z., Tricoci, P., Held, C., Van de Werf, F., Armstrong, P. W., Aylward, P. E., White, H. D., Moliterno, D. J., Wallentin, L., Chen, E., Harrington, et al
2016; 178: 176-184
- **Hospitalizations in patients with atrial fibrillation: an analysis from ROCKET AF.** *Europace*
DeVore, A. D., Hellkamp, A. S., Becker, R. C., Berkowitz, S. D., Breithardt, G., Hacke, W., Halperin, J. L., Hankey, G. J., Mahaffey, K. W., Nessel, C. C., Singer, D. E., Fox, K. A., Patel, et al
2016; 18 (8): 1135-1142
- **Management of Patients With NSTEMI/ACS A Comparison of the Recent AHA/ACC and ESC Guidelines** *JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY*
Rodriguez, F., Mahaffey, K. W.
2016; 68 (3): 313-321
- **Response by Piccini et al to Letters Regarding Article, "Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation"** *CIRCULATION*
Piccini, J. P., Hellkamp, A. S., Washam, J. B., Becker, R. C., Breithardt, G., Berkowitz, S. D., Halperin, J. L., Hankey, G. J., Hacke, W., Mahaffey, K. W., Nessel, C. C., Singer, D. E., Fox, et al
2016; 134 (2): E7-E8
- **On-Treatment Outcomes in Patients With Worsening Renal Function With Rivaroxaban Compared With Warfarin Insights From ROCKET AF** *CIRCULATION*
Fordyce, C. B., Hellkamp, A. S., Lokhnygina, Y., Lindner, S. M., Piccini, J. P., Becker, R. C., Berkowitz, S. D., Breithardt, G., Fox, K. A., Mahaffey, K. W., Nessel, C. C., Singer, D. E., Patel, et al
2016; 134 (1): 37-?
- **Cinacalcet, dialysate calcium concentration, and cardiovascular events in the EVOLVE trial** *HEMODIALYSIS INTERNATIONAL*
Pun, P. H., Abdalla, S., Block, G. A., Chertow, G. M., Correa-Rotter, R., Dehmel, B., Druke, T. B., Floege, J., Goodman, W. G., Herzog, C. A., London, G. M., Mahaffey, K. W., Moe, et al
2016; 20 (3): 421-431
- **Native valve disease in patients with non-valvular atrial fibrillation on warfarin or rivaroxaban** *HEART*
Breithardt, G., Baumgartner, H., Berkowitz, S. D., Hellkamp, A. S., Piccini, J. P., Lokhnygina, Y., Halperin, J. L., Singer, D. E., Hankey, G. J., Hacke, W., Becker, R. C., Nessel, C. C., Mahaffey, et al
2016; 102 (13): 1036-1043
- **Variation in Patient Profiles and Outcomes in US and Non-US Subgroups of the Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION) PHOENIX Trial** *CIRCULATION-CARDIOVASCULAR INTERVENTIONS*
Vaduganathan, M., Harrington, R. A., Stone, G. W., Steg, P. G., Gibson, C. M., Hamm, C. W., Price, M. J., Prats, J., Deliangyris, E. N., Mahaffey, K. W., White, H. D., Bhatt, D. L.
2016; 9 (6)
- **Association of Body Mass Index With Care and Outcomes in Patients With Atrial Fibrillation: Results From the ORBIT-AF Registry.** *JACC. Clinical electrophysiology*
Pandey, A., Gersh, B. J., McGuire, D. K., Shrader, P., Thomas, L., Kowey, P. R., Mahaffey, K. W., Hylek, E., Sun, S., Burton, P., Piccini, J., Peterson, E., Fonarow, et al
2016; 2 (3): 355-63

- **Triple vs Dual Antithrombotic Therapy in Patients with Atrial Fibrillation and Coronary Artery Disease** *AMERICAN JOURNAL OF MEDICINE*
Lopes, R. D., Rao, M., Simon, D. N., Thomas, L., Ansell, J., Fonarow, G. C., Gersh, B. J., Go, A. S., Hylek, E. M., Kowey, P., Piccini, J. P., Singer, D. E., Chang, et al
2016; 129 (6): 592-U197
- **Validation of BARC Bleeding Criteria in Patients With Acute Coronary Syndromes The TRACER Trial** *JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY*
Vranckx, P., White, H. D., Huang, Z., Mahaffey, K. W., Armstrong, P. W., Van de Werf, F., Moliterno, D. J., Wallentin, L., Held, C., Aylward, P. E., Cornel, J. H., Bode, C., Huber, et al
2016; 67 (18): 2135-2144
- **Lack of Concordance Between Local Investigators, Angiographic Core Laboratory, and Clinical Event Committee in the Assessment of Stent Thrombosis Results From the TRACER Angiographic Substudy** *CIRCULATION-CARDIOVASCULAR INTERVENTIONS*
Popma, C. J., Sheng, S., Korjian, S., Daaboul, Y., Chi, G., Tricoci, P., Huang, Z., Moliterno, D. J., White, H. D., Van de Werf, F., Harrington, R. A., Wallentin, L., Held, et al
2016; 9 (5)
- **Clinical Characteristics, Oral Anticoagulation Patterns, and Outcomes of Medicaid Patients With Atrial Fibrillation: Insights From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF I) Registry.** *Journal of the American Heart Association*
O'Brien, E. C., Kim, S., Thomas, L., Fonarow, G. C., Kowey, P. R., Mahaffey, K. W., Gersh, B. J., Piccini, J. P., Peterson, E. D.
2016; 5 (5)
- **North American Thrombosis Forum, AF Action Initiative Consensus Document** *AMERICAN JOURNAL OF MEDICINE*
Ruff, C. T., Ansell, J. E., Becker, R. C., Benjamin, E. J., Deicicchi, D. J., Estes, N. A., Ezekowitz, M. D., Fanikos, J., Fareed, J., Garcia, D., Giugliano, R. P., Goldhaber, S. Z., Granger, et al
2016; 129 (5): S1-S29
- **Design and rationale for the Effects of Ticagrelor and Clopidogrel in Patients with Peripheral Artery Disease (EUCLID) trial** *AMERICAN HEART JOURNAL*
Berger, J. S., Katona, B. G., Jones, W. S., Patel, M. R., Norgren, L., Baumgartner, I., Blomster, J., Mahaffey, K. W., Held, P., Millegard, M., Heizer, G., Reist, C., Fowkes, et al
2016; 175: 86-93
- **Family history of atrial fibrillation is associated with earlier-onset and more symptomatic atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry** *AMERICAN HEART JOURNAL*
Gundlund, A., Fosbol, E. L., Kim, S., Fonarow, G. C., Gersh, B. J., Kowey, P. R., Hylek, E., Mahaffey, K. W., Thomas, L., Piccini, J. P., Peterson, E. D.
2016; 175: 28-35
- **Trends in Enrollment, Clinical Characteristics, Treatment, and Outcomes According to Age in Non-ST-Segment-Elevation Acute Coronary Syndromes Clinical Trials** *CIRCULATION*
Kragholm, K., Goldstein, S. A., Yang, Q., Lopes, R. D., Schulte, P. J., Bernacki, G. M., White, H. D., Mahaffey, K. W., Giugliano, R. P., Armstrong, P. W., Harrington, R. A., Tricoci, P., Van de Werf, et al
2016; 133 (16): 1560-?
- **The effect of cangrelor and access site on ischaemic and bleeding events: insights from CHAMPION PHOENIX** *EUROPEAN HEART JOURNAL*
Gutierrez, J. A., Harrington, R. A., Blankenship, J. C., Stone, G. W., Steg, P. G., Gibson, C. M., Hamm, C. W., Price, M. J., Genereux, P., Prats, J., Deliargyris, E. N., Mahaffey, K., White, et al
2016; 37 (14): 1122-1130
- **THE EFFICACY AND SAFETY OF CANGRELOR WITH AND WITHOUT GLYCOPROTEIN IIB/IIIA INHIBITORS IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION: A POOLED ANALYSIS OF THE CHAMPION TRIALS**
Vaduganathan, M., Harrington, R., Stone, G., Steg, P., Gibson, C., Hamm, C., Price, M., Menozzi, A., Prats, J., Deliargyris, E., Mahaffey, K., White, H., Bhatt, et al
ELSEVIER SCIENCE INC.2016: 452
- **Racial/ethnic differences in atrial fibrillation symptoms, treatment patterns, and outcomes: Insights from Outcomes Registry for Better Informed Treatment for Atrial Fibrillation Registry** *AMERICAN HEART JOURNAL*
Golwala, H., Jackson, L. R., Simon, D. N., Piccini, J. P., Gersh, B., Go, A. S., Hylek, E. M., Kowey, P. R., Mahaffey, K. W., Thomas, L., Fonarow, G. C., Peterson, E. D., Thomas, et al
2016; 174: 29-36

- **Rhythm Control Versus Rate Control and Clinical Outcomes in Patients With Atrial Fibrillation: Results From the ORBIT-AF Registry.** *JACC. Clinical electrophysiology*
Noheria, A., Shrader, P., Piccini, J. P., Fonarow, G. C., Kowey, P. R., Mahaffey, K. W., Naccarelli, G., Noseworthy, P. A., Reiffel, J. A., Steinberg, B. A., Thomas, L. E., Peterson, E. D., Gersh, et al
2016; 2 (2): 221–29
- **Sudden Cardiac Death After Non-ST-Segment Elevation Acute Coronary Syndrome.** *JAMA cardiology*
Hess, P. L., Wojdyla, D. M., Al-Khatib, S. M., Lokhnygina, Y., Wallentin, L., Armstrong, P. W., Roe, M. T., Ohman, E. M., Harrington, R. A., Alexander, J. H., White, H. D., Van de Werf, F., Piccini, et al
2016; 1 (1): 73-79
- **Racial/ethnic differences in atrial fibrillation symptoms, treatment patterns, and outcomes: Insights from Outcomes Registry for Better Informed Treatment for Atrial Fibrillation Registry.** *American heart journal*
Golwala, H., Jackson, L. R., Simon, D. N., Piccini, J. P., Gersh, B., Go, A. S., Hylek, E. M., Kowey, P. R., Mahaffey, K. W., Thomas, L., Fonarow, G. C., Peterson, E. D., Thomas, et al
2016; 174: 29-36
- **Pooled analysis of adverse event collection from 4 acute coronary syndrome trials.** *American heart journal*
Zimmerman, A., Lopes, R. D., Stebbins, A. L., Guimarães, P. O., Haque, G., Melloni, C., Trollinger, K., James, S. K., Alexander, J. H., Tricoci, P., Roe, M. T., Ohman, E. M., Mahaffey, et al
2016; 174: 60-67
- **Pooled analysis of adverse event collection from 4 acute coronary syndrome trials** *AMERICAN HEART JOURNAL*
Zimmerman, A., Lopes, R. D., Stebbins, A. L., Guimaraes, P. O., Haque, G., Melloni, C., Trollinger, K., James, S. K., Alexander, J. H., Tricoci, P., Roe, M. T., Ohman, E. M., Mahaffey, et al
2016; 174: 60-67
- **Lessons Learned from EVOLVE for Planning of Future Randomized Trials in Patients on Dialysis** *CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY*
Parfrey, P. S., Block, G. A., Correa-Rotter, R., Drueke, T. B., Floege, J., Herzog, C. A., London, G. M., Mahaffey, K. W., Moe, S. M., Wheeler, D. C., Chertow, G. M.
2016; 11 (3): 539-546
- **The effects of cinacalcet on blood pressure, mortality and cardiovascular endpoints in the EVOLVE trial** *JOURNAL OF HUMAN HYPERTENSION*
Chang, T. I., Abdalla, S., London, G. M., Block, G. A., Correa-Rotter, R., Drueke, T. B., Floege, J., Herzog, C. A., Mahaffey, K. W., Moe, S. M., Parfrey, P. S., Wheeler, D. C., Dehmel, et al
2016; 30 (3): 204-209
- **Use of thienopyridine prior to presentation with non-ST-segment elevation acute coronary syndrome and association with safety and efficacy of vorapaxar: insights from the TRACER trial.** *European heart journal. Acute cardiovascular care*
Harskamp, R. E., Clare, R. M., Ambrosio, G., Held, C., Lokhnygina, Y., Moliterno, D. J., White, H. D., Aylward, P. E., Armstrong, P. W., Mahaffey, K. W., Harrington, R. A., Van de Werf, F., Wallentin, et al
2016
- **Sinus Node Dysfunction Is Associated With Higher Symptom Burden and Increased Comorbid Illness: Results From the ORBIT-AF Registry** *CLINICAL CARDIOLOGY*
Jackson, L. R., Kim, S. H., Piccini, J. P., Gersh, B. J., Naccarelli, G. V., Reiffel, J. A., Freeman, J., Thomas, L., Chang, P., Fonarow, G. C., Go, A. S., Mahaffey, K. W., Peterson, et al
2016; 39 (2): 119-125
- **Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation.** *Circulation*
Piccini, J. P., Hellkamp, A. S., Washam, J. B., Becker, R. C., Breithardt, G., Berkowitz, S. D., Halperin, J. L., Hankey, G. J., Hacke, W., Mahaffey, K. W., Nessel, C. C., Singer, D. E., Fox, et al
2016; 133 (4): 352-360
- **Efficacy and Safety of Cangrelor in Women Versus Men During Percutaneous Coronary Intervention Insights From the Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION PHOENIX) Trial** *CIRCULATION*
O'Donoghue, M. L., Bhatt, D. L., Stone, G. W., Steg, P. G., Gibson, C. M., Hamm, C. W., Price, M. J., Prats, J., Liu, T., Deliargyris, E. N., Mahaffey, K. W., White, H. D., Harrington, et al
2016; 133 (3): 248-255

- **Efficacy and Safety of Cangrelor in Women Versus Men During Percutaneous Coronary Intervention: Insights From the Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION PHOENIX) Trial.** *Circulation*
O'Donoghue, M. L., Bhatt, D. L., Stone, G. W., Steg, P. G., Gibson, C. M., Hamm, C. W., Price, M. J., Prats, J., Liu, T., Deliargyris, E. N., Mahaffey, K. W., White, H. D., Harrington, et al
2016; 133 (3): 248-55
- **Efficacy and safety of canagliflozin when used in conjunction with incretin-mimetic therapy in patients with type 2 diabetes** *DIABETES OBESITY & METABOLISM*
Fulcher, G., Matthews, D. R., Perkovic, V., de Zeeuw, D., Mahaffey, K. W., Mathieu, C., Woo, V., Wysham, C., Capuano, G., Desai, M., Shaw, W., Vercruyse, F., Meininger, et al
2016; 18 (1): 82-91
- **Racial Differences in Quality of Anticoagulation Therapy for Atrial Fibrillation (from the TREAT-AF Study)** *AMERICAN JOURNAL OF CARDIOLOGY*
Yong, C., Azarbal, F., Abnoui, F., Heidenreich, P. A., Schmitt, S., Fan, J., Than, C. T., Ullal, A. J., Yang, F., Phibbs, C. S., Frayne, S. M., Ho, P. M., Shore, et al
2016; 117 (1): 61-68
- **Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF.** *Journal of the American Heart Association*
Pokorney, S. D., Piccini, J. P., Stevens, S. R., Patel, M. R., Pieper, K. S., Halperin, J. L., Breithardt, G., Singer, D. E., Hankey, G. J., Hacke, W., Becker, R. C., Berkowitz, S. D., Nessel, et al
2016; 5 (3)
- **Racial Differences in Quality of Anticoagulation Therapy for Atrial Fibrillation (from the TREAT-AF Study)** *AMERICAN JOURNAL OF CARDIOLOGY*
Yong, C., Azarbal, F., Abnoui, F., Heidenreich, P. A., Schmitt, S., Fan, J., Than, C. T., Ullal, A. J., Yang, F., Phibbs, C. S., Frayne, S. M., Ho, P. M., Shore, et al
2016; 117 (1): 61-68
- **Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF.** *Journal of the American Heart Association*
Pokorney, S. D., Piccini, J. P., Stevens, S. R., Patel, M. R., Pieper, K. S., Halperin, J. L., Breithardt, G., Singer, D. E., Hankey, G. J., Hacke, W., Becker, R. C., Berkowitz, S. D., Nessel, et al
2016; 5 (3)
- **The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation.** *European heart journal*
O'Brien, E. C., Simon, D. N., Thomas, L. E., Hylek, E. M., Gersh, B. J., Ansell, J. E., Kowey, P. R., Mahaffey, K. W., Chang, P., Fonarow, G. C., Pencina, M. J., Piccini, J. P., Peterson, et al
2015; 36 (46): 3258-3264
- **Lost to Follow-up and Withdrawal of Consent in Contemporary Global Cardiovascular Randomized Clinical Trials.** *Critical pathways in cardiology*
Rodriguez, F., Harrison, R. W., Wojdyla, D., Mahaffey, K. W.
2015; 14 (4): 150-153
- **Cytokines profile in hypertensive patients with left ventricular remodeling and dysfunction.** *Journal of the American Society of Hypertension*
Kuznetsova, T., Haddad, F., Knez, J., Rosenberg-Hasson, Y., Sung, J., Cauwenberghs, N., Thijs, L., Karakikes, I., Maecker, H., Mahaffey, K. W., Wu, J. C., Staessen, J. A.
2015; 9 (12): 975-984 e3
- **Cytokines profile in hypertensive patients with left ventricular remodeling and dysfunction** *JOURNAL OF THE AMERICAN SOCIETY OF HYPERTENSION*
Kuznetsova, T., Haddad, F., Knez, J., Rosenberg-Hasson, Y., Sung, J., Cauwenberghs, N., Thijs, L., Karakikes, I., Maecker, H., Mahaffey, K. W., Wu, J. C., Staessen, J. A.
2015; 9 (12): 975-984
- **Gastrointestinal Bleeding in Patients With Atrial Fibrillation Treated With Rivaroxaban or Warfarin** *ROCKET AF Trial JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY*
Sherwood, M. W., Nessel, C. C., Hellkamp, A. S., Mahaffey, K. W., Piccini, J. P., Suh, E., Becker, R. C., Singer, D. E., Halperin, J. L., Hankey, G. J., Berkowitz, S. D., Fox, K. A., Patel, et al
2015; 66 (21): 2271-2281

- **Efficacy of Cangrelor in Lesions with High-Risk and Low-Risk Angiographic Characteristics: The CHAMPION PHOENIX trial**
Stone, G. W., Genereux, P., White, H. D., Gibson, C., Hamm, C., Mahaffey, K., Price, M. J., Prats, J., Harrington, R., Bhatt, D. L.
ELSEVIER SCIENCE INC.2015: B36–B37
- **Cangrelor Improves Ischemic Outcomes In Patients With Multivessel Disease And Single Vessel Disease Undergoing PCI: Insights From The CHAMPION PHOENIX Trial**
Abnoui, F., Sundaram, V., Prats, J., Deliarhyris, E. N., Stone, G. W., Hamm, C., Steg, P. G., Gibson, C., White, H. D., Price, M. J., Yong, C., Desai, M., Harrington, et al
ELSEVIER SCIENCE INC.2015: B35
- **Impact of cangrelor overdosing on bleeding complications in patients undergoing percutaneous coronary intervention: insights from the CHAMPION trials** *JOURNAL OF THROMBOSIS AND THROMBOLYSIS*
Angiolillo, D. J., Bhatt, D. L., Steg, P. G., Stone, G. W., White, H. D., Gibson, C. M., Hamm, C. W., Price, M. J., Prats, J., Liu, T., Mahaffey, K. W., Harrington, R. A.
2015; 40 (3): 317-322
- **2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards).** *Journal of nuclear cardiology*
Hicks, K. A., Tcheng, J. E., Bozkurt, B., Chaitman, B. R., Cutlip, D. E., Farb, A., Fonarow, G. C., Jacobs, J. P., Jaff, M. R., Lichtman, J. H., Limacher, M. C., Mahaffey, K. W., Mehran, et al
2015; 22 (5): 1041-1144
- **Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: The Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial).** *American heart journal*
Bansilal, S., Bloomgarden, Z., Halperin, J. L., Hellkamp, A. S., Lokhnygina, Y., Patel, M. R., Becker, R. C., Breithardt, G., Hacke, W., Hankey, G. J., Nessel, C. C., Singer, D. E., Berkowitz, et al
2015; 170 (4): 675-682 e8
- **Increased Heart Rate Is Associated With Higher Mortality in Patients With Atrial Fibrillation (AF): Results From the Outcomes Registry for Better Informed Treatment of AF (ORBIT-AF)** *JOURNAL OF THE AMERICAN HEART ASSOCIATION*
Steinberg, B. A., Kim, S., Thomas, L., Fonarow, G. C., Gersh, B. J., Holmqvist, F., Hylek, E., Kowey, P. R., Mahaffey, K. W., Naccarelli, G., Reiffel, J. A., Chang, P., Peterson, et al
2015; 4 (9)
- **Efficacy and Safety of Canagliflozin Used in Conjunction with Sulfonyleurea in Patients with Type 2 Diabetes Mellitus: A Randomized, Controlled Trial.** *Diabetes therapy : research, treatment and education of diabetes and related disorders*
Fulcher, G., Matthews, D. R., Perkovic, V., de Zeeuw, D., Mahaffey, K. W., Weiss, R., Rosenstock, J., Capuano, G., Desai, M., Shaw, W., Vercruyse, F., Meininger, G., Neal, et al
2015; 6 (3): 289-302
- **Heart Failure is Associated With Worse Quality of Life and Survival But Similar Stroke Risk in Atrial Fibrillation**
Cherian, T. S., Shrader, P., Fonarow, G. C., Allen, L. A., Peterson, E. D., Piccini, J., Thomas, L., Kowey, P. R., Burton, P., Gersh, B. J., Mahaffey, K. W.
CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS.2015: S115–S116
- **2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards)** *JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY*
Hicks, K. A., Tcheng, J. E., Bozkurt, B., Chaitman, B. R., Cutlip, D. E., Farb, A., Fonarow, G. C., Jacobs, J. P., Jaff, M. R., Lichtman, J. H., Limacher, M. C., Mahaffey, K. W., Mehran, et al
2015; 66 (4): 403-469
- **2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards).** *Circulation*
Hicks, K. A., Tcheng, J. E., Bozkurt, B., Chaitman, B. R., Cutlip, D. E., Farb, A., Fonarow, G. C., Jacobs, J. P., Jaff, M. R., Lichtman, J. H., Limacher, M. C., Mahaffey, K. W., Mehran, et al
2015; 132 (4): 302-361

- **2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards).** *Journal of the American College of Cardiology*
Hicks, K. A., Tcheng, J. E., Bozkurt, B., Chaitman, B. R., Cutlip, D. E., Farb, A., Fonarow, G. C., Jacobs, J. P., Jaff, M. R., Lichtman, J. H., Limacher, M. C., Mahaffey, K. W., Mehran, et al
2015; 66 (4): 403-469
- **2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards)** *CIRCULATION*
Hicks, K. A., Tcheng, J. E., Bozkurt, B., Chaitman, B. R., Cutlip, D. E., Farb, A., Fonarow, G. C., Jacobs, J. P., Jaff, M. R., Lichtman, J. H., Limacher, M. C., Mahaffey, K. W., Mehran, et al
2015; 132 (4): 302-361
- **Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial** *CIRCULATION*
Moe, S. M., Chertow, G. M., Parfrey, P. S., Kubo, Y., Block, G. A., Correa-Rotter, R., Drueeke, T. B., Herzog, C. A., London, G. M., Mahaffey, K. W., Wheeler, D. C., Stolina, M., Dehmel, et al
2015; 132 (1): 27-39
- **Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial.** *Circulation*
Moe, S. M., Chertow, G. M., Parfrey, P. S., Kubo, Y., Block, G. A., Correa-Rotter, R., Drueeke, T. B., Herzog, C. A., London, G. M., Mahaffey, K. W., Wheeler, D. C., Stolina, M., Dehmel, et al
2015; 132 (1): 27-39
- **Sex-Stratified Trends in Enrollment, Patient Characteristics, Treatment, and Outcomes Among Non-ST-Segment Elevation Acute Coronary Syndrome Patients Insights From Clinical Trials Over 17 Years** *CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES*
Kragholm, K., Halim, S. A., Yang, Q., Schulte, P. J., Hochman, J. S., Melloni, C., Mahaffey, K. W., Moliterno, D. J., Harrington, R. A., White, H. D., Armstrong, P. W., Ohman, E. M., Van de Werf, et al
2015; 8 (4): 357-367
- **Cardiac Safety Research Consortium (CSRC): Cardiovascular Safety and Adverse Event Case Report Forms** *THERAPEUTIC INNOVATION & REGULATORY SCIENCE*
Sabol, M., Finkle, J., Krucoff, M., Stockbridge, N., Parkhill, N., Shinagawa, K., Mahaffey, K., Tcheng, J., Lenihan, D., Melloni, C., Todaro, T., Michelson, E., Munley, et al
2015; 49 (4): 511-13
- **Association Between Atrial Fibrillation Symptoms, Quality of Life, and Patient Outcomes: Results From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF).** *Circulation. Cardiovascular quality and outcomes*
Freeman, J. V., Simon, D. N., Go, A. S., Spertus, J., Fonarow, G. C., Gersh, B. J., Hylek, E. M., Kowey, P. R., Mahaffey, K. W., Thomas, L. E., Chang, P., Peterson, E. D., Piccini, et al
2015; 8 (4): 393-402
- **Sex-Stratified Trends in Enrollment, Patient Characteristics, Treatment, and Outcomes Among Non-ST-Segment Elevation Acute Coronary Syndrome Patients: Insights From Clinical Trials Over 17 Years.** *Circulation. Cardiovascular quality and outcomes*
Kragholm, K., Halim, S. A., Yang, Q., Schulte, P. J., Hochman, J. S., Melloni, C., Mahaffey, K. W., Moliterno, D. J., Harrington, R. A., White, H. D., Armstrong, P. W., Ohman, E. M., Van de Werf, et al
2015; 8 (4): 357-367
- **Patients' time in therapeutic range on warfarin among US patients with atrial fibrillation: Results from ORBIT-AF registry** *AMERICAN HEART JOURNAL*
Pokorney, S. D., Simon, D. N., Thomas, L., Fonarow, G. C., Kowey, P. R., Chang, P., Singer, D. E., Ansell, J., Blanco, R. G., Gersh, B., Mahaffey, K. W., Hylek, E. M., Go, et al
2015; 170 (1): 141-U194
- **Association Between Atrial Fibrillation Symptoms, Quality of Life, and Patient Outcomes Results From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)** *CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES*
Freeman, J. V., Simon, D. N., Go, A. S., Spertus, J., Fonarow, G. C., Gersh, B. J., Hylek, E. M., Kowey, P. R., Mahaffey, K. W., Thomas, L. E., Chang, P., Peterson, E. D., Piccini, et al
2015; 8 (4): 393-402

- **Digoxin Use and Subsequent Outcomes Among Patients in a Contemporary Atrial Fibrillation Cohort** *JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY*
Allen, L. A., Fonarow, G. C., Simon, D. N., Thomas, L. E., Marzec, L. N., Pokorney, S. D., Gersh, B. J., Go, A. S., Hylek, E. M., Kowey, P. R., Mahaffey, K. W., Chang, P., Peterson, et al
2015; 65 (25): 2691-2698
- **Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF)** *LANCET*
Washam, J. B., Stevens, S. R., Lokhnygina, Y., Halperin, J. L., Breithardt, G., Singer, D. E., Mahaffey, K. W., Hankey, G. J., Berkowitz, S. D., Nessel, C. C., Fox, K. A., Califf, R. M., Piccini, et al
2015; 385 (9985): 2363-2370
- **Effects of Cinacalcet on Fracture Events in Patients Receiving Hemodialysis: The EVOLVE Trial.** *Journal of the American Society of Nephrology*
Moe, S. M., Abdalla, S., Chertow, G. M., Parfrey, P. S., Block, G. A., Correa-Rotter, R., Floege, J., Herzog, C. A., London, G. M., Mahaffey, K. W., Wheeler, D. C., Dehmel, B., Goodman, et al
2015; 26 (6): 1466-1475
- **The future of cardiovascular clinical research in North America and beyond-addressing challenges and leveraging opportunities through unique academic and grassroots collaborations.** *American heart journal*
Roe, M. T., Mahaffey, K. W., Ezekowitz, J. A., Alexander, J. H., Goodman, S. G., Hernandez, A., Temple, T., Berdan, L., Califf, R. M., Harrington, R. A., Peterson, E. D., Armstrong, P. W.
2015; 169 (6): 743-750
- **Effects of Cinacalcet on Fracture Events in Patients Receiving Hemodialysis: The EVOLVE Trial** *JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY*
Moe, S. M., Abdalla, S., Chertow, G. M., Parfrey, P. S., Block, G. A., Correa-Rotter, R., Floege, J., Herzog, C. A., London, G. M., Mahaffey, K. W., Wheeler, D. C., Dehmel, B., Goodman, et al
2015; 26 (6): 1466-1475
- **Magnitude of troponin elevation and long-term clinical outcomes in acute coronary syndrome patients treated with and without revascularization.** *Circulation. Cardiovascular interventions*
Bagai, A., Huang, Z., Lokhnygina, Y., Harrington, R. A., Armstrong, P. W., Strony, J., White, H. D., Leonardi, S., Held, C., Van de Werf, F., Wallentin, L., Tricoci, P., Mahaffey, et al
2015; 8 (6)
- **Meta-Analysis of Intracranial Hemorrhage in Acute Coronary Syndromes: Incidence, Predictors, and Clinical Outcomes** *JOURNAL OF THE AMERICAN HEART ASSOCIATION*
Mahaffey, K. W., Hager, R., Wojdyla, D., White, H. D., Armstrong, P. W., Alexander, J. H., Tricoci, P., Lopes, R. D., Ohman, E. M., Roe, M. T., Harrington, R. A., Wallentin, L.
2015; 4 (6)
- **Heart rate is associated with progression of atrial fibrillation, independent of rhythm** *HEART*
Holmqvist, F., Kim, S., Steinberg, B. A., Reiffel, J. A., Mahaffey, K. W., Gersh, B. J., Fonarow, G. C., Naccarelli, G. V., Chang, P., Freeman, J. V., Kowey, P. R., Thomas, L., Peterson, et al
2015; 101 (11): 894-899
- **Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: Data from the PLATO Trial** *EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY*
Patel, M. R., Becker, R. C., Wojdyla, D. M., Emanuelsson, H., Hiatt, W. R., Horrow, J., Husted, S., Mahaffey, K. W., Steg, P. G., Storey, R. F., Wallentin, L., James, S. K.
2015; 22 (6): 734-742
- **The future of cardiovascular clinical research in North America and beyond-addressing challenges and leveraging opportunities through unique academic and grassroots collaborations** *AMERICAN HEART JOURNAL*
Roe, M. T., Mahaffey, K. W., Ezekowitz, J. A., Alexander, J. H., Goodman, S. G., Hernandez, A., Temple, T., Berdan, L., Califf, R. M., Harrington, R. A., Peterson, E. D., Armstrong, P. W.
2015; 169 (6): 743-750
- **Glycoprotein IIb/IIIa Receptor Inhibitors in Combination With Vorapaxar, a Platelet Thrombin Receptor Antagonist, Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes (from the TRACER Trial)** *AMERICAN JOURNAL OF CARDIOLOGY*

- Cornel, J. H., Tricoci, P., Lokhnygina, Y., Moliterno, D. J., Wallentin, L., Armstrong, P. W., Aylward, P. E., Clare, R. M., Chen, E., Leonardi, S., de Werf, F. V., White, H. D., Held, et al
2015; 115 (10): 1325-1332
- **Glycoprotein IIb/IIIa Receptor Inhibitors in Combination With Vorapaxar, a Platelet Thrombin Receptor Antagonist, Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes (from the TRACER Trial).** *American journal of cardiology*
Cornel, J. H., Tricoci, P., Lokhnygina, Y., Moliterno, D. J., Wallentin, L., Armstrong, P. W., Aylward, P. E., Clare, R. M., Chen, E., Leonardi, S., Van de Werf, F., White, H. D., Held, et al
2015; 115 (10): 1325-1332
 - **The Effects of Cinacalcet in Older and Younger Patients on Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial.** *Clinical journal of the American Society of Nephrology*
Parfrey, P. S., Drüeke, T. B., Block, G. A., Correa-Rotter, R., Floege, J., Herzog, C. A., London, G. M., Mahaffey, K. W., Moe, S. M., Wheeler, D. C., Kubo, Y., Dehmel, B., Goodman, et al
2015; 10 (5): 791-799
 - **Impact of obstructive sleep apnea and continuous positive airway pressure therapy on outcomes in patients with atrial fibrillation-Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)** *AMERICAN HEART JOURNAL*
Holmqvist, F., Guan, N., Zhu, Z., Kowey, P. R., Allen, L. A., Fonarow, G. C., Hylek, E. M., Mahaffey, K. W., Freeman, J. V., Chang, P., Holmes, D. N., Peterson, E. D., Piccini, et al
2015; 169 (5): 647-U93
 - **Assessing the treatment effect in a randomized controlled trial with extensive non-adherence: the EVOLVE trial** *PHARMACEUTICAL STATISTICS*
Kubo, Y., Sterling, L. R., Parfrey, P. S., Gill, K., Mahaffey, K. W., Gioni, I., Trotman, M., Dehmel, B., Chertow, G. M.
2015; 14 (3): 242-251
 - **The Effects of Cinacalcet in Older and Younger Patients on Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial** *CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY*
Parfrey, P. S., Druceke, T. B., Block, G. A., Correa-Rotter, R., Floege, J., Herzog, C. A., London, G. M., Mahaffey, K. W., Moe, S. M., Wheeler, D. C., Kubo, Y., Dehmel, B., Goodman, et al
2015; 10 (5): 791-799
 - **Efficacy and safety of canagliflozin, an inhibitor of sodium-glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes.** *Diabetes care*
Neal, B., Perkovic, V., de Zeeuw, D., Mahaffey, K. W., Fulcher, G., Ways, K., Desai, M., Shaw, W., Capuano, G., Alba, M., Jiang, J., Vercruyse, F., Meininger, et al
2015; 38 (3): 403-411
 - **Outcomes With Cangrelor Versus Clopidogrel on a Background of Bivalirudin Insights From the CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention [PCI])** *JACC-CARDIOVASCULAR INTERVENTIONS*
White, H. D., Bhatt, D. L., Gibson, C. M., Hamm, C. W., Mahaffey, K. W., Price, M. J., Steg, P. G., Stone, G. W., Cortese, B., Wilensky, M., Deliangyris, E. N., Liu, T., Prats, et al
2015; 8 (3): 424-433
 - **Use and Outcomes Associated With Bridging During Anticoagulation Interruptions in Patients With Atrial Fibrillation: Findings From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF).** *Circulation*
Steinberg, B. A., Peterson, E. D., Kim, S., Thomas, L., Gersh, B. J., Fonarow, G. C., Kowey, P. R., Mahaffey, K. W., Sherwood, M. W., Chang, P., Piccini, J. P., Ansell, J.
2015; 131 (5): 488-494
 - **Centralized adjudication of cardiovascular end points in cardiovascular and noncardiovascular pharmacologic trials: A report from the Cardiac Safety Research Consortium** *AMERICAN HEART JOURNAL*
Seltzer, J. H., Turner, J. R., Geiger, M. J., Rosano, G., Mahaffey, K. W., White, W. B., Sabol, M. B., Stockbridge, N., Sager, P. T.
2015; 169 (2): 197-204
 - **Centralized adjudication of cardiovascular end points in cardiovascular and noncardiovascular pharmacologic trials: a report from the Cardiac Safety Research Consortium.** *American heart journal*
Seltzer, J. H., Turner, J. R., Geiger, M. J., Rosano, G., Mahaffey, K. W., White, W. B., Sabol, M. B., Stockbridge, N., Sager, P. T.
2015; 169 (2): 197-204

- **Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial.** *European heart journal*
Steinberg, B. A., Hellkamp, A. S., Lokhnygina, Y., Patel, M. R., Breithardt, G., Hankey, G. J., Becker, R. C., Singer, D. E., Halperin, J. L., Hacke, W., Nessel, C. C., Berkowitz, S. D., Mahaffey, et al
2015; 36 (5): 288-296
- **Effects of Cinacalcet on Atherosclerotic and Nonatherosclerotic Cardiovascular Events in Patients Receiving Hemodialysis: The Evaluation Of Cinacalcet HCl Therapy to Lower CardioVascular Events (EVOLVE) Trial** *JOURNAL OF THE AMERICAN HEART ASSOCIATION*
Wheeler, D. C., London, G. M., Parfrey, P. S., Block, G. A., Correa-Rotter, R., Dehmel, B., Drueeke, T. B., Floege, J., Kubo, Y., Mahaffey, K. W., Goodman, W. G., Moe, S. M., Trotman, et al
2015; 4 (1)
- **Efficacy and Safety of Vorapaxar in Non-ST-Segment Elevation Acute Coronary Syndrome Patients Undergoing Noncardiac Surgery.** *Journal of the American Heart Association*
van Diepen, S., Tricoci, P., Podder, M., Westerhout, C. M., Aylward, P. E., Held, C., Van de Werf, F., Strony, J., Wallentin, L., Moliterno, D. J., White, H. D., Mahaffey, K. W., Harrington, et al
2015; 4 (12)
- **Alternative Calculations of Individual Patient Time in Therapeutic Range While Taking Warfarin: Results From the ROCKET AF Trial.** *Journal of the American Heart Association*
Singer, D. E., Hellkamp, A. S., Yuan, Z., Lokhnygina, Y., Patel, M. R., Piccini, J. P., Hankey, G. J., Breithardt, G., Halperin, J. L., Becker, R. C., Hacke, W., Nessel, C. C., Mahaffey, et al
2015; 4 (3)
- **Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial** *EUROPEAN HEART JOURNAL*
Breithardt, G., Baumgartner, H., Berkowitz, S. D., Hellkamp, A. S., Piccini, J. P., Stevens, S. R., Lokhnygina, Y., Patel, M. R., Halperin, J. L., Singer, D. E., Hankey, G. J., Hacke, W., Becker, et al
2014; 35 (47): 3377-3385
- **Effects of Cinacalcet on Atherosclerotic and Nonatherosclerotic Cardiovascular Events in Patients Receiving Hemodialysis: The Evaluation Of Cinacalcet HCl Therapy to Lower CardioVascular Events (EVOLVE) Trial** *JOURNAL OF THE AMERICAN HEART ASSOCIATION*
Wheeler, D. C., London, G. M., Parfrey, P. S., Block, G. A., Correa-Rotter, R., Dehmel, B., Drueeke, T. B., Floege, J., Kubo, Y., Mahaffey, K. W., Goodman, W. G., Moe, S. M., Trotman, et al
2014; 3 (6)
- **Vorapaxar with or without clopidogrel after non-ST-segment elevation acute coronary syndromes: results from the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome trial.** *American heart journal*
Tricoci, P., Lokhnygina, Y., Huang, Z., Van de Werf, F., Cornel, J. H., Chen, E., Wallentin, L., Held, C., Aylward, P. E., Moliterno, D. J., Jennings, L. K., White, H. D., Armstrong, et al
2014; 168 (6): 869-77.e1
- **Effects of cinacalcet on atherosclerotic and nonatherosclerotic cardiovascular events in patients receiving hemodialysis: the Evaluation Of Cinacalcet HCl Therapy to Lower CardioVascular Events (EVOLVE) trial.** *Journal of the American Heart Association*
Wheeler, D. C., London, G. M., Parfrey, P. S., Block, G. A., Correa-Rotter, R., Dehmel, B., Drueeke, T. B., Floege, J., Kubo, Y., Mahaffey, K. W., Goodman, W. G., Moe, S. M., Trotman, et al
2014; 3 (6)
- **Vorapaxar with or without clopidogrel after non-ST-segment elevation acute coronary syndromes: Results from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome trial** *AMERICAN HEART JOURNAL*
Tricoci, P., Lokhnygina, Y., Huang, Z., Van de Werf, F., Cornel, J. H., Chen, E., Wallentin, L., Held, C., Aylward, P. E., Moliterno, D. J., Jennings, L. K., White, H. D., Armstrong, et al
2014; 168 (6): 869-?
- **Causes of mortality with ticagrelor compared with clopidogrel in acute coronary syndromes** *HEART*
Varenhorst, C., Alstrom, U., Braun, O. O., Storey, R. F., Mahaffey, K. W., Bertilsson, M., Cannon, C. P., Scirica, B. M., Himmelmann, A., James, S. K., Wallentin, L., Held, C.
2014; 100 (22): 1762-?

- **Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: Rationale and design of the ODYSSEY Outcomes trial** *AMERICAN HEART JOURNAL*
Schwartz, G. G., Bessac, L., Berdan, L. G., Bhatt, D. L., Bittner, V., Diaz, R., Goodman, S. G., Hanotin, C., Harrington, R. A., Jukema, J. W., Mahaffey, K. W., Moryusef, A., Pordy, et al
2014; 168 (5): 682-689
- **Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial.** *American heart journal*
Schwartz, G. G., Bessac, L., Berdan, L. G., Bhatt, D. L., Bittner, V., Diaz, R., Goodman, S. G., Hanotin, C., Harrington, R. A., Jukema, J. W., Mahaffey, K. W., Moryusef, A., Pordy, et al
2014; 168 (5): 682-9
- **Causes of mortality with ticagrelor compared with clopidogrel in acute coronary syndromes.** *Heart (British Cardiac Society)*
Varenhorst, C., Alström, U., Braun, O. Ö., Storey, R. F., Mahaffey, K. W., Bertilsson, M., Cannon, C. P., Scirica, B. M., Himmelman, A., James, S. K., Wallentin, L., Held, C.
2014; 100 (22): 1762-9
- **Challenges and solutions to pre- and post-randomization subgroup analyses.** *Current cardiology reports*
Desai, M., Pieper, K. S., Mahaffey, K.
2014; 16 (10): 531-?
- **Vorapaxar in patients with peripheral artery disease and acute coronary syndrome: insights from Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER).** *American heart journal*
Jones, W. S., Tricoci, P., Huang, Z., Moliterno, D. J., Harrington, R. A., Sinnaeve, P. R., Strony, J., Van de Werf, F., White, H. D., Held, C., Armstrong, P. W., Aylward, P. E., Chen, et al
2014; 168 (4): 588-96
- **Prognostic implications of creatine kinase-MB measurements in ST-segment elevation myocardial infarction patients treated with primary percutaneous coronary intervention** *AMERICAN HEART JOURNAL*
Bagai, A., Schulte, P. J., Granger, C. B., Mahaffey, K. W., Christenson, R. H., Bell, G., Lopes, R. D., Green, C. L., Lincoff, A. M., Armstrong, P. W., Roe, M. T.
2014; 168 (4): 503-?
- **Reasons for warfarin discontinuation in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)** *AMERICAN HEART JOURNAL*
O'Brien, E. C., Simon, D. N., Allen, L. A., Singer, D. E., Fonarow, G. C., Kowey, P. R., Thomas, L. E., Ezekowitz, M. D., Mahaffey, K. W., Chang, P., Piccini, J. P., Peterson, E. D.
2014; 168 (4): 487-494
- **Vorapaxar in patients with peripheral artery disease and acute coronary syndrome: Insights from Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER)** *AMERICAN HEART JOURNAL*
Jones, W. S., Tricoci, P., Huang, Z., Moliterno, D. J., Harrington, R. A., Sinnaeve, P. R., Strony, J., Van de Werf, F., White, H. D., Held, C., Armstrong, P. W., Aylward, P. E., Chen, et al
2014; 168 (4): 588-596
- **Challenges and Priorities for Research A Report From the National Heart, Lung, and Blood Institute (NHLBI)/National Institutes of Health (NIH) Working Group on Thrombosis in Pediatric Cardiology and Congenital Heart Disease** *CIRCULATION*
McCordle, B. W., Li, J. S., Manlihot, C., Tweddell, J. S., Giglia, T. M., Massicotte, M. P., Monagle, P., Krishnamurthy, R., Mahaffey, K. W., Michelson, A. D., Verdun, N., Almond, C. S., Newburger, et al
2014; 130 (14): 1192-1203
- **Challenges and priorities for research: a report from the National Heart, Lung, and Blood Institute (NHLBI)/National Institutes of Health (NIH) Working Group on thrombosis in pediatric cardiology and congenital heart disease.** *Circulation*
McCordle, B. W., Li, J. S., Manlihot, C., Tweddell, J. S., Giglia, T. M., Massicotte, M. P., Monagle, P., Krishnamurthy, R., Mahaffey, K. W., Michelson, A. D., Verdun, N., Almond, C. S., Newburger, et al
2014; 130 (14): 1192-203
- **Effect of Cangrelor on Ischemic Endpoints: Further Analyses from CHAMPION PHOENIX**
Bhatt, D. L., Stone, G. W., Mahaffey, K., Gibson, C., Steg, P. G., Hamm, C., Price, M. J., Liu, T., Deliangyris, E. N., Skerjanec, S., Prats, J., White, H. D., Harrington, et al
ELSEVIER SCIENCE INC.2014: B142

- **Vorapaxar, a platelet thrombin-receptor antagonist, in medically managed patients with non-ST-segment elevation acute coronary syndrome: results from the TRACER trial.** *European heart journal. Acute cardiovascular care*
Held, C., Tricoci, P., Huang, Z., Van de Werf, F., White, H. D., Armstrong, P. W., Ambrosio, G., Aylward, P. E., Moliterno, D. J., Wallentin, L., Chen, E., Erkan, A., Jiang, et al
2014; 3 (3): 246-256
- **No misrepresentation of vital status follow-up in PLATO: Predefined analyses guarantee the integrity of the benefits of ticagrelor over clopidogrel in the PLATO trial** Commentary on: DiNicolantonio JJ, Tomek A, Misrepresentation of vital status follow-up: Challenging the integrity of the PLATO trial and the claimed mortality benefit of ticagrelor versus clopidogrel, *International Journal of Cardiology*, 2013 Serebruany VL. Discrepancies in the primary PLATO trial publication and the FDA reviews, *International Journal of Cardiology*, 2014 *INTERNATIONAL JOURNAL OF CARDIOLOGY*
Wallentin, L., Becker, R. C., Cannon, C. P., Held, C., Himmelmann, A., Husted, S., James, S. K., Katus, H. A., Mahaffey, K. M., Pieper, K. S., Storey, R. F., Steg, P., Harrington, et al
2014; 176 (1): 300–302
- **Usefulness and Safety of Vorapaxar in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention (from the TRACER Trial).** *American journal of cardiology*
Valgimigli, M., Tricoci, P., Huang, Z., Aylward, P. E., Armstrong, P. W., Van de Werf, F., Leonardi, S., White, H. D., Widimsky, P., Harrington, R. A., Cequier, A., Chen, E., Lokhnygina, et al
2014; 114 (5): 665-673
- **Independent data monitoring committees: Preparing a path for the future.** *American heart journal*
Hess, C. N., Roe, M. T., Gibson, C. M., J Temple, R., Pencina, M. J., Zarin, D. A., Anstrom, K. J., Alexander, J. H., Sherman, R. E., Fiedorek, F. T., Mahaffey, K. W., Lee, K. L., Chow, et al
2014; 168 (2): 135-141 e1
- **Long-term outcomes associated with hospital acquired thrombocytopenia among patients with non-ST-segment elevation acute coronary syndrome** *AMERICAN HEART JOURNAL*
Vora, A. N., Chenier, M., Schulte, P. J., Goodman, S., Peterson, E. D., Pieper, K., Jolicoeur, M. E., Mahaffey, K. W., White, H., Wang, T. Y.
2014; 168 (2): 189-?
- **Population Pharmacokinetics and Pharmacodynamics of Rivaroxaban in Patients with Non-valvular Atrial Fibrillation: Results from ROCKET AF** *JOURNAL OF CLINICAL PHARMACOLOGY*
Girgis, I. G., Patel, M. R., Peters, G. R., Moore, K. T., Mahaffey, K. W., Nessel, C. C., Halperin, J. L., Califf, R. M., Fox, K. A., Becker, R. C.
2014; 54 (8): 917-927
- **Outcomes registry for better informed treatment of atrial fibrillation II: Rationale and design of the ORBIT-AF II registry.** *American heart journal*
Steinberg, B. A., Blanco, R. G., Ollis, D., Kim, S., Holmes, D. N., Kowey, P. R., Fonarow, G. C., Ansell, J., Gersh, B., Go, A. S., Hylek, E., Mahaffey, K. W., Thomas, et al
2014; 168 (2): 160-167
- **Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial.** *European heart journal*
Piccini, J. P., Garg, J., Patel, M. R., Lokhnygina, Y., Goodman, S. G., Becker, R. C., Berkowitz, S. D., Breithardt, G., Hacke, W., Halperin, J. L., Hankey, G. J., Nessel, C. C., Mahaffey, et al
2014; 35 (28): 1873-1880
- **Efficacy and Safety of Rivaroxaban Compared With Warfarin Among Elderly Patients With Nonvalvular Atrial Fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF)** *CIRCULATION*
Halperin, J. L., Hankey, G. J., Wojdyla, D. M., Piccini, J. P., Lokhnygina, Y., Patel, M. R., Breithardt, G., Singer, D. E., Becker, R. C., Hacke, W., Paolini, J. F., Nessel, C. C., Mahaffey, et al
2014; 130 (2): 138-U45
- **Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF).** *Circulation*
Halperin, J. L., Hankey, G. J., Wojdyla, D. M., Piccini, J. P., Lokhnygina, Y., Patel, M. R., Breithardt, G., Singer, D. E., Becker, R. C., Hacke, W., Paolini, J. F., Nessel, C. C., Mahaffey, et al
2014; 130 (2): 138-146

- **Use and outcomes of antiarrhythmic therapy in patients with atrial fibrillation receiving oral anticoagulation: Results from the ROCKET AF trial.** *Heart rhythm*
Steinberg, B. A., Hellkamp, A. S., Lokhnygina, Y., Halperin, J. L., Breithardt, G., Passman, R., Hankey, G. J., Patel, M. R., Becker, R. C., Singer, D. E., Hacke, W., Berkowitz, S. D., Nessel, et al
2014; 11 (6): 925-932
- **Comparison of clinical trial outcome patterns in patients following acute coronary syndromes and in patients with chronic stable atherosclerosis.** *Clinical cardiology*
Mahaffey, K. W., Wojdyla, D. M., Pieper, K. S., Tricoci, P., Alexander, J. H., Lincoff, A. M., Brennan, D. M., Bhatt, D. L., Wallentin, L., Harrington, R. A.
2014; 37 (6): 337-342
- **Rivaroxaban for Stroke Prevention in East Asian Patients From the ROCKET AF Trial** *STROKE*
Wong, K. S., Hu, D. Y., Oomman, A., Tan, R., Patel, M. R., Singer, D. E., Breithardt, G., Mahaffey, K. W., Becker, R. C., Califf, R., Fox, K. A., Berkowitz, S. D., Hacke, et al
2014; 45 (6): 1739-?
- **Comparison of Clinical Trial Outcome Patterns in Patients Following Acute Coronary Syndromes and in Patients With Chronic Stable Atherosclerosis** *CLINICAL CARDIOLOGY*
Mahaffey, K. W., Wojdyla, D. M., Pieper, K. S., Tricoci, P., Alexander, J. H., Lincoff, A. M., Brennan, D. M., Bhatt, D. L., Wallentin, L., Harrington, R. A.
2014; 37 (6): 337-342
- **Lack of concordance between empirical scores and physician assessments of stroke and bleeding risk in atrial fibrillation: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry.** *Circulation*
Steinberg, B. A., Kim, S., Thomas, L., Fonarow, G. C., Hylek, E., Ansell, J., Go, A. S., Chang, P., Kowey, P., Gersh, B. J., Mahaffey, K. W., Singer, D. E., Piccini, et al
2014; 129 (20): 2005-2012
- **Lack of Concordance Between Empirical Scores and Physician Assessments of Stroke and Bleeding Risk in Atrial Fibrillation: Results From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry.** *Circulation*
Steinberg, B. A., Kim, S., Thomas, L., Fonarow, G. C., Hylek, E., Ansell, J., Go, A. S., Chang, P., Kowey, P., Gersh, B. J., Mahaffey, K. W., Singer, D. E., Piccini, et al
2014; 129 (20): 2005-2012
- **Response to Letter Regarding Article, "Stent Thrombosis With Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes: An Analysis From the Prospective, Randomized PLATO Trial"** *CIRCULATION*
Steg, P., Harrington, R. A., Emanuelsson, H., Katus, H. A., Mahaffey, K. W., Meier, B., Storey, R. F., Wojdyla, D. M., Lewis, B. S., Maurer, G., Wallentin, L., James, S. K.
2014; 129 (19): E494-E495
- **Outcomes of Temporary Interruption of Rivaroxaban Compared With Warfarin in Patients With Nonvalvular Atrial Fibrillation: Results From the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF).** *Circulation*
Sherwood, M. W., Douketis, J. D., Patel, M. R., Piccini, J. P., Hellkamp, A. S., Lokhnygina, Y., Spyropoulos, A. C., Hankey, G. J., Singer, D. E., Nessel, C. C., Mahaffey, K. W., Fox, K. A., Califf, et al
2014; 129 (18): 1850-1859
- **Outcomes of Temporary Interruption of Rivaroxaban Compared With Warfarin in Patients With Nonvalvular Atrial Fibrillation** *CIRCULATION*
Sherwood, M. W., Douketis, J. D., Patel, M. R., Piccini, J. P., Hellkamp, A. S., Lokhnygina, Y., Spyropoulos, A. C., Hankey, G. J., Singer, D. E., Nessel, C. C., Mahaffey, K. W., Fox, K. A., Califf, et al
2014; 129 (18): 1850-1859
- **Effects of vorapaxar on platelet reactivity and biomarker expression in non-ST-elevation acute coronary syndromes. The TRACER Pharmacodynamic Substudy.** *Thrombosis and haemostasis*
Storey, R. F., Kotha, J., Smyth, S. S., Moliterno, D. J., Rorick, T. L., Moccetti, T., Valgimigli, M., Dery, J. P., Cornel, J. H., Thomas, G. S., Huber, K., Harrington, R. A., Hord, et al
2014; 111 (5): 883-891
- **Intracranial hemorrhage among patients with atrial fibrillation anticoagulated with warfarin or rivaroxaban: the rivaroxaban once daily, oral, direct factor xa inhibition compared with vitamin k antagonism for prevention of stroke and embolism trial in atrial fibrillation.** *Stroke; a journal of cerebral circulation*
Hankey, G. J., Stevens, S. R., Piccini, J. P., Lokhnygina, Y., Mahaffey, K. W., Halperin, J. L., Patel, M. R., Breithardt, G., Singer, D. E., Becker, R. C., Berkowitz, S. D., Paolini, J. F., Nessel, et al

2014; 45 (5): 1304-1312

- **Darapladib for Preventing Ischemic Events in Stable Coronary Heart Disease** *NEW ENGLAND JOURNAL OF MEDICINE*
White, H. D., Held, C., Stewart, R., Tarka, E., Brown, R., Davies, R. Y., Budaj, A., Harrington, R. A., Steg, P. G., Ardis-Sino, D., Armstrong, P. W., Avezum, A., Aylward, et al
2014; 370 (18): 1702-1711
- **Effects of vorapaxar on platelet reactivity and biomarker expression in non-ST-elevation acute coronary syndromes** *THROMBOSIS AND HAEMOSTASIS*
Storey, R. F., Kotha, J., Smyth, S. S., Moliterno, D. J., Rorick, T. L., Moccetti, T., Valgimigli, M., Dery, J. P., Cornel, J. H., Thomas, G. S., Huber, K., Harrington, R. A., Hord, et al
2014; 111 (5): 883-891
- **Drivers of hospitalization for patients with atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)** *AMERICAN HEART JOURNAL*
Steinberg, B. A., Kim, S., Fonarow, G. C., Thomas, L., Ansell, J., Kowey, P. R., Mahaffey, K. W., Gersh, B. J., Hylek, E., Naccarelli, G., Go, A. S., Reiffel, J., Chang, et al
2014; 167 (5): 735-U131
- **Drivers of hospitalization for patients with atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF).** *American heart journal*
Steinberg, B. A., Kim, S., Fonarow, G. C., Thomas, L., Ansell, J., Kowey, P. R., Mahaffey, K. W., Gersh, B. J., Hylek, E., Naccarelli, G., Go, A. S., Reiffel, J., Chang, et al
2014; 167 (5): 735-42 e2
- **Ticagrelor Effects on Myocardial Infarction and the Impact of Event Adjudication in the PLATO (Platelet Inhibition and Patient Outcomes) Trial.** *Journal of the American College of Cardiology*
Mahaffey, K. W., Held, C., Wojdyla, D. M., James, S. K., Katus, H. A., Husted, S., Steg, P. G., Cannon, C. P., Becker, R. C., Storey, R. F., Khurmi, N. S., Nicolau, J. C., Yu, et al
2014; 63 (15): 1493-1499
- **Physician practices regarding contraindications to oral anticoagulation in atrial fibrillation: findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry.** *American heart journal*
O'Brien, E. C., Holmes, D. N., Ansell, J. E., Allen, L. A., Hylek, E., Kowey, P. R., Gersh, B. J., Fonarow, G. C., Koller, C. R., Ezekowitz, M. D., Mahaffey, K. W., Chang, P., Peterson, et al
2014; 167 (4): 601-609 e1
- **REDUCED DEATH, MYOCARDIAL INFARCTION, AND EARLY STENT THROMBOSIS WITH CANGRELOR VERSUS CLOPIDOGREL ON A BACKGROUND OF BIVALIRUDIN: INSIGHTS FROM CHAMPION PHOENIX**
White, H. D., Bhatt, D. L., Gibson, C., Hamm, C. W., Mahaffey, K. W., Price, M. J., Steg, P., Stone, G. W., Cortese, B., Wilensky, M., Deliargyris, E. N., Liu, T., Prats, et al
ELSEVIER SCIENCE INC.2014: A36
- **Relationship Between Time in Therapeutic Range and Comparative Treatment Effect of Rivaroxaban and Warfarin: Results From the ROCKET AF Trial** *JOURNAL OF THE AMERICAN HEART ASSOCIATION*
Piccini, J. P., Hellkamp, A. S., Lokhnygina, Y., Patel, M. R., Harrell, F. E., Singer, D. E., Becker, R. C., Breithardt, G., Halperin, J. L., Hankey, G. J., Berkowitz, S. D., Nessel, C. C., Mahaffey, et al
2014; 3 (2)
- **Physician practices regarding contraindications to oral anticoagulation in atrial fibrillation: Findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry** *AMERICAN HEART JOURNAL*
O'Brien, E. C., Holmes, D. N., Ansell, J. E., Allen, L. A., Hylek, E., Kowey, P. R., Gersh, B. J., Fonarow, G. C., Koller, C. R., Ezekowitz, M. D., Mahaffey, K. W., Chang, P., Peterson, et al
2014; 167 (4): 601-U229
- **Vorapaxar in Acute Coronary Syndrome Patients Undergoing Coronary Artery Bypass Graft Surgery: Subgroup Analysis From the TRACER Trial (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome).** *Journal of the American College of Cardiology*
Whellan, D. J., Tricoci, P., Chen, E., Huang, Z., Leibowitz, D., Vranckx, P., Marhefka, G. D., Held, C., Nicolau, J. C., Storey, R. F., Ruzylo, W., Huber, K., Sinnaeve, et al
2014; 63 (11): 1048-1057

- **Vorapaxar in Acute Coronary Syndrome Patients Undergoing Coronary Artery Bypass Graft Surgery** *JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY*
Whellan, D. J., Tricoci, P., Chen, E., Huang, Z., Leibowitz, D., Vranckx, P., Marhefka, G. D., Held, C., Nicolau, J. C., Storey, R. F., Ruzyllo, W., Huber, K., Sinnaeve, et al
2014; 63 (11): 1048-1057
- **Association of Aspirin Dose and Vorapaxar Safety and Efficacy in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome (from the TRACER Trial).** *American journal of cardiology*
Mahaffey, K. W., Huang, Z., Wallentin, L., Storey, R. F., Jennings, L. K., Tricoci, P., White, H. D., Armstrong, P. W., Aylward, P. E., Moliterno, D. J., Van de Werf, F., Chen, E., Leonardi, et al
2014; 113 (6): 936-944
- **Factors Associated With Major Bleeding Events** *JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY*
Goodman, S. G., Wojdyla, D. M., Piccini, J. P., White, H. D., Paolini, J. F., Nessel, C. C., Berkowitz, S. D., Mahaffey, K. W., Patel, M. R., Sherwood, M. W., Becker, R. C., Halperin, J. L., Hacke, et al
2014; 63 (9): 891-900
- **Factors associated with major bleeding events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation).** *Journal of the American College of Cardiology*
Goodman, S. G., Wojdyla, D. M., Piccini, J. P., White, H. D., Paolini, J. F., Nessel, C. C., Berkowitz, S. D., Mahaffey, K. W., Patel, M. R., Sherwood, M. W., Becker, R. C., Halperin, J. L., Hacke, et al
2014; 63 (9): 891-900
- **Impact of Intraprocedural Stent Thrombosis During Percutaneous Coronary Intervention: Insights From the CHAMPION PHOENIX Trial (Clinical Trial Comparing Cangrelor to Clopidogrel Standard of Care Therapy in Subjects Who Require Percutaneous Coronary Intervention).** *Journal of the American College of Cardiology*
Généreux, P., Stone, G. W., Harrington, R. A., Gibson, C. M., Steg, P. G., Brener, S. J., Angiolillo, D. J., Price, M. J., Prats, J., Lasalle, L., Liu, T., Todd, M., Skerjanec, et al
2014; 63 (7): 619-629
- **Impact of Intraprocedural Stent Thrombosis During Percutaneous Coronary Intervention** *JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY*
Genereux, P., Stone, G. W., Harrington, R. A., Gibson, C. M., Steg, P. G., Brener, S. J., Angiolillo, D. J., Price, M. J., Prats, J., Lasalle, L., Liu, T., Todd, M., Skerjanec, et al
2014; 63 (7): 619-629
- **Release kinetics of circulating cardiac myosin binding protein-C following cardiac injury** *AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY*
Kuster, D. W., Cardenas-Ospina, A., Miller, L., Liebetrau, C., Troidl, C., Nef, H. M., Moellmann, H., Hamm, C. W., Pieper, K. S., Mahaffey, K. W., Kleiman, N. S., Stuyvers, B. D., Marian, et al
2014; 306 (4): H547-H556
- **Biomarkers in Relation to the Effects of Ticagrelor in Comparison With Clopidogrel in Non-ST-Elevation Acute Coronary Syndrome Patients Managed With or Without In-Hospital Revascularization A Substudy From the Prospective Randomized Platelet Inhibition and Patient Outcomes (PLATO) Trial** *CIRCULATION*
Wallentin, L., Lindholm, D., Siegbahn, A., Wernroth, L., Becker, R. C., Cannon, C. P., Cornel, J. H., Himmelmann, A., Giannitsis, E., Harrington, R. A., Held, C., Husted, S., Katus, et al
2014; 129 (3): 293-303
- **Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial.** *European heart journal*
Mahaffey, K. W., Stevens, S. R., White, H. D., Nessel, C. C., Goodman, S. G., Piccini, J. P., Patel, M. R., Becker, R. C., Halperin, J. L., Hacke, W., Singer, D. E., Hankey, G. J., Califf, et al
2014; 35 (4): 233-241
- **Review of the accumulated PLATO documentation supports reliable and consistent superiority of ticagrelor over clopidogrel in patients with acute coronary syndrome: Commentary on: DiNicolantonio JJ, Tomek A, Inactivations, deletions, non-adjudications, and downgrades of clinical endpoints on ticagrelor: serious concerns over the reliability of the PLATO trial, International Journal of Cardiology, 2013.** *International journal of cardiology*
Wallentin, L., Becker, R. C., Cannon, C. P., Held, C., Himmelmann, A., Husted, S., James, S. K., Katus, H. S., Mahaffey, K. W., Pieper, K. S., Storey, R. F., Steg, P. G., Harrington, et al

2014; 170 (3): e59-62

- **Efficacy and safety of rivaroxaban compared with warfarin in patients with peripheral artery disease and non-valvular atrial fibrillation: insights from ROCKET AF** *EUROPEAN HEART JOURNAL*
Jones, W. S., Hellkamp, A. S., Halperin, J., Piccini, J. P., Breithardt, G., Singer, D. E., Fox, K. A., Hankey, G. J., Mahaffey, K. W., Califf, R. M., Patel, M. R.
2014; 35 (4): 242-249
- **Gastrointestinal ulcers, role of aspirin, and clinical outcomes: pathobiology, diagnosis, and treatment.** *Journal of multidisciplinary healthcare*
Cryer, B., Mahaffey, K. W.
2014; 7: 137-146
- **Reduction in Overall Occurrences of Ischemic Events With Vorapaxar: Results From TRACER.** *Journal of the American Heart Association*
White, H. D., Huang, Z., Tricoci, P., Van de Werf, F., Wallentin, L., Lokhnygina, Y., Moliterno, D. J., Aylward, P. E., Mahaffey, K. W., Armstrong, P. W.
2014; 3 (4)
- **Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data** *LANCET*
Steg, P. G., Bhatt, D. L., Hamm, C. W., Stone, G. W., Gibson, C. M., Mahaffey, K. W., Leonardi, S., Liu, T., Skerjanec, S., Day, J. R., Iwaoka, R. S., Stuckey, T. D., Gogia, et al
2013; 382 (9909): 1981-1992
- **Early Adoption of Dabigatran and Its Dosing in US Patients With Atrial Fibrillation: Results From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation** *JOURNAL OF THE AMERICAN HEART ASSOCIATION*
Steinberg, B. A., Holmes, D. N., Piccini, J. P., Ansell, J., Chang, P., Fonarow, G. C., Gersh, B., Mahaffey, K. W., Kowey, P. R., Ezekowitz, M. D., Singer, D. E., Thomas, L., Peterson, et al
2013; 2 (6)
- **5-Year Results of a Randomized Comparison of XIENCE V Everolimus-Eluting and TAXUS Paclitaxel-Eluting Stents Final Results From the SPIRIT III Trial (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions)** *JACC-CARDIOVASCULAR INTERVENTIONS*
Gada, H., Kirtane, A. J., Newman, W., Sanz, M., Hermiller, J. B., Mahaffey, K. W., Cutlip, D. E., Sudhir, K., Hou, L., Koo, K., Stone, G. W.
2013; 6 (12): 1263-1266
- **The Clinical Course of Treated Hyperparathyroidism Among Patients Receiving Hemodialysis and the Effect of Cinacalcet: The EVOLVE Trial** *JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM*
Parfrey, P. S., Chertow, G. M., Block, G. A., Correa-Rotter, R., Druce, T. B., Floege, J., Herzog, C. A., London, G. M., Mahaffey, K. W., Moe, S. M., Wheeler, D. C., Dehmel, B., Trotman, et al
2013; 98 (12): 4834-4844
- **Vorapaxar in Non-ST-Segment Elevation Acute Coronary Syndrome Patients With Peripheral Artery Disease: Results From TRACER**
Jones, S., Tricoci, P., Huang, Z., Moliterno, D. J., Harrington, R. A., Sinnaeve, P., Strony, J., Van de Werf, F., White, H. D., Held, C., Armstrong, P. W., Aylward, P. E., Chen, et al
LIPPINCOTT WILLIAMS & WILKINS.2013
- **Trends in Enrollment, Patient Characteristics, Treatments and Outcomes of Older Adults With Non-ST-segment Elevation Acute Coronary Syndromes (ACS) in Clinical Trials**
Bernacki, G. M., Alexander, K. P., Newby, L., Yang, Q., Schulte, P., White, H. D., Ohman, E., Mahaffey, K. W., Shah, B. R., Giugliano, R. P., Armstrong, P. W., Harrington, R. A., Tricoci, et al
LIPPINCOTT WILLIAMS & WILKINS.2013
- **Arterial Access Site and Outcomes in Patients Undergoing Percutaneous Coronary Intervention With and Without Vorapaxar**
Dery, J. P., Mahaffey, K., Tricoci, P., White, H., Podder, M., Moliterno, D., Harrington, R., Chen, E., Strony, J., Van de Werf, F., Ziada, K. M., Held, C., Aylward, et al
LIPPINCOTT WILLIAMS & WILKINS.2013
- **Efficacy and Safety of Vorapaxar in Elderly Patients With Non-ST-Segment Elevation Acute Coronary Syndrome: Insights From the TRACER Trial**
Armaganjian, L., Lopes, R., Huang, Z., Tricoci, P., Held, C., Van de Werf, F., Armstrong, P. W., Aylward, P. E., White, H. D., Moliterno, D. J., Wallentin, L., Chen, E., Harrington, et al
LIPPINCOTT WILLIAMS & WILKINS.2013
- **Differential Prognostic Implications of Peak Troponin Level in Acute Coronary Syndrome Treated With and Without Revascularization**

Bagai, A., Huang, Z., Likhnygina, Y., Harrington, R. A., Armstrong, P. W., Strony, J., Chen, E., White, H. D., Held, C., Van de Werf, F., Wallentin, L., Tricoci, P., Mahaffey, et al
LIPPINCOTT WILLIAMS & WILKINS.2013

- **Evolution of Differences in Women and Men With Non-ST-Segment Elevation Acute Coronary Syndromes: Insights From Clinical Trials Over 15 Years**
Halim, S., Yang, Q., Schulte, P., Hochman, J., Melloni, C., Mahaffey, K. W., Moliterno, D. J., Harrington, R. A., White, H. D., Armstrong, P. W., Ohman, E., Van de Werf, F., Giugliano, et al
LIPPINCOTT WILLIAMS & WILKINS.2013
- **CYP2C19 Polymorphism and PON-1 Activity in NSTEMI ACS: Vorapaxar Effect in Relation to Clopidogrel Metabolism in the TRACER Trial**
Tricoci, P., Chen, E., Neely, M. L., Warner, A., Wong, P. H., Sinnaeve, P., Wallentin, L., Jennings, L. K., Storey, R. F., Aylward, P. E., White, H. D., Van de Werf, F., Armstrong, et al
LIPPINCOTT WILLIAMS & WILKINS.2013
- **Prognostic implications of left ventricular end-diastolic pressure during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: Findings from the Assessment of Pexelizumab in Acute Myocardial Infarction study** *AMERICAN HEART JOURNAL*
Bagai, A., Armstrong, P. W., Stebbins, A., Mahaffey, K. W., Hochman, J. S., Weaver, W. D., Patel, M. R., Granger, C. B., Lopes, R. D.
2013; 166 (5): 913-919
- **Prognostic relevance of baseline pro- and anti-inflammatory markers in STEMI: An APEX AMI substudy** *INTERNATIONAL JOURNAL OF CARDIOLOGY*
van Diepen, S., Newby, L. K., Lopes, R. D., Stebbins, A., Hasselblad, V., James, S., Roe, M. T., Ezekowitz, J. A., Moliterno, D. J., Neumann, F., Reist, C., Mahaffey, K. W., Hochman, et al
2013; 168 (3): 2127-2133
- **Response to Letter Regarding Article, "Renal Dysfunction as a Predictor of Stroke and Systemic Embolism in Patients With Nonvalvular Atrial Fibrillation: Validation of the R(2)CHADS(2) Index in the ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study Cohorts"** *CIRCULATION*
Piccini, J. P., Stevens, S. R., Chang, Y., Singer, D. E., Likhnygina, Y., Go, A. S., Patel, M. R., Mahaffey, K. W., Halperin, J. L., Breithardt, G., Hankey, G. J., Hacke, W., Becker, et al
2013; 128 (11): E172-E173
- **Stent Thrombosis With Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes: An Analysis From the Prospective, Randomized PLATO Trial** *CIRCULATION*
Steg, P. G., Harrington, R. A., Emanuelsson, H., Katus, H. A., Mahaffey, K. W., Meier, B., Storey, R. F., Wojdyla, D. M., Lewis, B. S., Maurer, G., Wallentin, L., James, S. K.
2013; 128 (10): 1055-1065
- **A novel approach to systematically implement the universal definition of myocardial infarction: insights from the CHAMPION PLATFORM trial** *HEART*
Leonardi, S., Truffa, A. A., Neely, M. L., Tricoci, P., White, H. D., Gibson, C. M., Wilson, M., Stone, G. W., Harrington, R. A., Bhatt, D. L., Mahaffey, K. W.
2013; 99 (17): 1282-1287
- **The Systemic Inflammatory Response Syndrome in Patients With ST-Segment Elevation Myocardial Infarction** *CRITICAL CARE MEDICINE*
van Diepen, S., Vavalle, J. P., Newby, L. K., Clare, R., Pieper, K. S., Ezekowitz, J. A., Hochman, J. S., Mahaffey, K. W., Armstrong, P. W., Granger, C. B.
2013; 41 (9): 2080-2087
- **Use and Associated Risks of Concomitant Aspirin Therapy With Oral Anticoagulation in Patients With Atrial Fibrillation Insights From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry** *CIRCULATION*
Steinberg, B. A., Kim, S., Piccini, J. P., Fonarow, G. C., Lopes, R. D., Thomas, L., Ezekowitz, M. D., Ansell, J., Kowey, P., Singer, D. E., Gersh, B., Mahaffey, K. W., Hylek, et al
2013; 128 (7): 721-728
- **Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)-A randomized placebo-controlled trial** *AMERICAN HEART JOURNAL*
Neal, B., Perkovic, V., de Zeeuw, D., Mahaffey, K. W., Fulcher, G., Stein, P., Desai, M., Shaw, W., Jiang, J., Vercruyse, F., Meininger, G., Matthews, D.

2013; 166 (2): 217-?

- **Methodology of a reevaluation of cardiovascular outcomes in the RECORD trial: Study design and conduct** *AMERICAN HEART JOURNAL*
Lopes, R. D., Dickerson, S., Hafley, G., Burns, S., Tourt-Uhlig, S., White, J., Newby, L. K., Komajda, M., McMurray, J., Bigelow, R., Home, P. D., Mahaffey, K. W.
2013; 166 (2): 208-?
- **Provider Specialty and Atrial Fibrillation Treatment Strategies in United States Community Practice: Findings From the ORBIT-AF Registry** *JOURNAL OF THE AMERICAN HEART ASSOCIATION*
Fosbol, E. L., Holmes, D. N., Piccini, J. P., Thomas, L., Reiffel, J. A., Mills, R. M., Kowey, P., Mahaffey, K., Gersh, B. J., Peterson, E. D.
2013; 2 (4)
- **Results of a reevaluation of cardiovascular outcomes in the RECORD trial** *AMERICAN HEART JOURNAL*
Mahaffey, K. W., Hafley, G., Dickerson, S., Burns, S., Tourt-Uhlig, S., White, J., Newby, L. K., Komajda, M., McMurray, J., Bigelow, R., Home, P. D., Lopes, R. D.
2013; 166 (2): 240-?
- **Trends in clinical trials of non-ST-segment elevation acute coronary syndromes over 15 years** *INTERNATIONAL JOURNAL OF CARDIOLOGY*
Chan, M. Y., Sun, J., Newby, L. K., Lokhnygina, Y., White, H. D., Moliterno, D. J., Theroux, P., Ohman, E. M., Simoons, M. L., Mahaffey, K. W., Pieper, K. S., Giugliano, R. P., Armstrong, et al
2013; 167 (2): 548-554
- **Cardiac Troponin After Percutaneous Coronary Intervention and 1-Year Mortality in Non-ST-Segment Elevation Acute Coronary Syndrome Using Systematic Evaluation of Biomarker Trends** *JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY*
Tricoci, P., Leonardi, S., White, J., White, H. D., Armstrong, P. W., Montalescot, G., Giugliano, R. P., Gibson, C. M., Van de Werf, F., Califf, R. M., Harrington, R. A., Braunwald, E., Mahaffey, et al
2013; 62 (3): 242-251
- **Use of Evidence-based Cardiac Prevention Therapy Among Outpatients with Atrial Fibrillation** *AMERICAN JOURNAL OF MEDICINE*
Hess, P. L., Kim, S., Piccini, J. P., Allen, L. A., Ansell, J. E., Chang, P., Freeman, J. V., Gersh, B. J., Kowey, P. R., Mahaffey, K. W., Thomas, L., Peterson, E. D., Fonarow, et al
2013; 126 (7): 625-?
- **Highlights from the fifth international symposium of thrombosis and anticoagulation (ISTA V), October 18-19, 2012, Belo Horizonte, Minas Gerais, Brazil.** *Journal of thrombosis and thrombolysis*
Lopes, R. D., Becker, R. C., Newby, L. K., Peterson, E. D., Hylek, E. M., Giugliano, R., Granger, C. B., Mahaffey, K. W., Carvalho, A. C., Berwanger, O., Giraldez, R. R., Feitosa-Filho, G. S., Barbosa, et al
2013; 36 (1): 115-130
- **Efficacy and Safety of Rivaroxaban in Patients With Heart Failure and Nonvalvular Atrial Fibrillation Insights From ROCKET AF** *CIRCULATION-HEART FAILURE*
van Diepen, S., Hellkamp, A. S., Patel, M. R., Becker, R. C., Breithardt, G., Hacke, W., Halperin, J. L., Hankey, G. J., Nessel, C. C., Singer, D. E., Berkowitz, S. D., Califf, R. M., Fox, et al
2013; 6 (4): 740-747
- **End of Study Transition From Study Drug to Open-Label Vitamin K Antagonist Therapy: The ROCKET AF Experience** *CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES*
Mahaffey, K. W., Hellkamp, A. S., Patel, M. R., Hannan, K. L., Schwabe, K., Nessel, C. C., Berkowitz, S. D., Halperin, J. L., Hankey, G. J., Becker, R. C., Piccini, J. P., Breithardt, G., Hacke, et al
2013; 6 (4): 470-478
- **Risks and Benefits of Anticoagulation in Atrial Fibrillation: Insights From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry** *CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES*
Cullen, M. W., Kim, S., Piccini, J. P., Ansell, J. E., Fonarow, G. C., Hylek, E. M., Singer, D. E., Mahaffey, K. W., Kowey, P. R., Thomas, L., Go, A. S., Lopes, R. D., Chang, et al
2013; 6 (4): 461-469
- **Prognostic Significance of Bleeding Location and Severity Among Patients With Acute Coronary Syndromes** *JACC-CARDIOVASCULAR INTERVENTIONS*
Vavalle, J. P., Clare, R., Chiswell, K., Rao, S. V., Petersen, J. L., Kleiman, N. S., Mahaffey, K. W., Wang, T. Y.
2013; 6 (7): 709-717

- **Highlights from the fifth international symposium of thrombosis and anticoagulation (ISTA V), october 18-19, 2012, Belo Horizonte, Minas Gerais, Brazil** *JOURNAL OF THROMBOSIS AND THROMBOLYSIS*
Lopes, R. D., Becker, R. C., Newby, L. K., Peterson, E. D., Hylek, E. M., Giugliano, R., Granger, C. B., Mahaffey, K. W., Carvalho, A. C., Berwanger, O., Giraldez, R. R., Feitosa-Filho, G. S., Barbosa, et al
2013; 36 (1): 115-130
- **Clinical Outcomes With Rivaroxaban in Patients Transitioned From Vitamin K Antagonist Therapy A Subgroup Analysis of a Randomized Trial** *ANNALS OF INTERNAL MEDICINE*
Mahaffey, K. W., Wojdyla, D., Hankey, G. J., White, H. D., Nessel, C. C., Piccini, J. P., Patel, M. R., Berkowitz, S. D., Becker, R. C., Halperin, J. L., Singer, D. E., Califf, R. M., Fox, et al
2013; 158 (12): 861-?
- **Effect of vorapaxar on myocardial infarction in the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRA.CER) trial** *EUROPEAN HEART JOURNAL*
Leonardi, S., Tricoci, P., White, H. D., Armstrong, P. W., Huang, Z., Wallentin, L., Aylward, P. E., Moliterno, D. J., Van de Werf, F., Chen, E., Providencia, L., Nordrehaug, J. E., Held, et al
2013; 34 (23): 1723-1731
- **Heart Failure Complicating Non-ST-Segment Elevation Acute Coronary Syndrome Timing, Predictors, and Clinical Outcomes** *JACC-HEART FAILURE*
Bahit, M. C., Lopes, R. D., Clare, R. M., Newby, L. K., Pieper, K. S., Van de Werf, F., Armstrong, P. W., Mahaffey, K. W., Harrington, R. A., Diaz, R., Ohman, E. M., White, H. D., James, et al
2013; 1 (3): 223-229
- **Quantification of the effect of clopidogrel on enzymatic infarct size related to a percutaneous coronary intervention in patients with acute coronary syndromes: insights from the CHAMPION percutaneous coronary intervention trial** *CORONARY ARTERY DISEASE*
Leonardi, S., Stebbins, A., Lopes, R. D., Lokhnygina, Y., Todd, M., Bhatt, D. L., Stone, G. W., Lincoff, A. M., Dauerman, H. L., Gibson, C. M., White, H. D., Parikh, K. H., Gruberg, et al
2013; 24 (4): 321-327
- **Heart Failure Complicating Non-ST-Segment Elevation Acute Coronary Syndrome: Timing, Predictors, and Clinical Outcomes.** *JACC. Heart failure*
Bahit, M. C., Lopes, R. D., Clare, R. M., Newby, L. K., Pieper, K. S., Van de Werf, F., Armstrong, P. W., Mahaffey, K. W., Harrington, R. A., Diaz, R., Ohman, E. M., White, H. D., James, et al
2013; 1 (3): 223-229
- **Outcomes After Cardioversion and Atrial Fibrillation Ablation in Patients Treated With Rivaroxaban and Warfarin in the ROCKET AF Trial** *JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY*
Piccini, J. P., Stevens, S. R., Lokhnygina, Y., Patel, M. R., Halperin, J. L., Singer, D. E., Hankey, G. J., Hacke, W., Becker, R. C., Nessel, C. C., Mahaffey, K. W., Fox, K. A., Califf, et al
2013; 61 (19): 1998-2006
- **Methods of creatine kinase-MB analysis to predict mortality in patients with myocardial infarction treated with reperfusion therapy** *TRIALS*
Lopes, R. D., Lokhnygina, Y., Hasselblad, V., Newby, K. L., Yow, E., Granger, C. B., Armstrong, P. W., Hochman, J. S., Mills, J. S., Ruzylo, W., Mahaffey, K. W.
2013; 14
- **Incorporation of bleeding as an element of the composite end point in clinical trials of antithrombotic therapies in patients with non-ST-segment elevation acute coronary syndrome: Validity, pitfalls, and future approaches** *AMERICAN HEART JOURNAL*
Subherwal, S., Ohman, E. M., Mahaffey, K. W., Rao, S. V., Alexander, J. H., Wang, T. Y., Alexander, K. P., Hasselblad, V., Roe, M. T.
2013; 165 (5): 644-?
- **Effect of Platelet Inhibition with Cangrelor during PCI on Ischemic Events** *NEW ENGLAND JOURNAL OF MEDICINE*
Bhatt, D. L., Stone, G. W., Mahaffey, K. W., Gibson, C. M., Steg, P. G., Hamm, C. W., Price, M. J., Leonardi, S., Gallup, D., Bramucci, E., Radke, P. W., Widimsky, P., Tousek, et al
2013; 368 (14): 1303-1313
- **Left Bundle Branch Block in Non-ST-Segment Elevation Acute Coronary Syndromes Incidence, Angiographic Characteristics, and Clinical Outcomes** *JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY*
Rose, J. J., Newby, L. K., Broderick, S., Chiswell, K., Van de Werf, F., Armstrong, P. W., Mahaffey, K. W., Harrington, R. A., Ohman, E. M., Giugliano, R. P., Goodman, S. G., White, H. D., Califf, et al
2013; 61 (13): 1461-1463

- **Rate versus rhythm control for management of atrial fibrillation in clinical practice: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry** *AMERICAN HEART JOURNAL*
Steinberg, B. A., Holmes, D. N., Ezekowitz, M. D., Fonarow, G. C., Kowey, P. R., Mahaffey, K. W., Naccarelli, G., Reiffel, J., Chang, P., Peterson, E. D., Piccini, J. P.
2013; 165 (4): 622-629
- **Dynamic modeling of 90-day mortality in ST-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention** *AMERICAN HEART JOURNAL*
Westerhout, C. M., Pieper, K. S., James, S. K., Mahaffey, K. W., Van de Werf, F., Califf, R. M., Granger, C. B., Armstrong, P. W.
2013; 165 (3): 354-?
- **Outcomes of Discontinuing Rivaroxaban Compared With Warfarin in Patients With Nonvalvular Atrial Fibrillation Analysis From the ROCKET AF Trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation)** *JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY*
Patel, M. R., Hellkamp, A. S., Lokhnygina, Y., Piccini, J. P., Zhang, Z., Mohanty, S., Singer, D. E., Hacke, W., Breithardt, G., Halperin, J. L., Hankey, G. J., Becker, R. C., Nessel, et al
2013; 61 (6): 651-658
- **Impact of Global Geographic Region on Time in Therapeutic Range on Warfarin Anticoagulant Therapy: Data From the ROCKET AF Clinical Trial** *JOURNAL OF THE AMERICAN HEART ASSOCIATION*
Singer, D. E., Hellkamp, A. S., Piccini, J. P., Mahaffey, K. W., Lokhnygina, Y., Pan, G., Halperin, J. L., Becker, R. C., Breithardt, G., Hankey, G. J., Hacke, W., Nessel, C. C., Patel, et al
2013; 2 (1)
- **Renal Dysfunction as a Predictor of Stroke and Systemic Embolism in Patients With Nonvalvular Atrial Fibrillation Validation of the R(2)CHADS(2) Index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonist for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) Study Cohorts** *CIRCULATION*
Piccini, J. P., Stevens, S. R., Chang, Y., Singer, D. E., Lokhnygina, Y., Go, A. S., Patel, M. R., Mahaffey, K. W., Halperin, J. L., Breithardt, G., Hankey, G. J., Hacke, W., Becker, et al
2013; 127 (2): 224-?
- **Effect of Cinacalcet on Cardiovascular Disease in Patients Undergoing Dialysis** *NEW ENGLAND JOURNAL OF MEDICINE*
Chertow, G. M., Block, G. A., Correa-Rotter, R., Drueeke, T. B., Floege, J., Goodman, W. G., Herzog, C. A., Kubo, Y., London, G. M., Mahaffey, K. W., Mix, T. C., Moe, S. M., Trotman, et al
2012; 367 (26): 2482-2494
- **Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis.** *New England journal of medicine*
Chertow, G. M., Block, G. A., Correa-Rotter, R., Drueeke, T. B., Floege, J., Goodman, W. G., Herzog, C. A., Kubo, Y., London, G. M., Mahaffey, K. W., Mix, T. C., Moe, S. M., Trotman, et al
2012; 367 (26): 2482-2494
- **Comparison of the Prognosis of Spontaneous and Percutaneous Coronary Intervention-Related Myocardial Infarction** *JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY*
Leonardi, S., Thomas, L., Neely, M. L., Tricoci, P., Lopes, R. D., White, H. D., Armstrong, P. W., Giugliano, R. P., Antman, E. M., Califf, R. M., Newby, L. K., Mahaffey, K. W.
2012; 60 (22): 2296-2304
- **ESC Guidelines on the management of acute myocardial infarction with persistent ST-segment elevation** *KARDIOLOGIA POLSKA*
Steg, G., James, S. K., Atar, D., Badano, L. P., Lundquist, C. B., Borger, M. A., Di Mario, C., Dickstein, K., Ducrocq, G., Fernandes-Aviles, F., Gershlick, A. H., Gianuzzi, P., Halvorsen, et al
2012; 70: S255-S318
- **Factors Contributing to the Lower Mortality With Ticagrelor Compared With Clopidogrel in Patients Undergoing Coronary Artery Bypass Surgery** *JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY*
Varenhorst, C., Alstrom, U., Scirica, B. M., Hogue, C. W., Asenblad, N., Storey, R. F., Steg, G., Horrow, J., Mahaffey, K. W., Becker, R. C., James, S., Cannon, C. P., Brandrup-Wognsen, et al
2012; 60 (17): 1623-1630
- **Venous Thromboembolism Yet Another Cardiovascular Complication of Chronic Kidney Disease?** *CIRCULATION*
Chertow, G. M., Mahaffey, K. W.
2012; 126 (16): 1937-1938

- **Antithrombotic therapy for atrial fibrillation and coronary artery disease in older patients** *AMERICAN HEART JOURNAL*
Hess, C. N., Broderick, S., Piccini, J. P., Alexander, K. P., Newby, L. K., Shaw, L. K., Mahaffey, K. W., Alexander, J. H., Peterson, E. D., Granger, C. B., Lopes, R. D.
2012; 164 (4): 607-615
- **ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation** *EUROPEAN HEART JOURNAL*
Steg, P. G., James, S. K., Atar, D., Badano, L. P., Blomstrom-Lundqvist, C., Borger, M. A., Di Mario, C., Dickstein, K., Ducrocq, G., Fernandez-Aviles, F., Gershlick, A. H., Giannuzzi, P., Halvorsen, et al
2012; 33 (20): 2569-2619
- **Ticagrelor Versus Clopidogrel in Elderly Patients With Acute Coronary Syndromes A Substudy From the Prospective Randomized PLATelet Inhibition and Patient Outcomes (PLATO) Trial** *CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES*
Husted, S., James, S., Becker, R. C., Horrow, J., Katus, H., Storey, R. F., Cannon, C. P., Heras, M., Lopes, R. D., Morais, J., Mahaffey, K. W., Bach, R. G., Wojdyla, et al
2012; 5 (5): 680-688
- **Search for a diagnostic/prognostic biomarker for the brain cancer glioblastoma multiforme by 2D-DIGE-MS technique** *MOLECULAR AND CELLULAR BIOCHEMISTRY*
Banerjee, H. n., Mahaffey, K., Riddick, E., Banerjee, A., Bhowmik, N., Patra, M.
2012; 367 (1-2): 59-63
- **Baseline characteristics of subjects enrolled in the Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) trial** *NEPHROLOGY DIALYSIS TRANSPLANTATION*
Chertow, G. M., Correa-Rotter, R., Block, G. A., Drueke, T. B., Floege, J., Goodman, W. G., Herzog, C. A., Kubo, Y., London, G. M., Mahaffey, K. W., Mix, T., Moe, S. M., Wheeler, et al
2012; 27 (7): 2872-2879
- **Baseline NT-proBNP and biomarkers of inflammation and necrosis in patients with ST-segment elevation myocardial infarction: insights from the APEX-AMI trial** *JOURNAL OF THROMBOSIS AND THROMBOLYSIS*
van Diepen, S., Roe, M. T., Lopes, R. D., Stebbins, A., James, S., Newby, L. K., Moliterno, D. J., Neumann, F., Ezekowitz, J. A., Mahaffey, K. W., Hochman, J. S., Hamm, C. W., Armstrong, et al
2012; 34 (1): 106-113
- **Activated partial thromboplastin time measurement is not associated with clinical outcomes in patients with high-risk non-ST-segment elevation acute coronary syndromes treated with unfractionated heparin** *JOURNAL OF THROMBOSIS AND THROMBOLYSIS*
Thomas, M. P., Mahaffey, K. W., Chiswell, K., Cohen, M., Kontos, M. C., Antman, E. M., Ferguson, J. J., Califf, R. M., Goodman, S. G., Becker, R. C.
2012; 34 (1): 114-119
- **Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes and a History of Stroke or Transient Ischemic Attack** *CIRCULATION*
James, S. K., Storey, R. F., Khurmi, N. S., Husted, S., Keltai, M., Mahaffey, K. W., Maya, J., Morais, J., Lopes, R. D., Nicolau, J. C., Pais, P., Raev, D., Lopez-Sendon, et al
2012; 125 (23): 2914-?
- **Rationale and design of the Cangrelor versus standard therapy to achieve optimal Management of Platelet Inhibition PHOENIX trial** *AMERICAN HEART JOURNAL*
Leonardi, S., Mahaffey, K. W., White, H. D., Gibson, C. M., Stone, G. W., Steg, P. G., Hamm, C. W., Price, M. J., Todd, M., Dietrich, M., Gallup, D., Liu, T., Skerjanec, et al
2012; 163 (5): 768-?
- **Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF** *LANCET NEUROLOGY*
Hankey, G. J., Patel, M. R., Stevens, S. R., Becker, R. C., Breithardt, G., Carolei, A., Diener, H., Donnan, G. A., Halperin, J. L., Mahaffey, K. W., Mas, J., Massaro, A., Norrving, et al
2012; 11 (4): 315-322
- **Prediction of enzymatic infarct size in ST-segment elevation myocardial infarction** *CORONARY ARTERY DISEASE*
Mills, J. S., Mahaffey, K. W., Lokhnygina, Y., Nicolau, J. C., Ruzyllo, W., Adams, P. X., Todaro, T. G., Armstrong, P. W., Granger, C. B.
2012; 23 (2): 118-125

- **Association of Proton Pump Inhibitor Use on Cardiovascular Outcomes With Clopidogrel and Ticagrelor Insights From the Platelet Inhibition and Patient Outcomes Trial** *CIRCULATION*
Goodman, S. G., Clare, R., Pieper, K. S., Nicolau, J. C., Storey, R. F., Cantor, W. J., Mahaffey, K. W., Angiolillo, D. J., Husted, S., Cannon, C. P., James, S. K., Kilhamn, J., Steg, et al
2012; 125 (8): 978-986
- **Reduced immediate ischemic events with cangrelor in PCI: A pooled analysis of the CHAMPION trials using the universal definition of myocardial infarction** *AMERICAN HEART JOURNAL*
White, H. D., Chew, D. P., Dauerman, H. L., Mahaffey, K. W., Gibson, C. M., Stone, G. W., Gruberg, L., Harrington, R. A., Bhatt, D. L.
2012; 163 (2): 182-U275
- **Promise of Factor Xa Inhibition in Atrial Fibrillation** *CURRENT CARDIOLOGY REPORTS*
Al-Khatib, S. M., Alexander, J. H., Lopes, R. D., Mahaffey, K. W., Patel, M. R., Granger, C. B.
2012; 14 (1)
- **Clopidogrel and PPI Interaction: Clinically Relevant or Not?** *CURRENT CARDIOLOGY REPORTS*
Harrison, R. W., Mahaffey, K. W.
2012; 14 (1)
- **Promises of PAR-1 inhibition in acute coronary syndrome.** *Current cardiology reports*
Leonardi, S., Tricoci, P., Mahaffey, K. W.
2012; 14 (1): 32-39
- **Promise of factor Xa inhibition in atrial fibrillation.** *Current cardiology reports*
Al-Khatib, S. M., Alexander, J. H., Lopes, R. D., Mahaffey, K. W., Patel, M. R., Granger, C. B.
2012; 14 (1): 70-78
- **Promises of PAR-1 Inhibition in Acute Coronary Syndrome** *CURRENT CARDIOLOGY REPORTS*
Leonardi, S., Tricoci, P., Mahaffey, K. W.
2012; 14 (1)
- **Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes** *NEW ENGLAND JOURNAL OF MEDICINE*
Tricoci, P., Huang, Z., Held, C., Moliterno, D. J., Armstrong, P. W., Van de Werf, F., White, H. D., Aylward, P. E., Wallentin, L., Chen, E., Lokhnygina, Y., Pei, J., Leonardi, et al
2012; 366 (1): 20-33
- **Pattern of liver enzyme elevations in acute ST-elevation myocardial infarction** *CORONARY ARTERY DISEASE*
Lofthus, D. M., Stevens, S. R., Armstrong, P. W., Granger, C. B., Mahaffey, K. W.
2012; 23 (1): 22-30
- **Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATElet inhibition and patient Outcomes (PLATO) trial** *EUROPEAN HEART JOURNAL*
Becker, R. C., Bassand, J. P., Budaj, A., Wojdyla, D. M., James, S. K., Cornel, J. H., French, J., Held, C., Horrow, J., Husted, S., Lopez-Sendon, J., Lassila, R., Mahaffey, et al
2011; 32 (23): 2933-2944
- **Determinants of plasma vitamin D levels in patients with acute coronary syndromes** *EUROPEAN JOURNAL OF CLINICAL INVESTIGATION*
Rodriguez, G., Starr, A. Z., Czernuszewicz, G. Z., Manhas, A., Alhariri, A., Willerson, J. T., Reist, C. J., Pieper, K., Mahaffey, K. W., Marian, A. J., Kleiman, N. S.
2011; 41 (12): 1299-1309
- **Mode of Death and Hospitalization from the Second Follow-Up Serial Infusions of Nesiritide (FUSION II) Trial and Comparison of Clinical Events Committee Adjudicated Versus Investigator Reported Outcomes** *AMERICAN JOURNAL OF CARDIOLOGY*
O'Connor, C. M., Fiuzat, M., Lindenfeld, J., Miller, A., Lombardi, C., Carson, P., Shaw, L. K., Wang, L., Connolly, P., Mills, R., Yancy, C., Mahaffey, K.
2011; 108 (10): 1449-1457
- **Outcomes registry for better informed treatment of atrial fibrillation: Rationale and design of ORBIT-AF** *AMERICAN HEART JOURNAL*
Piccini, J. P., Fraulo, E. S., Ansell, J. E., Fonarow, G. C., Gersh, B. J., Go, A. S., Hylek, E. M., Kowey, P. R., Mahaffey, K. W., Thomas, L. E., Kong, M. H., Lopes, R. D., Mills, et al
2011; 162 (4): 606-U54

- **Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment** *EUROPEAN HEART JOURNAL*
Fox, K. A., Piccini, J. P., Wojdyla, D., Becker, R. C., Halperin, J. L., Nessel, C. C., Paolini, J. F., Hankey, G. J., Mahaffey, K. W., Patel, M. R., Singer, D. E., Califf, R. M.
2011; 32 (19): 2387-2394
- **Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation** *NEW ENGLAND JOURNAL OF MEDICINE*
Patel, M. R., Mahaffey, K. W., Garg, J., Pan, G., Singer, D. E., Hacke, W., Breithardt, G., Halperin, J. L., Hankey, G. J., Piccini, J. P., Becker, R. C., Nessel, C. C., Paolini, et al
2011; 365 (10): 883-891
- **Ticagrelor Compared With Clopidogrel by Geographic Region in the Platelet Inhibition and Patient Outcomes (PLATO) Trial** *CIRCULATION*
Mahaffey, K. W., Wojdyla, D. M., Carroll, K., Becker, R. C., Storey, R. F., Angiolillo, D. J., Held, C., Cannon, C. P., James, S., Pieper, K. S., Horrow, J., Harrington, R. A., Wallentin, et al
2011; 124 (5): 544-U78
- **Highlights from the III International Symposium of Thrombosis and Anticoagulation (ISTA), October 14-16, 2010, Sao Paulo, Brazil** *JOURNAL OF THROMBOSIS AND THROMBOLYSIS*
Lopes, R. D., Becker, R. C., Alexander, J. H., Armstrong, P. W., Califf, R. M., Chan, M. Y., Crowther, M., Granger, C. B., Harrington, R. A., Hylek, E. M., James, S. K., Jolicoeur, E. M., Mahaffey, et al
2011; 32 (2): 242-266
- **Cardiogenic shock and heart failure post-percutaneous coronary intervention in ST-elevation myocardial infarction: Observations from "Assessment of Pexelizumab in Acute Myocardial Infarction"** *AMERICAN HEART JOURNAL*
French, J. K., Armstrong, P. W., Cohen, E., Kleiman, N. S., O'Connor, C. M., Hellkamp, A. S., Stebbins, A., Holmes, D. R., Hochman, J. S., Granger, C. B., Mahaffey, K. W.
2011; 162 (1): 89-97
- **Inference on treatment effects from a randomized clinical trial in the presence of premature treatment discontinuation: the SYNERGY trial** *BIOSTATISTICS*
Zhang, M., Tsiatis, A. A., Davidian, M., Pieper, K. S., Mahaffey, K. W.
2011; 12 (2): 258-269
- **The Impact of Postrandomization Crossover of Therapy in Acute Coronary Syndromes Care** *CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES*
Mahaffey, K. W., Pieper, K. S., Lokhnygina, Y., Califf, R. M., Antman, E. M., Kleiman, N. S., Goodman, S. G., White, H. D., Rao, S. V., Hochman, J. S., Cohen, M., Col, J. J., Roe, et al
2011; 4 (2): 211-U119
- **Mortality Implications of Primary Percutaneous Coronary Intervention Treatment Delays: Insights From the Assessment of Pexelizumab in Acute Myocardial Infarction Trial** *CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES*
Hudson, M. P., Armstrong, P. W., O'Neil, W. W., Stebbins, A. L., Weaver, W. D., Widimsky, P., Aylward, P. E., Ruzyllo, W., Holmes, D., Mahaffey, K. W., Granger, C. B.
2011; 4 (2): 183-192
- **Strategic lessons from the clinical event classification process for the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial** *CONTEMPORARY CLINICAL TRIALS*
Mahaffey, K. W., Wampole, J. L., Stebbins, A., Berdan, L. G., McAfee, D., Rorick, T. L., French, J. K., Kleiman, N. S., O'Connor, C. M., Cohen, E. A., Granger, C. B., Armstrong, P. W.
2011; 32 (2): 178-187
- **Association of Myocardial Enzyme Elevation and Survival Following Coronary Artery Bypass Graft Surgery** *JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION*
Domanski, M. J., Mahaffey, K., Hasselblad, V., Brener, S. J., Smith, P. K., Hillis, G., Engoren, M., Alexander, J. H., Levy, J. H., Chaitman, B. R., Broderick, S., Mack, M. J., Pieper, et al
2011; 305 (6): 585-591
- **Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes Undergoing Coronary Artery Bypass Surgery Results From the PLATO (Platelet Inhibition and Patient Outcomes) Trial** *JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY*
Held, C., Asenblad, N., Bassand, J. P., Becker, R. C., Cannon, C. P., Claeys, M. J., Harrington, R. A., Horrow, J., Husted, S., James, S. K., Mahaffey, K. W., Nicolau, J. C., Scirica, et al
2011; 57 (6): 672-684

- **Heparin-associated anti-Xa activity and platelet-derived prothrombotic and proinflammatory biomarkers in moderate to high-risk patients with acute coronary syndrome** *JOURNAL OF THROMBOSIS AND THROMBOLYSIS*
Becker, R. C., Mahaffey, K. W., Yang, H., Marian, A. J., Furman, M. I., Lincoff, A. M., Hazen, S. L., Petersen, J. L., Reist, C. J., Kleiman, N. S.
2011; 31 (2): 146-153
- **ACCF/ACG/AHA 2010 Expert Consensus Document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents.** *Circulation*
Abraham, N. S., Hlatky, M. A., Antman, E. M., Bhatt, D. L., Bjorkman, D. J., Clark, C. B., Furberg, C. D., Johnson, D. A., Kahi, C. J., Laine, L., Mahaffey, K. W., Quigley, E. M., Scheiman, et al
2010; 122 (24): 2619-2633
- **ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents** *CIRCULATION*
Abraham, N. S., Hlatky, M. A., Antman, E. M., Bhatt, D. L., Bjorkman, D. J., Clark, C. B., Furberg, C. D., Johnson, D. A., Kahi, C. J., Laine, L., Mahaffey, K. W., Quigley, E. M., Scheiman, et al
2010; 122 (24): 2619-2633
- **ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents** *JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY*
Abraham, N. S., Hlatky, M. A., Antman, E. M., Bhatt, D. L., Bjorkman, D. J., Clark, C. B., Furberg, C. D., Johnson, D. A., Kahi, C. J., Laine, L., Mahaffey, K. W., Quigley, E. M., Scheiman, et al
2010; 56 (24): 2051-2066
- **ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use** *AMERICAN JOURNAL OF GASTROENTEROLOGY*
Abraham, N. S., Hlatky, M. A., Antman, E. M., Bhatt, D. L., Bjorkman, D. J., Clark, C. B., Furberg, C. D., Johnson, D. A., Kahi, C. J., Laine, L., Mahaffey, K. W., Quigley, E. M., Scheiman, et al
2010; 105 (12): 2533-2549
- **Patterns of discharge antiplatelet therapy and late outcomes among 8,582 patients with bleeding during acute coronary syndrome: A pooled analysis from PURSUIT, PARAGON-A, PARAGON-B, and SYNERGY** *AMERICAN HEART JOURNAL*
Chan, M. Y., Sun, J. L., Wang, T. Y., Lopes, R. D., Jolicoeur, M. E., Pieper, K. S., Rao, S. V., Newby, L. K., Mahaffey, K. W., Harrington, R. A., Peterson, E. D.
2010; 160 (6): 1056-U95
- **Effect of Home Testing of International Normalized Ratio on Clinical Events.** *NEW ENGLAND JOURNAL OF MEDICINE*
Matchar, D. B., Jacobson, A., Dolor, R., Edson, R., Uyeda, L., Phibbs, C. S., Vertrees, J. E., Shih, M., Holodniy, M., Lavori, P.
2010; 363 (17): 1608-1620
- **An evaluation of patient self-testing competency of prothrombin time for managing anticoagulation: pre-randomization results of VA Cooperative Study #481-The Home INR Study (THINRS)** *JOURNAL OF THROMBOSIS AND THROMBOLYSIS*
Dolor, R. J., Ruybalid, R. L., Uyeda, L., Edson, R. G., Phibbs, C., Vertrees, J. E., Shih, M., Jacobson, A. K., Matchar, D. B.
2010; 30 (3): 263-275
- **Relationship between renal function and outcomes in high-risk patients with non-ST-segment elevation acute coronary syndromes: Results from SYNERGY** *INTERNATIONAL JOURNAL OF CARDIOLOGY*
Spinler, S. A., Mahaffey, K. W., Gallup, D., Levine, G. N., Ferguson, J. J., Rao, S. V., Gallo, R., Ducas, J., Goodman, S. G., Antman, E., White, H. D., Biasucci, L., Becker, et al
2010; 144 (1): 36-41
- **Independent Adjudication of Symptomatic Heart Failure With the Use of Doxorubicin and Cyclophosphamide Followed by Trastuzumab Adjuvant Therapy: A Combined Review of Cardiac Data From the National Surgical Adjuvant Breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 Clinical Trials** *JOURNAL OF CLINICAL ONCOLOGY*
Russell, S. D., Blackwell, K. L., Lawrence, J., Pippen, J. E., Roe, M. T., Wood, F., Paton, V., Holmgren, E., Mahaffey, K. W.
2010; 28 (21): 3416-3421
- **Oral factor Xa inhibitors for the prevention of stroke in atrial fibrillation** *CURRENT OPINION IN CARDIOLOGY*

- Piccini, J. P., Lopes, R. D., Mahaffey, K. W.
2010; 25 (4): 312-320
- **Enoxaparin 0.3 mg/kg IV Supplement for Patients Transitioning to PCI after Subcutaneous Enoxaparin Therapy for NSTEMI ACS: A Subgroup Analysis from the SYNERGY Trial** *CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS*
Cohen, M., Levine, G. N., Pieper, K. S., Lan, L., Antman, E. M., Aylward, P. E., White, H. D., Kleiman, N. S., Califf, R. M., Mahaffey, K. W.
2010; 75 (6): 928-935
 - **A Systematic Assessment of Cardiovascular Outcomes in the Saxagliptin Drug Development Program for Type 2 Diabetes** *POSTGRADUATE MEDICINE*
Frederich, R., Alexander, J. H., Fiedorek, F. T., Donovan, M., Berglind, N., Harris, S., Chen, R., Wolf, R., Mahaffey, K. W.
2010; 122 (3): 16-27
 - **Prognostic utility of quantifying evolutionary ST-segment depression on early follow-up electrocardiogram in patients with non-ST-segment elevation acute coronary syndromes** *EUROPEAN HEART JOURNAL*
Yan, R. T., Yan, A. T., Mahaffey, K. W., White, H. D., Pieper, K., Sun, J., Pepine, C. J., Biasucci, L. M., Gulba, D. C., Lopez-Sendon, J., Goodman, S. G.
2010; 31 (8): 958-966
 - **Obesity in patients with non-ST-segment elevation acute coronary syndromes: Results from the SYNERGY trial** *INTERNATIONAL JOURNAL OF CARDIOLOGY*
Mahaffey, K. W., Tonev, S. T., Spinler, S. A., Levine, G. N., Gallo, R., Ducas, J., Goodman, S. G., Antman, E. M., Becker, R. C., Langer, A., White, H. D., Aylward, P. E., Col, et al
2010; 139 (2): 123-133
 - **Resolution of ST-segment depression: a new prognostic marker in ST-segment elevation myocardial infarction** *EUROPEAN HEART JOURNAL*
Tjandrawidjaja, M. C., Fu, Y., Westerhout, C. M., White, H. D., Todaro, T. G., Van de Werf, F., Mahaffey, K. W., Wagner, G. S., Granger, C. B., Armstrong, P. W.
2010; 31 (5): 573-581
 - **Influence of Clinical Trial Participation on Subsequent Antithrombin Use** *CLINICAL CARDIOLOGY*
Shah, B. R., Peterson, E. D., Chen, A. Y., Mahaffey, K. W., DeLong, E. R., Ohman, E. M., Pollack, C. V., Gibler, W. B., Roe, M. T.
2010; 33 (3): E49-E55
 - **Influence of clinical trial participation on subsequent antithrombin use.** *Clinical cardiology*
Shah, B. R., Peterson, E. D., Chen, A. Y., Mahaffey, K. W., DeLong, E. R., Ohman, E. M., Pollack, C. V., Gibler, W. B., Roe, M. T.
2010; 33 (3): E49-55
 - **Warfarin Use and Outcomes in Patients with Atrial Fibrillation Complicating Acute Coronary Syndromes** *AMERICAN JOURNAL OF MEDICINE*
Lopes, R. D., Starr, A., Pieper, C. F., Al-Khatib, S. M., Newby, L. K., Mehta, R. H., Van de Werf, F., Mahaffey, K. W., Armstrong, P. W., Harrington, R. A., White, H. D., Wallentin, L., Granger, et al
2010; 123 (2): 134-140
 - **Mechanical Complications After Percutaneous Coronary Intervention in ST-Elevation Myocardial Infarction (from APEX-AMI)** *AMERICAN JOURNAL OF CARDIOLOGY*
French, J. K., Hellkamp, A. S., Armstrong, P. W., Cohen, E., Kleiman, N. S., O'Connor, C. M., Holmes, D. R., Hochman, J. S., Granger, C. B., Mahaffey, K. W.
2010; 105 (1): 59-63
 - **Intravenous Platelet Blockade with Cangrelor during PCI.** *NEW ENGLAND JOURNAL OF MEDICINE*
Bhatt, D. L., Lincoff, A. M., Gibson, C. M., Stone, G. W., McNulty, S., Montalescot, G., Kleiman, N. S., Goodman, S. G., White, H. D., Mahaffey, K. W., Pollack, C. V., Manoukian, S. V., Widimsky, et al
2009; 361 (24): 2330-2341
 - **Platelet Inhibition with Cangrelor in Patients Undergoing PCI.** *NEW ENGLAND JOURNAL OF MEDICINE*
Harrington, R. A., Stone, G. W., McNulty, S., White, H. D., Lincoff, A. M., Gibson, C. M., Pollack, C. V., Montalescot, G., Mahaffey, K. W., Kleiman, N. S., Goodman, S. G., Amine, M., Angiolillo, et al
2009; 361 (24): 2318-2329

- **Comparison of Site-Reported and Core Laboratory-Reported Creatine Kinase-MB Values in Non-ST-Segment Elevation Acute Coronary Syndrome (from the International Trial SYNERGY)** *AMERICAN JOURNAL OF CARDIOLOGY*
Linefsky, J. P., Lin, M., Pieper, K. S., Reist, C. J., Berdan, L. G., Antman, E. M., Goodman, S. G., French, J. K., Guneri, S., Roe, M. T., Newby, L. K., Harrington, R. A., Ferguson, et al
2009; 104 (10): 1330-1335
- **Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes** *NEW ENGLAND JOURNAL OF MEDICINE*
Wallentin, L., Becker, R. C., Budaj, A., Cannon, C. P., Emanuelsson, H., Held, C., Horrow, J., Husted, S., James, S., Katus, H., Mahaffey, K. W., Scirica, B. M., Skene, et al
2009; 361 (11): 1045-1057
- **The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA.CER) trial: study design and rationale** *AMERICAN HEART JOURNAL*
Harrington, R. A., Van de Werf, F., Armstrong, P. W., Aylward, P., Veltri, E., Mahaffey, K. W., Moliterno, D. J., Strony, J., Wallentin, L., White, H. D., Diaz, R., Huber, K., Nicolau, et al
2009; 158 (3): 327-U5
- **Influence of body mass index on the efficacy of revascularization in patients with coronary artery disease** *JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY*
Turer, A. T., Mahaffey, K. W., Honeycutt, E., Tuttle, R. H., Shaw, L. K., Sketch, M. H., Smith, P. K., Califf, R. M., Alexander, J. H.
2009; 137 (6): 1468-1474
- **Baseline Q-Wave Surpasses Time From Symptom Onset as a Prognostic Marker in ST-Segment Elevation Myocardial Infarction Patients Treated With Primary Percutaneous Coronary Intervention** *JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY*
Armstrong, P. W., Fu, Y., Westerhout, C. M., Hudson, M. P., Mahaffey, K. W., White, H. D., Todaro, T. G., Adams, P. X., Aylward, P. E., Granger, C. B.
2009; 53 (17): 1503-1509
- **Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study** *LANCET*
Becker, R. C., Moliterno, D. J., Jennings, L. K., Pieper, K. S., Pei, J., Niederman, A., Ziada, K. M., Berman, G., Strony, J., Joseph, D., Mahaffey, K. W., Van de Werf, F., Veltri, et al
2009; 373 (9667): 919-928
- **Integrating ancillary studies in a large clinical trial: The design and rationale of the APEX library** *CONTEMPORARY CLINICAL TRIALS*
Mahaffey, K. W., Reist, C. J., Fu, Y., Brener, S. J., Theroux, P., Patel, M. R., Stebbins, A., Westerhout, C. M., Todaro, T. G., Adams, P. X., Granger, C. B., Armstrong, P. W.
2008; 29 (6): 887-895
- **ST-segment recovery and outcome after primary percutaneous coronary intervention for ST-elevation myocardial infarction - Insights from the Assessment of PEXelizumab in Acute Myocardial Infarction (APEX-AMI) trial** *56th Annual Scientific Session of the American-College-of-Cardiology*
Buller, C. E., Fu, Y., Mahaffey, K. W., Todaro, T. G., Adams, P., Westerhout, C. M., White, H. D., 't Hof, A. W., de Werf, F. J., Wagner, G. S., Granger, C. B., Armstrong, P. W.
LIPPINCOTT WILLIAMS & WILKINS.2008: 1335-46
- **Impact of perioperative myocardial infarction on angiographic and clinical outcomes following coronary artery bypass grafting (from PProject of Ex-vivo Vein Graft ENGINEERING via Transfection [PREVENT] IV)** *AMERICAN JOURNAL OF CARDIOLOGY*
Yau, J. M., Alexander, J. H., Hafley, G., Mahaffey, K. W., Mack, M. J., Kouchoukos, N., Goyal, A., Peterson, E. D., Gibson, C. M., Califf, R. M., Harrington, R. A., Ferguson, T. B.
2008; 102 (5): 546-551
- **Prevalence, Predictors, and Impact of Conservative Medical Management for Patients With Non-ST-Segment Elevation Acute Coronary Syndromes Who Have Angiographically Documented Significant Coronary Disease** *JACC-CARDIOVASCULAR INTERVENTIONS*
Chan, M. Y., Mahaffey, K. W., Sun, L. J., Pieper, K. S., White, H. D., Aylward, P. E., Ferguson, J. J., Califf, R. M., Roe, M. T.
2008; 1 (4): 369-378
- **Initial risk stratification and presenting characteristics of patients with evolving myocardial infarctions** *EMERGENCY MEDICINE JOURNAL*
Miller, C. D., Fermann, G. J., Lindsell, C. J., Mahaffey, K. W., Peacock, W. F., Pollack, C. V., Hollander, J. E., Diercks, D. B., Gibler, W. B., Hoekstra, J. W.
2008; 25 (8): 492-497

- **Outcomes in elderly patients with acute coronary syndromes randomized to enoxaparin vs. unfractionated heparin: results from the SYNERGY trial** *EUROPEAN HEART JOURNAL*
Lopes, R. D., Alexander, K. P., Marcucci, G., White, H. D., Spinler, S., Col, J., Aylward, P. E., Califf, R. M., Mahaffey, K. W.
2008; 29 (15): 1827-1833
- **Smoking status and antithrombin therapy in patients with non-ST-segment elevation acute coronary syndrome** *AMERICAN HEART JOURNAL*
Leung, S., Gallup, D., Mahaffey, K. W., Cohen, M., Antman, E. M., Goodman, S. G., Harrington, R. A., Langer, A., Aylward, P., Ferguson, J. J., Califf, R. M.
2008; 156 (1): 177-184
- **Short- and long-term outcomes following atrial fibrillation in patients with acute coronary syndromes with or without ST-segment elevation** *HEART*
Lopes, R. D., Pieper, K. S., Horton, J. R., Al-Khatib, S. M., Newby, L. K., Mehta, R. H., De Werf, F. V., Armstrong, P. W., Mahaffey, K. W., Harrington, R. A., Ohman, E. M., White, H. D., Wallentin, et al
2008; 94 (7): 867-873
- **Management of acute coronary syndromes in patients with renal dysfunction** *CURRENT OPINION IN CARDIOLOGY*
Melloni, C., Mahaffey, K. W.
2008; 23 (4): 320-326
- **Rivaroxaban, an oral direct factor Xa inhibitor** *EXPERT OPINION ON INVESTIGATIONAL DRUGS*
Piccini, J. P., Patel, M. R., Mahaffey, K. W., Fox, K. A., Califf, R. M.
2008; 17 (6): 925-937
- **Coronary artery bypass surgery in patients with acute coronary syndromes is difficult to predict** *AMERICAN HEART JOURNAL*
Chew, D. P., Mahaffey, K. W., White, H. D., Huang, Z., Hockstra, J. W., Ferguson, J. J., Califf, R. M., Aylward, P. E.
2008; 155 (5): 841-847
- **Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease - A randomized trial** *JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION*
Stone, G. W., Midei, M., Newman, W., Sanz, M., Hermiller, J. B., Williams, J., Farhat, N., Mahaffey, K. W., Cutlip, D. E., Fitzgerald, P. J., Sood, P., Su, X., Lansky, et al
2008; 299 (16): 1903-1913
- **Prediction of one-year survival in high-risk patients with acute coronary syndromes: Results from the SYNERGY trial** *JOURNAL OF GENERAL INTERNAL MEDICINE*
Mahaffey, K. W., Yang, Q., Pieper, K. S., Antman, E. M., White, H. D., Goodman, S. G., Cohen, M., Kleiman, N. S., Langer, A., Aylward, P. E., Col, J. J., Reist, C., Ferguson, et al
2008; 23 (3): 310-316
- **Patients with non-ST-elevation acute coronary syndromes undergoing coronary artery bypass grafting in the modern era of antithrombotic therapy** *AMERICAN HEART JOURNAL*
Chew, D. P., Huang, Z., Pieper, K. S., White, H., Mahaffey, K. W., Ferguson, J. J., Califf, R. M., Aylward, P. G.
2008; 155 (2): 239-244
- **Time to coronary angiography and outcomes among patients with high-risk non-ST-segment-elevation acute coronary syndromes: Results from the SYNERGY trial** *CIRCULATION*
Tricoci, P., Lokhnygina, Y., Berdan, L. G., Steinhubl, S. R., Gulba, D. C., White, H. D., Kleiman, N. S., Aylward, P. E., Langer, A., Califf, R. M., Ferguson, J. J., Antman, E. M., Newby, et al
2007; 116 (23): 2669-2677
- **Evaluation of cinacalcet therapy to lower cardiovascular events (EVOLVE): Rationale and design overview** *CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY*
Chertow, G. M., Pupim, L. B., Block, G. A., Correa-Rotter, R., Drueke, T. B., Floege, J., Goodman, W. G., London, G. M., Mahaffey, K. W., Moe, S. M., Wheeler, D. C., Albizem, M., Olson, et al
2007; 2 (5): 898-905
- **Baseline glucose and left ventricular remodeling after acute myocardial infarction** *JOURNAL OF DIABETES AND ITS COMPLICATIONS*
Nicolau, J. C., Maia, L. N., Vitola, J. V., Mahaffey, K. W., Machado, M. N., Ramires, J. A.
2007; 21 (5): 294-299

- **Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a meta-analysis** *EUROPEAN HEART JOURNAL*
Murphy, S. A., Gibson, C. M., Morrow, D. A., de Werf, F. V., Menown, I. B., Goodman, S. G., Mahaffey, K. W., Cohen, M., McCabe, C. H., Antman, E. M., Braunwald, E.
2007; 28 (17): 2077-2086
- **Treatment and outcomes of patients with evolving myocardial infarction: experiences from the SYNERGY trial** *EUROPEAN HEART JOURNAL*
Miller, C. D., Banerjee, A., Mahaffey, K. W., Kontos, M. C., Fermann, G., Pollack, C. V., Antman, E., Aylward, P., Goodman, S. G., Santos, R., Ferguson, J. J., Califf, R. M., Hoekstra, et al
2007; 28 (9): 1079-1084
- **Publication or presentation of results from multicenter clinical trials: Evidence from an academic medical center** *AMERICAN HEART JOURNAL*
Turer, A. T., Mahaffey, K. W., Compton, K. L., Califf, R. M., Schulman, K. A.
2007; 153 (4): 674-680
- **Creatine kinase-MB elevation after coronary artery bypass grafting surgery in patients with non-ST-segment elevation acute coronary syndromes predict worse outcomes: results from four large clinical trials** *EUROPEAN HEART JOURNAL*
Mahaffey, K. W., Roe, M. T., Kilaru, R., Alexander, J. H., Van de Werf, F., Califf, R. M., Simoons, M. L., Topol, E. J., Harrington, R. A.
2007; 28 (4): 425-432
- **Racial differences among high-risk patients presenting with non-ST-segment elevation acute coronary syndromes (results from the SYNERGY trial)** *AMERICAN JOURNAL OF CARDIOLOGY*
Echols, M. R., Mahaffey, K. W., Banerjee, A., Pieper, K. S., Stebbins, A., Lansky, A., Cohen, M. G., Velazquez, E., Santos, R., Newby, L. K., Gurfinkel, E. P., Biasucci, L., Ferguson, et al
2007; 99 (3): 315-321
- **Racial differences among high-risk patients presenting with non-ST-segment elevation acute coronary syndromes (results from the SYNERGY trial)** *AMERICAN JOURNAL OF CARDIOLOGY*
Echols, M. R., Mahaffey, K. W., Banerjee, A., Pieper, K. S., Stebbins, A., Lansky, A., Cohen, M. G., Velazquez, E., Santos, R., Newby, L. K., Gurfinkel, E. P., Biasucci, L., Ferguson, et al
2007; 99 (3): 315-321
- **Bleeding complications in patients with acute coronary syndrome undergoing early invasive management can be reduced with radial access, smaller sheath sizes, and timely sheath removal** *CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS*
Cantor, W. J., Mahaffey, K. W., Huang, Z., Das, P., Gulba, D. C., Glezer, S., Gallo, R., Ducas, J., Cohen, M., Antman, E. M., Langer, A., Kleiman, N. S., White, et al
2007; 69 (1): 73-83
- **Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial** *AMERICAN HEART JOURNAL*
White, H. D., Kleiman, N. S., Mahaffey, K. W., Lokhnygina, Y., Pieper, K. S., Chiswell, K., Cohen, M., Harrington, R. A., Chew, D. P., Petersen, J. L., Berdan, L. G., Aylward, P. E., Nessel, et al
2006; 152 (6): 1042-1050
- **A subgroup analysis of the impact of prerandomization antithrombin therapy on outcomes in the SYNERGY trial: Enoxaparin versus unfractionated heparin in non-ST-segment elevation acute coronary syndromes** *JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY*
Cohen, M., Mahaffey, K. W., Pieper, K., Pollack, C. V., Antman, E. M., Hoekstra, J., Goodman, S. G., Langer, A., Col, J. J., White, H. D., Califf, R. M., Ferguson, J. J.
2006; 48 (7): 1346-1354
- **Effect of pexelizumab on mortality in patients with acute myocardial infarction or undergoing coronary artery bypass surgery: A systematic overview** *AMERICAN HEART JOURNAL*
Mahaffey, K. W., Van de Werf, F., Shernan, S. K., Granger, C. B., Verrier, E. D., Filloon, T. G., Todaro, T. G., Adams, P. X., Levy, J. H., Hasselblad, V., Armstrong, P. W.
2006; 152 (2): 291-296
- **Prognosis of patients taking selective serotonin reuptake inhibitors before coronary artery bypass grafting** *AMERICAN JOURNAL OF CARDIOLOGY*
Xiong, G. L., Jiang, W., Clare, R., Shaw, L. K., Smith, P. K., Mahaffey, K. W., O'Connor, C. M., Krishnan, K. R., Newby, L. K.

2006; 98 (1): 42-47

- **Prognostic significance of the change in glucose level in the first 24 h after acute myocardial infarction: results from the CARDINAL study** *EUROPEAN HEART JOURNAL*
Goyal, A., Mahaffey, K. W., Garg, J., Nicolau, J. C., Hochman, J. S., Weaver, W. D., Theroux, P., Oliveira, G. B., Todaro, T. G., Mojciak, C. F., Armstrong, P. W., Granger, C. B.
2006; 27 (11): 1289-1297
- **Low-molecular-weight heparin compared with unfractionated heparin for patients with non-ST-segment elevation acute coronary syndromes treated with glycoprotein IIb/IIIa inhibitors: Results from the CRUSADE initiative** *JOURNAL OF THROMBOSIS AND THROMBOLYSIS*
Singh, K. P., Roe, M. T., Peterson, E. D., Chen, A. Y., Mahaffey, K. W., Goodman, S. G., Harrington, R. A., Smith, S. C., Gibler, W. B., Ohman, E. M., Pollack, C. V.
2006; 21 (3): 211-220
- **Statin use and sex-specific stroke outcomes in patients with vascular disease** *STROKE*
Bushnell, C. D., Griffin, J., Newby, L. K., Goldstein, L. B., Mahaffey, K. W., Graffagnino, C. A., Harrington, R. A., White, H. D., Simes, R. J., Califf, R. M., Topol, E. J., Easton, J. D.
2006; 37 (6): 1427-1431
- **Comparing classifications of death in the Mode Selection Trial: Agreement and disagreement among site investigators and a clinical events committee** *CONTEMPORARY CLINICAL TRIALS*
Petersen, J. L., Haque, G., Hellkamp, A. S., Flaker, G. C., Estes, N. A., Marchlinski, F. E., McAnulty, J. H., Greenspon, A. J., Marinchak, R. A., Lee, K. L., Lamas, G. A., Mahaffey, K. W.
2006; 27 (3): 260-268
- **N-terminal pro-brain natriuretic peptide and the timing, extent and mortality in ST elevation myocardial infarction** *CANADIAN JOURNAL OF CARDIOLOGY*
Ezekowitz, J. A., Theroux, P., Chang, W. C., Mahaffey, K. W., Granger, C. B., Weaver, W. D., Hochman, J. S., Armstrong, P. W.
2006; 22 (5): 393-397
- **Concerning the mechanism of pexelizumab's benefit in acute myocardial infarction** *AMERICAN HEART JOURNAL*
Armstrong, P. W., Mahaffey, K. W., Chang, W. C., Weaver, W. D., Hochman, J. S., Theroux, P., Rollins, S., Todaro, T. G., Granger, C. B.
2006; 151 (4): 787-790
- **A comparison of the clinical impact of bleeding measured by two different classifications among patients with acute coronary syndromes** *JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY*
Rao, S. V., O'Grady, K., Pieper, K. S., Granger, C. B., Newby, L. K., Mahaffey, K. W., Moliterno, D. J., Lincof, A. M., Armstrong, P. W., Van de Werf, F., Califf, R. M., Harrington, R. A.
2006; 47 (4): 809-816
- **Forecasting mortality: dynamic assessment of risk in ST-segment elevation acute myocardial infarction** *EUROPEAN HEART JOURNAL*
Chang, W. C., Kaul, P., Fu, Y. L., Westerhout, C. M., Granger, C. B., Mahaffey, K. W., Wallentin, L., Van de Werf, F., Armstrong, P. W.
2006; 27 (4): 419-426
- **Elevated creatine kinase-MB with normal creatine kinase predicts worse outcomes in patients with acute coronary syndromes: Results from 4 large clinical trials** *AMERICAN HEART JOURNAL*
Galla, J. M., Mahaffey, K. W., Sapp, S. K., Alexander, J. H., Roe, M. T., Ohman, E. M., Granger, C. B., Armstrong, P. W., Harrington, R. A., White, H. D., Simoons, M. L., Newby, L. K., Califf, et al
2006; 151 (1): 16-24
- **High-risk patients with acute coronary syndromes treated with low-molecular-weight or unfractionated heparin - Outcomes at 6 months and 1 year in the SYNERGY trial** *JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION*
Mahaffey, K. W., Cohen, M., Garg, J., Antman, E., Kleiman, N. S., Goodman, S. G., Berdan, L. G., Reist, C. J., Langer, A., White, H. D., Aylward, P. E., Col, J. J., Ferguson, et al
2005; 294 (20): 2594-2600
- **Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes** *AMERICAN JOURNAL OF CARDIOLOGY*
Rao, S. V., O'Grady, K., Pieper, K. S., Granger, C. B., Newby, L. K., Van de Werf, F., Mahaffey, K. W., Califf, R. M., Harrington, R. A.
2005; 96 (9): 1200-1206

- **Utilization of catheterization and revascularization procedures in patients with non-ST segment elevation acute coronary syndrome over the last decade** *CATHERIZATION AND CARDIOVASCULAR INTERVENTIONS*
Levine, G. N., Lincoff, A. M., Ferguson, J. J., Mahaffey, K. W., Goodman, S. G., Cannon, C. P., Theroux, P., Fox, K. A.
2005; 66 (2): 149-157
- **Heart failure on admission and the risk of stroke following acute myocardial infarction: the VALIANT registry** *EUROPEAN HEART JOURNAL*
Szummer, K. E., Solomon, S. D., Velazquez, E. J., Kilaru, R., McMurray, J., Rouleau, J. L., Mahaffey, K. W., Maggioni, A. P., Califf, R. M., Pfeffer, M. A., White, H. D.
2005; 26 (20): 2114-2119
- **Electrocardiographic infarct size assessment after thrombolysis: Insights from the Acute Myocardial Infarction STudy Adenosine (AMISTAD) trial** *AMERICAN HEART JOURNAL*
Barbagelata, A., Di Carli, M. F., Califf, R. M., Garg, J., Birnbaum, Y., Grinfeld, L., Gibbons, R. J., Granger, C. B., Goodman, S. G., Wagner, G. S., Mahaffey, K. W.
2005; 150 (4): 659-665
- **Prognostic significance of blood markers of inflammation in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty and effects of pexelizumab, a C5 inhibitor: a substudy of the COMMA trial** *EUROPEAN HEART JOURNAL*
Theroux, P., Armstrong, P. W., Mahaffey, K. W., Hochman, J. S., Malloy, K. J., Rollins, S., Nicolau, J. C., Lavoie, J., Luong, T. M., Burchenal, J., Granger, C. B.
2005; 26 (19): 1964-1970
- **Enzyme estimates of infarct size correlate with functional and clinical outcomes in the setting of ST-segment elevation myocardial infarction** *CURRENT CONTROLLED TRIALS IN CARDIOVASCULAR MEDICINE*
Turer, A. T., Mahaffey, K. W., Gallup, D., Weaver, W. D., Christenson, R. H., Every, N. R., Ohman, E. M.
2005; 6
- **Characterization of myocardial infarction as an end point in two large trials of acute coronary syndromes** *AMERICAN JOURNAL OF CARDIOLOGY*
Mahaffey, K. W., Roe, M. T., Kilaru, R., French, J. K., Alexander, J. H., Berdan, L. G., Van de Werf, F., Simoons, M. L., Weaver, W. D., White, H. D., Lincoff, A. M., Kleiman, N. S., Topol, et al
2005; 95 (12): 1404-1408
- **Clinical use of enoxaparin in the management of non-ST segment elevation acute coronary syndromes** *EXPERT OPINION ON PHARMACOTHERAPY*
Galla, J. M., Mahaffey, K. W.
2005; 6 (7): 1241-1251
- **A perspective on trials comparing enoxaparin and unfractionated heparin in the treatment of non-ST-elevation acute coronary syndromes** *Symposium on Staying the Course - Evidence-based Management of ACS*
Califf, R. M., Petersen, J. L., Hasselblad, V., Mahaffey, K. W., Ferguson, J. J.
MOSBY-ELSEVIER.2005: S91-S99
- **Exploring the role of enoxaparin in the management of high-risk patients with non-ST-elevation acute coronary syndromes: The SYNERGY trial** *AMERICAN HEART JOURNAL*
Mahaffey, K. W., Ferguson, J. J.
2005; 149 (4): S81-S90
- **Prognostic usefulness of White Blood Cell count and temperature in acute myocardial infarction (from the CARDINAL Trial)** *AMERICAN JOURNAL OF CARDIOLOGY*
Patel, M. R., Mahaffey, K. W., Armstrong, P. W., Weaver, W. D., Tasissa, G., Hochman, J. S., Todaro, T. G., Malloy, K. J., Rollins, S., Theroux, P., Ruzyllo, W., Nicolau, J. C., Granger, et al
2005; 95 (5): 614-618
- **Platelet glycoprotein IIb/IIIa receptor antagonists in non-ST segment elevation acute coronary syndromes - A review and guide to patient selection** *DRUGS*
Atwater, B. D., Roe, M. T., Mahaffey, K. W.
2005; 65 (3): 313-324
- **Incidence and characteristics of stroke during 90-day follow-up in patients stabilized after an acute coronary syndrome** *AMERICAN HEART JOURNAL*

- Kassem-Moussa, H., Mahaffey, K. W., Graffagnino, C., Tasissa, G., Sila, C. A., Simes, R. J., White, H. D., Califf, R. M., Bhapkar, M. V., Newby, L. K. 2004; 148 (3): 439-446
- **Coordinated series of studies to evaluate characteristics and mechanisms of acute coronary syndromes in high-risk patients randomly assigned to enoxaparin or unfractionated heparin: Design and rationale of the SYNERGY Library** *AMERICAN HEART JOURNAL*
Petersen, J. L., Mahaffey, K. W., Becker, R. C., Goodman, S. G., Kleiman, N. S., Marian, A. J., Stone, G. W., Lansky, A. J., Lincoff, A. M., Hazen, S. L., Nessel, C. C., Toro-Figueroa, L., Tate, et al
2004; 148 (2): 269-276
 - **Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-segment elevation acute coronary syndromes - A systematic overview** *JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION*
Petersen, J. L., Mahaffey, K. W., Hasselblad, V., Antman, E. M., Cohen, M., Goodman, S. G., Langer, A., Blazing, M. A., Le-Moigne-Amrani, A., de Lemos, J. A., Nessel, C. C., Harrington, R. A., Ferguson, et al
2004; 292 (1): 89-96
 - **Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy - Primary results of the SYNERGY randomized trial** *JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION*
Ferguson, J. J., Califf, R. M., Antman, E. M., Cohen, M., Grines, C. L., Goodman, S., Kereiakes, D. J., Langer, A., Mahaffey, K. W., Langer, A., Mahaffey, K. W., Nessel, C. C., Armstrong, et al
2004; 292 (1): 45-54
 - **The evaluation and management of dyslipidemia and impaired glucose metabolism during acute coronary syndromes.** *Current cardiology reports*
Goyal, A., Petersen, J. L., Mahaffey, K. W.
2004; 6 (4): 300-307
 - **Risk factors for intracranial hemorrhage and nonhemorrhagic stroke after fibrinolytic therapy (from the GUSTO-I trial)** *AMERICAN JOURNAL OF CARDIOLOGY*
Kandzari, D. E., Granger, C. B., Simoons, M. L., White, H. D., Simes, J., Mahaffey, K. W., Gore, J., Weaver, W. D., Longstreth, W. T., Stebbins, A., Lee, K. L., Califf, R. M., Topol, et al
2004; 93 (4): 458-461
 - **Creatine kinase-MB elevation after percutaneous coronary intervention predicts adverse outcomes in patients with acute coronary syndromes** *EUROPEAN HEART JOURNAL*
Roe, M. T., Mahaffey, K. W., Kilaru, R., Alexander, J. H., Akkerhuis, K. M., Simoons, M. L., Harrington, R. A., Tardiff, B. E., Granger, C. B., Ohman, E. M., Moliterno, D. J., Lincoff, A. M., Armstrong, et al
2004; 25 (4): 313-321
 - **Integrating antithrombin and antiplatelet therapies with early invasive management for non-ST-segment elevation acute coronary syndromes** *AMERICAN JOURNAL OF MEDICINE*
Rebeiz, A. G., Roe, M. T., Alexander, J. H., Mahaffey, K. W., Granger, C. B., Peterson, E. D., Califf, R. M., Harrington, R. A.
2004; 116 (2): 119-129
 - **Prognostic importance of new small Q waves following non-ST-elevation acute coronary syndromes** *AMERICAN JOURNAL OF MEDICINE*
Alexander, J. H., Harrington, R. A., Bhapkar, M., Mahaffey, K. W., Lincoff, A. M., Ohman, E. M., Klootwijk, P., Pahlm, O., Henden, B., Deckers, J. W., Simoons, M. L., Califf, R. M., Wagner, et al
2003; 115 (8): 613-619
 - **Current perspectives on reperfusion therapy for acute ST-segment elevation myocardial infarction: integrating pharmacologic and mechanical reperfusion strategies** *AMERICAN HEART JOURNAL*
Waters, R. E., Mahaffey, K. W., Granger, C. B., Roe, M. T.
2003; 146 (6): 958-968
 - **Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both** *NEW ENGLAND JOURNAL OF MEDICINE*
Pfeffer, M. A., McMurray, J. J., Velazquez, E. J., Rouleau, J. L., Kober, L., Maggioni, A. P., Solomon, S. D., Swedberg, K., Van de Werf, F., White, H., Leimberger, J. D., Henis, M., Edwards, et al
2003; 349 (20): 1893-1906
 - **The anticoagulant therapy with bivalirudin to assist in the performance of percutaneous coronary intervention in patients with heparin-induced thrombocytopenia (ATBAT) study: main results.** *journal of invasive cardiology*

Mahaffey, K. W., Lewis, B. E., Wildermann, N. M., Berkowitz, S. D., Oliverio, R. M., Turco, M. A., Shalev, Y., Ver Lee, P., Traverse, J. H., Rodriguez, A. R., Ohman, E. M., Harrington, R. A., Califf, et al
2003; 15 (11): 611-616

- **Effect of pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction - The COMPLEMENT inhibition in myocardial infarction treated with thromboLYtics (COMPLY) trial** *CIRCULATION*
Mahaffey, K. W., Granger, C. B., Nicolau, J. C., Ruzyllo, W., Weaver, W. D., Theroux, P., Hochman, J. S., Filloon, T. G., Mojcik, C. F., Todaro, T. G., Armstrong, P. W.
2003; 108 (10): 1176-1183
- **Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction - The COMPLEMENT inhibition in myocardial infarction treated with angioplasty (COMMA) trial** *CIRCULATION*
Granger, C. B., Mahaffey, K. W., Weaver, W. D., Theroux, P., Hochman, J. S., Filloon, T. G., Rollins, S., Todaro, T. G., Nicolau, J. C., Ruzyllo, W., Armstrong, P. W.
2003; 108 (10): 1184-1190
- **Does the discharge ECG provide additional prognostic insight(s) in non-ST elevation ACS patients from that acquired on admission?** *European heart journal*
HERSI, A., Fu, Y., Wong, B., Mahaffey, K. W., Harrington, R. A., Califf, R. M., Van de Werf, F., Armstrong, P. W.
2003; 24 (6): 522-531
- **Does the discharge ECG provide additional prognostic insight(s) in non-ST elevation ACS patients from that acquired on admission?** *EUROPEAN HEART JOURNAL*
HERSI, A., Fu, Y., Wong, B., Mahaffey, K. W., Harrington, R. A., Califf, R. M., Van de Werf, F., Armstrong, P. W.
2003; 24 (6): 524-533
- **Troponin T and quantitative ST-segment depression offer complementary prognostic information in the risk stratification of acute coronary syndrome patients** *JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY*
Kaul, P., Newby, L. K., Fu, Y. L., Hasselblad, V., Mahaffey, K. W., Christenson, R. H., Harrington, R. A., Ohman, E. M., Topol, E. J., Califf, R. M., Van de Werf, F., Armstrong, P. W.
2003; 41 (3): 371-380
- **Evaluation of a novel point-of-care enoxaparin monitor with central laboratory anti-Xa levels** *THROMBOSIS RESEARCH*
Saw, J., Kereiakes, D. J., Mahaffey, K. W., Applegate, R. J., Braden, G. A., Brent, B. N., Brodie, B. R., Groce, J. B., Levine, G. N., Leya, F., Moliterno, D. J.
2003; 112 (5-6): 301-306
- **Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: Results from platelet IIb/IIIa antagonist for the reduction of Acute Coronary Syndrome Events in a Global Organization Network B (PARAGON b)** *AMERICAN HEART JOURNAL*
Mukherjee, D., Mahaffey, K. W., Moliterno, D. J., Harrington, R. A., Yadav, J. S., Pieper, K. S., Gallup, D., Dyke, C., Roe, M. T., Berdan, L., Lauer, M. S., MANTTARI, M., White, et al
2002; 144 (6): 995-1002
- **Troponin T levels in patients with acute coronary syndromes, with or without renal dysfunction** *NEW ENGLAND JOURNAL OF MEDICINE*
Aviles, R. J., Askari, A. T., Lindahl, B., Wallentin, L., Jia, G., Ohman, E. M., Mahaffey, K. W., Newby, L. K., Califf, R. M., Simoons, M. L., Topol, E. J., Lauer, M. S., Berger, et al
2002; 346 (26): 2047-2052
- **The SYNERGY trial: Study design and rationale** *AMERICAN HEART JOURNAL*
Ferguson, J. J., Califf, R. M., Antman, E. M., Cohen, M., Grines, C. L., Kereiakes, D. J., Langer, A., Mahaffey, K. W., Nessel, C. C., Rios-Nogales, L.
2002; 143 (6): 952-960
- **Safety and efficacy of only 2 weeks of ticlopidine therapy in patients at increased risk of coronary stent thrombosis: Results from the Antiplatelet Therapy alone versus Lovenox plus Antiplatelet therapy in patients at increased risk of Stent Thrombosis (ATLAST) trial** *AMERICAN HEART JOURNAL*
Berger, P. B., Mahaffey, K. W., Meier, S. J., Buller, C. E., Batchelor, W., Fry, E. T., Zidar, J. P.
2002; 143 (5): 841-846
- **Experience with glycoprotein IIb/IIIa antagonists in patients with acute coronary syndromes.** *Journal of interventional cardiology*
Kandzari, D. E., Mahaffey, K. W.
2002; 15 (2): 121-129

- **Misreporting of myocardial infarction end points: Results of adjudication by a central clinical events committee in the PARAGON-B trial** *AMERICAN HEART JOURNAL*
Mahaffey, K. W., Roe, M. T., Dyke, C. K., Newby, L. K., Kleiman, N. S., Connolly, P., Berdan, L. G., Sparapani, R., Lee, K. L., Armstrong, P. W., Topol, E. J., Califf, R. M., Harrington, et al
2002; 143 (2): 242-248
- **Misreporting of myocardial infarction end points: results of adjudication by a central clinical events committee in the PARAGON-B trial. Second Platelet IIb/IIIa Antagonist for the Reduction of Acute Coronary Syndrome Events in a Global Organization Network Trial.** *American heart journal*
Mahaffey, K. W., Roe, M. T., Dyke, C. K., Newby, L. K., Kleiman, N. S., Connolly, P., Berdan, L. G., Sparapani, R., Lee, K. L., Armstrong, P. W., Topol, E. J., Califf, R. M., Harrington, et al
2002; 143 (2): 242-248
- **Grade III ischemia on presentation with acute myocardial infarction predicts rapid progression of necrosis and less myocardial salvage with thrombolysis** *CARDIOLOGY*
Birnbaum, Y., Mahaffey, K. W., Criger, D. A., Gates, K. B., Barbash, G. I., Barbagelata, A., Clemmensen, P., Sgarbossa, E. B., Gibbons, R. J., Rahman, M. A., Califf, R. M., Granger, C. B., Wagner, et al
2002; 97 (3): 166-174
- **A randomized, placebo-controlled trial of enoxaparin after high-risk coronary stenting: The ATLAST trial** *JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY*
Batchelor, W. B., Mahaffey, K. W., Berger, P. B., DEUTSCH, E., Meier, S., Hasselblad, V., Fry, E. T., Teirstein, P. S., Ross, A. M., Binanay, C. A., Zidar, J. P.
2001; 38 (6): 1608-1613
- **Atrial fibrillation and mortality among patients with acute coronary syndromes without ST-segment elevation: results from the PURSUIT trial.** *American journal of cardiology*
Al-Khatib, S. M., Pieper, K. S., Lee, K. L., Mahaffey, K. W., Hochman, J. S., Pepine, C. J., Kopecky, S. L., Akkerhuis, M., Stepinska, J., Simoons, M. L., Topol, E. J., Califf, R. M., Harrington, et al
2001; 88 (1): A7-?
- **Atrial fibrillation and mortality among patients with acute coronary syndromes without ST-segment elevation: Results from the PURSUIT trial** *AMERICAN JOURNAL OF CARDIOLOGY*
Al-Khatib, S. M., Pieper, K. S., Lee, K. L., Mahaffey, K. W., Hochman, J. S., Pepine, C. J., Kopecky, S. L., Akkerhuis, M., Stepinska, J., Simoons, M. L., Topol, E. J., Califf, R. M., Harrington, et al
2001; 88 (1): 76-79
- **Disagreements between central clinical events committee and site investigator assessments of myocardial infarction endpoints in an international clinical trial: review of the PURSUIT study** *CURRENT CONTROLLED TRIALS IN CARDIOVASCULAR MEDICINE*
Mahaffey, K. W., Harrington, R. A., Akkerhuis, M., Kleiman, N. S., Berdan, L. G., Crenshaw, B. S., Tardiff, B. E., Granger, C. B., DeJong, I., Bhapkar, M., Widimsky, P., Corbalon, R., Lee, et al
2001; 2 (4): 187-194
- **Shifting the open-artery hypothesis downstream: The quest for optimal reperfusion** *JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY*
Roe, M. T., Ohman, E. M., Maas, A. C., Christenson, R. H., Mahaffey, K. W., Granger, C. B., Harrington, R. A., Califf, R. M., Krucoff, M. W.
2001; 37 (1): 9-18
- **Systematic adjudication of myocardial infarction end-points in an international clinical trial** *CURRENT CONTROLLED TRIALS IN CARDIOVASCULAR MEDICINE*
Mahaffey, K. W., Harrington, R. A., Akkerhuis, M., Kleiman, N. S., Berdan, L. G., Crenshaw, B. S., Tardiff, B. E., Granger, C. B., DeJong, I., Bhapkar, M., Widimsky, P., Corbalon, R., Lee, et al
2001; 2 (4): 180-186
- **Novel dosing regimen of eptifibatid in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial** *LANCET*
Tcheng, J. E., O'Shea, J. C., Cohen, E. A., Pacchiana, C. M., Kitt, M. M., Lorenz, T. J., Greenberg, S., Strony, J., Califf, R. M., Buller, C., Cantor, W. J., Joseph, D. M., Kitt, et al
2000; 356 (9247): 2037-2044
- **Bivalirudin in patients with heparin-induced thrombocytopenia undergoing percutaneous coronary intervention.** *journal of invasive cardiology*
Campbell, K. R., Mahaffey, K. W., Lewis, B. E., Weitz, J. I., Berkowitz, S. D., Ohman, E. M., Califf, R. M.

2000; 12: 14F-9

- **Geographic variability in outcomes within an international trial of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes - Results from PURSUIT** *EUROPEAN HEART JOURNAL*
Akkerhuis, K. M., Deckers, J. W., Boersma, E., Harrington, R. A., Stepinska, J., Mahaffey, K. W., Wilcox, R. G., Lincoff, A. M., Keltai, M., Topol, E. J., Califf, R. M., Simoons, M. L.
2000; 21 (5): 371-381
- **Cost-effectiveness of platelet glycoprotein IIb/IIIa inhibition with eptifibatide in patients with non-ST-elevation acute coronary syndromes** *CIRCULATION*
Mark, D. B., Harrington, R. A., Lincoff, A. M., Califf, R. M., Nelson, C. L., Tsiatis, A. A., Buell, H., Mahaffey, K. W., Davidson-Ray, L., Topol, E. J.
2000; 101 (4): 366-371
- **Association between minor elevations of creatine kinase-MB level and mortality in patients with acute coronary syndromes without ST-segment elevation** *JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION*
Alexander, J. H., Sparapani, R. A., Mahaffey, K. W., Deckers, J. W., Newby, L. K., Ohman, E. M., Corbalan, R., Chierchia, S. L., Boland, J. B., Simoons, M. L., Califf, R. M., Topol, E. J., Harrington, et al
2000; 283 (3): 347-353
- **Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction - Results of a multicenter, randomized, placebo-controlled trial: The Acute Myocardial Infarction Study of Adenosine (AMISTAD) Trial** *JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY*
Mahaffey, K. W., Puma, J. A., Barbagelata, N. A., DiCarli, M. F., Leeser, M. A., Browne, K. F., Eisenberg, P. R., Bolli, R., Casas, A. C., Molina-Viamonte, V., Orlandi, C., Blevins, R., Gibbons, et al
1999; 34 (6): 1711-1720
- **Neurosurgical evacuation of intracranial hemorrhage after thrombolytic therapy for acute myocardial infarction: Experience from the GUSTO-I Trial** *AMERICAN HEART JOURNAL*
Mahaffey, K. W., Granger, C. B., Sloan, M. A., Green, C. L., Gore, J. M., Weaver, W. D., White, H. D., Simoons, M. L., Barbash, G. I., Topol, E. J., Califf, R. M.
1999; 138 (3): 493-499
- **Stroke in patients with acute coronary syndromes - Incidence and outcomes in the platelet glycoprotein IIb/IIIa in unstable angina: Receptor suppression using integrilin therapy (PURSUIT) trial** *CIRCULATION*
Mahaffey, K. W., Harrington, R. A., Simoons, M. L., Granger, C. B., Graffagnino, C., Alberts, M. J., Laskowitz, D. T., MILLER, J. M., Sloan, M. A., Berdan, L. G., MacAulay, C. M., Lincoff, A. M., Deckers, et al
1999; 99 (18): 2371-2377
- **Effects of stroke on medical resource use and costs in acute myocardial infarction** *CIRCULATION*
Tung, C. Y., Granger, C. B., Sloan, M. A., Topol, E. J., KNIGHT, J. D., Weaver, W. D., Mahaffey, K. W., White, H., Clapp-Channing, N., Simoons, M. L., Gore, J. M., Califf, R. M., Mark, et al
1999; 99 (3): 370-376
- **The use of tomographic myocardial perfusion scanning to evaluate an electrocardiographic salvage estimation method in patients with acute myocardial infarction: An AMISTAD substudy** *24th Annual ISCE Conference on Research and Technology Transfer in Computerized Electrocardiology*
Barbagelata, A., Di Carli, M. F., Sgarbossa, E. B., Califf, R. M., Clemmensen, P., Criger, D. A., Gates, K. B., Gibbons, R. J., Casabe, H., Granger, C. B., Wagner, G. S., Mahaffey, K. W.
CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS. 1999: 111-113
- **Clinical outcomes after detection of elevated cardiac enzymes in patients undergoing percutaneous intervention** *JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY*
Tardiff, B. E., Califf, R. M., Tchong, J. E., Lincoff, A. M., Sigmon, K. N., Harrington, R. A., Mahaffey, K. W., Ohman, E. M., Teirstein, P. S., Blankenship, J. C., Kitt, M. M., Topol, E. J.
1999; 33 (1): 88-96
- **Prediction of 30-day mortality among patients with thrombolysis-related intracranial hemorrhage** *CIRCULATION*
Sloan, M. A., Sila, C. A., Mahaffey, K. W., Granger, C. B., Longstreth, W. T., Koudstaal, P., White, H. D., Gore, J. M., Simoons, M. L., Weaver, W. D., Green, C. L., Topol, E. J., Califf, et al
1998; 98 (14): 1376-1382
- **Comparison of the ABC/2 estimation technique to computer-assisted volumetric analysis of intraparenchymal and subdural hematomas complicating the GUSTO-1 trial** *STROKE*
Gebel, J. M., Sila, C. A., Sloan, M. A., Granger, C. B., Weisenberger, J. P., Green, C. L., Topol, E. J., Mahaffey, K. W.

1998; 29 (9): 1799-1801

- **Risk factors for in-hospital nonhemorrhagic stroke in patients with acute myocardial infarction treated with thrombolysis** *CIRCULATION*
Mahaffey, K. W., Granger, C. B., Sloan, M. A., Thompson, T. D., Gore, J. M., Weaver, W. D., White, H. D., Simoons, M. L., Barbash, G. I., Topol, E. J., Califf, R. M.
1998; 97 (8): 757-764
- **Thrombolysis-related intracranial hemorrhage - A radiographic analysis of 244 cases from the GUSTO-1 trial with clinical correlation** *STROKE*
Gebel, J. M., Sila, C. A., Sloan, M. A., Granger, C. B., Mahaffey, K. W., Weisenberger, J., Green, C. L., White, H. D., Gore, J. M., Weaver, W. D., Califf, R. M., Topol, E. J.
1998; 29 (3): 563-569
- **Myonecrosis after revascularization procedures** *JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY*
Califf, R. M., Abdelmeguid, A. E., Kuntz, R. E., Popma, J. J., Davidson, C. J., Cohen, E. A., Kleiman, N. S., Mahaffey, K. W., Topol, E. J., Pepine, C. J., Lipicky, R. J., Granger, C. B., Harrington, et al
1998; 31 (2): 241-251
- **Diabetic retinopathy should not be a contraindication to thrombolytic therapy for acute myocardial infarction: Review of ocular hemorrhage incidence and location in the GUSTO-I trial** *JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY*
Mahaffey, K. W., Granger, C. B., Toth, C. A., White, H. D., Stebbins, A. L., Barbash, G. I., Vahanian, A., Topol, E. J., Califf, R. M.
1997; 30 (7): 1606-1610
- **A comparison of reteplase with alteplase for acute myocardial infarction** *NEW ENGLAND JOURNAL OF MEDICINE*
Topol, E., Califf, R., Ohman, E., Wilcox, R., Grinfeld, L., Aylward, P., Simes, R., Probst, P., VandeWerf, F., ARMSTRONG, P., HEIKKILA, J., Vahanian, A., Bode, et al
1997; 337 (16): 1118-1123
- **Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization** *NEW ENGLAND JOURNAL OF MEDICINE*
Topol, E. J., Califf, R. M., Lincoff, A. M., Tchong, J. E., Cabot, C. F., Weisman, H. F., Kereiakes, D., Lausten, D., Runyon, J. P., Howard, W., Kelly, T., Muncy, D., Timmis, et al
1997; 336 (24): 1689-1696
- **Randomised placebo-controlled trial of effect of eptifibatid on complications of percutaneous coronary intervention: IMPACT-II** *LANCET*
Tchong, J. E., Lincoff, A. M., Sigmon, K. N., Lee, K. L., Kitt, M. M., Califf, R. M., Topol, E. J., Juran, N., Worley, S., Tuzi, J., Hollywood, L., Kleiman, N. S., Ali, et al
1997; 349 (9063): 1422-1428
- **Overview of randomized trials of intravenous heparin in patients with acute acute myocardial infarction treated with thrombolytic therapy** *AMERICAN JOURNAL OF CARDIOLOGY*
Mahaffey, K. W., Granger, C. B., Collins, R., OCONNOR, C. M., Ohman, E. M., Bleich, S. D., Col, J. J., Califf, R. M.
1996; 77 (8): 551-556
- **LEFT-VENTRICULAR PERFORMANCE AND REMODELING IN RABBITS AFTER MYOCARDIAL-INFARCTION - EFFECTS OF A THYROID-HORMONE ANALOG** *CIRCULATION*
Mahaffey, K. W., Raya, T. E., Pennock, G. D., Morkin, E., Goldman, S.
1995; 91 (3): 794-801
- **RAPID BIOASSAY SYSTEM FOR LEAD USING YOUNG JAPANESE QUAIL** *JOURNAL OF ENVIRONMENTAL PATHOLOGY AND TOXICOLOGY*
Stone, C. L., Mahaffey, K. R., FOX, M. R.
1979; 2 (3): 767-779
- **DELTA-AMINOLEVULINIC-ACID DEHYDRATASE - SENSITIVE INDICATOR OF LEAD-EXPOSURE IN JAPANESE QUAIL** *POULTRY SCIENCE*
Stone, C. L., FOX, M. R., Jones, A. L., Mahaffey, K. R.
1977; 56 (1): 174-181
- **INFLUENCE OF ETHANOL INGESTION ON LEAD TOXICITY IN RATS FED ISOCALORIC DIETS** *ARCHIVES OF ENVIRONMENTAL HEALTH*
Mahaffey, K. R., Goyer, R. A., Wilson, M. H.
1974; 28 (4): 217-222